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Abstract 
The human thyroid epithelial cell HTori-3 has been transformed with doses of either 
chronic and acute x-rays or strontium beta particles. Models of the past have relied 
upon animal cell systems to mimic in vitro carcinogenesis. The HTori-3 system 
hoped to overcome the limitations associated with these types of models by using a 
human thyroid cell line immortalised with the SV40 virus. 
HTori-3 human thyroid epithelial cells were irradiated in vitro, passaged and then 
transplanted into nude mice. Tumours that grew over a 2-6 month period were 
excised and re-established in culture. Samples were stored and all tumours were 
taken for histological examination. Chromosome spreads confirmed the human 
nature of all tumours. 
Following exposure to acute x-rays in the range of 0.25-2.0 Gy 13 tumours were 
observed in 25 recipients. Following 0.25-2.0 Gy of chronic x-rays 10 tumours from 
25 recipients were observed. From a single 2 Gy exposure of strontium beta 
particles 3 primary tumours from 5 recipients were observed. The largest of these 
was re-transplanted in nude mice resulting in 100% incidence. All tumours were 
classified as undifferentiated anaplastic carcinomas. A small number of tumours 
were observed in the control cell lines, these may be the result of a general 
instability found with the partial transformed parental cell line. 
All 2Gy tumours and those previously established from this laboratory after alpha or 
gamma radiation were used to test for the presence of the delayed lethal death 
phenotype. A number of cell and molecular endpoints were used. These included 
plating efficiency, cell adherence, micronucleus formation and p53 status. In all 
incidences, the reproductive viability of irradiated cells was below that of non-
irradiated cells at up to 4 weeks post-irradiation. 
The Mori-3 cell line and the techniques used to study the delayed effects of 
radiation may be applicable to other cell systems and may be a useful model to study 
the long-term effects of radiation induced genomic instability. 
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Chapter 1 
INTRODUCTION 
1.1 	 General Introduction 
Ionising radiation is something to which we are all exposed, those who work with or 
are exposed directly to radiation have an increased risk of carcinogenesis. Although 
all the steps in the progression from an irradiated cell to a fully malignant cancer are 
not fully understood, research into this area will help formulate our understanding 
and direct solutions. A key problem within this field is the delayed effects of 
exposure to radiation. It is the subtly changes induced by low and chronic doses that 
may go unnoticed and yet may be the cause of the greatest concern. 
One way of understanding the complexities involved in the transformation of human 
cells is to develop in vitro models that mimic the events that are occurring in vivo. 
The use of cultured animal cell systems has yielded important answers to many 
questions. However, there are intrinsic problems with these models, the use of 
human cells to solve a human problem are likely to result in a clearer picture of the 
processes involved. 
This work attempts to use a human thyroid epithelial cell line designated HTori-3 as 
a model of in vitro transformation. A variety of ionising radiation sources will be 
used to transform these cells. Tumours produced can then be studied at the cellular 
and molecular level. A number of in vitro assays will be used to test the changes 
that have occurred during transformation, the model permits the comparison of 
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transformed cell lines to the non-transformed parental cell line from which all 
tumours are originally derived. 
Genomic instability has been defined as the increased rate in the accumulation of 
new DNA mutations over time and is a common characteristic of both tumour and 
non-tumour lines. Genomic instability is expressed in vitro through a variety of 
phenotypic changes, these include decreased plating efficiency, elevated micronuclei 
formation and increased cell cycle time. Data from these and other variables will be 
collected from both tumour and non-tumours. In an attempt to study the delayed 
characteristic of in vitro irradiation on human cells data will be collected 
immediately following radiation (T=0 weeks) and at intervals post irradiation (e.g. 
T=2 weeks, T=4 weeks, etc). Tumours produced from this model will also be 
analysed for genetic alterations characteristic of radiation induced genomic 
instability using appropriate molecular techniques. 
1.2 	 Initiation, Promotion and Progression 
To understand how radiation transforms human cells from normal to malignant it is 
first important to understand how radiation induces damage in cells. DNA is the 
critical target for radiation induced damage which can form a complex array of 
changes to its structure, from minute point mutation to large chromosomal 
rearrangements (Watson et al, 1994). 
1.2.1 Initiation 
Initiation is the first alteration to the DNA helix, which is usually a rapid and 
irreversible process. The agent of initiation can be chemical, biological or 
environmental. Each of these mutagens has its own particular method of inducing a 
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lesion in the target molecule e.g. ionising radiation often causes point mutations, 
while UV produces bulky adducts. Any variety of DNA alterations can be thought 
of as the initiating lesion. These include point mutations, inversions, substitutions 
and amplifications. Proto-oncogenes, oncogenes and tumour suppressor genes are 
all potential targets. 
1.2.2 Promotion 
Promotion can be defined as the phenotypic changes that result from the primary 
initiating lesion. The cellular changes can be seen in vitro as differences between 
individual cells or colonies. These changes may include increased cell cycle time, 
increased tolerance to DNA damage or increased cytoplasmic volume. In vivo these 
changes may be exemplified as the formation of nodules or in the case of HNPCC 
(Hereditary Non-polyposis Colon Cancer) the formation of colonic polyps. The time 
course for these changes may be years or decades. 
1.2.3 Progression 
Progression is the final stage whereby a mutated cell has accumulated enough 
damage that it is able to break free from the normal growth constraints. The tumour 
now has an infinite potential for growth and reproduction. Moreover, it has 
metastatic potential. It is able to enter the systemic circulation and produce new 
tumours at sites distant from the original. Certain genes have been identified which 
when mutated transfer the cell from a state of promotion to independent progression 
and eventually to full tumourigenesis. P53 is a known candidate in HNPCC. 
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1.3 	 Clonal nature of cancer 
It is now proven that cancers can arise from single cells (King, 1996). Although 
many mutated cells may be present in a population, selection pressure ensures that 
usually only one of these will survive to dominant. Evidence for this initially came 
from studies investigating cellular products e.g. immunoglobulin and certain 
isoenzymes. Under normal conditions a variety of immunogloblins are produced 
from the heterogeneous population of B cells, but a B cell cancer will produce only a 
single immunoglobulin. (Ruddon, 1995) Using molecular techniques that involve 
genetic analysis it has now been proven that all the cells in a tumour can contain the 
same mutation e.g. Philadelphia chromosome. Research into colorectal cancers has 
provided proof of the classical multi-step process from normal epithelium to a full 
malignancy (see figure 1.1). At each step specific gene loci have been implicated in 
the phenotypic changes that occur during the development of the tumour. 
Normal 
Epithelium 
Hypoproliferative 
Epithelium 
Late Adenoma 
Carcinoma Metastatic 
Figure 1.1 Multistage Carcinogenesis. Cancers like HNPCC are known to follow 
a stepwise progression from normal epithelium to full malignancy. 
Investigations have shown that changes in the phenotype of the tissue can be directly 
correlated with losses at specific gene loci. It is not known whether all tissue have 
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to follow the same path to transformation or whether certain genes can be missed, 
skipped and gone back to or replaced with equivalents, though it is presumed likely. 
1.4 DNA Damage 
All cancers are characterised by mutations in their DNA. A long list of molecular 
rearrangements in human neoplasms has been created to which new members are 
continually added. Translocations such as the Philadelphia chromosome described 
by Nowell and Hungerford in patients with chronic myelocytic leukaemia (CML) 
spans lengthy sequences of coding DNA. 	 Techniques to resolve these 
rearrangements, such as G-banding could only ever define areas on a chromosome 
of 5x10E6 base pairs. Deletions of 2 million base pairs or less would be difficult if 
not impossible to spot, bearing in mind that an average protein of MW 50,000 is 
encoded by 1200 base pairs. This means that over 1000 genes could be lost in the 
smallest area resolved by G-banding, (Ruddon, 1995). Mutations can come in many 
forms: deletions, substitutions, inversions and amplifications are just a few. Point 
mutations are one of the commonest types of mutations and are able to directly 
inactivate entire exons preventing gene transcription or inactivating protein products. 
It is thought that the accumulation of these mutations gives rise to the defective 
genotype termed aneuploidy also associated with oncogenic cells and cell lines. 
Aneuploidy refers to cells containing unusual numbers of chromosomes, either too 
few or too many. Where as polyploidy refers to the duplication of the entire 
genome. The increased frequency of mutations is thought to destabilise the genome 
and increase the rate of accumulation of mutations (Morgan, 1996). 
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All cells are subjected to a barrage of insults and genomic DNA is key target for 
most of these. It is DNA that holds the code for all molecular processes within the 
cell. Damage to key regulatory genes such as p53 by ionising radiation has been 
found to directly effect a cells reproductive capacity and its subsequent ability to 
transform. An important question is not only how ionising radiation damages DNA 
but what kinds of damage are induced so that by understanding the processes 
involved unwanted effects can be minimised. 
1.4.1 Double Strand breaks 
One of the most important types of DNA damage is the double strand break (dsb). 
A double strand break is defined as two complete breaks across the DNA molecular. 
Approximately, 40 double strand breaks are induced per Gy of radiation (Bryant and 
Blocher, 1980, Blocher, 1982). Work initially investigating DNA damage and repair 
using yeast mutants strongly supported the view that double strand breaks were the 
lethal event (Resnick 1978, Frankenberg et al 1984). Even a single double strand 
break could lead to cell death (Blocher and Pohlit 1982, Harbich et al 1984). More 
importantly, evidence suggests they are the lesions responsible for chromosomal 
aberrations, leading to gross rearrangements and possibly genome instability, this is 
detailed in later sections. 
1.4.2 Single Strand Breaks 
DNA damage that results in the loss of at least a single nucleotide, usually at the 
phosphodiester linkage, has been defined as a single strand break. Single strand 
breaks are more readily repaired due to the close proximity of the two ends of the 
lesion (Hutchinson, 1985). Single strand breaks are often caused by hydroxyl free 
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radicals but can be induced by both the direct and indirect mechanism of DNA 
damage (Hutchinson, 1985). Approximately 3000 single strand breaks (ssb) are 
induced per Gy of ionising radiation. 
1.4.3 Other DNA damage 
DNA protein crosslinks, sugar damage and base damage are other methods which 
have been shown to disrupt either the histone packaging of the DNA (Oleinick et al„ 
1986), or the component parts of the helix structure. Both the direct and indirect 
action of radiation have been shown to produce these effects. (Hutchinson, 1985) 
1.4.4 Chromosomal damage 
Chromosome damage has been classically defined by Sax (1940) as the result of 
single interactions of ionising radiation with chromosomes. The one hit model 
suggests that any chromatid lesion induced is either repaired or remains unrepaired 
and appears as a break at the next metaphase when the chromosomes are re-
condensed. Sax discovered that there was a linear relationship between dose and the 
induction of isochromatid breaks. However, Sax proposed that the initial lesion 
causes the loss observed. This is unlikely, as interstitial lesions can be of the order 
of 40MBp, the human haploid genome contain only 3000Mbp (Bryant , 1998). To 
induce such large losses of DNA exonuclease activity would have to occur on a 
massive scale initiating from the site of the double strand break. However, if two 
doublestrand breaks occurred on the same strand than the internal segment could 
feasibly be lost, though the chance of two dsb one a single strand is remote. 
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Revells model (1955, 1959) suggested that breaks occurred sometime after radiation 
by the failure of recombinational events at the damaged site. Although still 
requiring two double strand breaks (dsb) the model does help explain the number of 
exchanges that are observed in the sister chromatid assay. Differential harlequin 
staining by the incorporation of bromodeoxyuridine and giemsa staining readily 
shows switches of large chromosome segments. Bryant has recently extended this 
model by suggesting that single dsb breaks can be converted into chromatid breaks 
by a signalling mechanism that triggers the cell to initiate a recombinational 
exchange which if incomplete leads to a chromatid break (Bryant, 1998). 
1.5 DNA Repair 
Maintaining genetic stability is essential for life. DNA is a highly reactive 
molecular species and as such is in a continuous dynamic state of chemical flux. 
Enzymatic processes are involved in sustaining the integrity of the DNA molecule 
and are collectively referred to as DNA repair (Alberts, 1994). The rate at which 
stable changes occur in DNA is called the mutation rate (Alberts, 1994). Most 
mutations are deleterious, but a low frequency is required for evolutionary 
development. Therefore a balance between those mutations that can be tolerated and 
those which are lethal must be made. Spontaneous reactions such as those induced 
by background radiation for example or other chemical reactions producing free 
radicals alter 5000 purine bases in every genome in every cell every day (Alberts, 
1994). Thermal collisions, solvent molecules and reactive species all contribute to 
the thousands of base changes occurring daily. On average one in every thousand 
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mutations is stabilised and incorporated into the genome. Therefore, approximately 
50 mutations are accumulated in an average cells lifetime. 
Over 50 genes have been discovered in yeast that are involved in different repair 
pathways. A number of known mechanisms exist in mammalian cells, these include: 
nucleotide excision repair mismatch repair, abnormal precursor repair, base 
excision repair, and use of 06 —alkylguanine-DNA alkyltransferases. All are well 
documented, (King, 1996, Alberts, 1994, Ruddon, 1995). 
Repair enzymes have been found to work in concert with some transcription factors 
and it has been found that actively transcribed genes are repaired more efficiently 
than those that are not (Alberts, 1994). Fast and slow repair are thought to be the two 
main mechanisms involved. 
1.5.1 Mismatch Repair 
All cells contain repair pathways that assist with the repair of damage sustained to 
the genome. Mismatch repair is currently one of the most important types repair 
because it is thought that damage to these genes prevent any further repair to single 
point and mismatch damage events. This is thought to create a positive feedback 
loop, whereby further damage is either mis-repaired or not repaired at all. The first 
mismatch repair genes h_MSH3, hMSH6 and hPMS2 were found to form unique 
dimers: hMSH2, hMLH1 (Fishel and Kolodner, 1993). Subsequently other dimers 
were found to be involved in this pathway. Human MSH genes are Mut S 
homologues of the mismatch repair genes discovered in bacteria. (Fishel et al, 1993) 
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While human MLH1 another repair gene is a homologue of the Mut L gene in 
bacteria. (Modrich, 1994). 
hMSH-2 and hMSH-3 	 hMSH-2 and hMSH-6 	 hMLH-1 and hPMS2 
Another protein, GTBP was also found independently by groups in Rome and 
Boston and is thought to act as a proof-reader and possibly instigator of the 
mismatch repair cascade (Holzman, 1996). This gene has since been found as a 
germline mutation in hereditary non-polyposis colon cancer (HNPCC) which 
accounts for 15% of all colon cancers. Multiple roles have been discovered for 
mismatch repair genes (Davis et a!, 1998). In addition to correcting the genetic 
anomalies that occur during normal cell replication, these genes fix environmentally 
induced DNA damage and have also been implicated in regulating the cell cycle. 
Mismatch repair proteins are known to repair a variety of environmentally induced 
lesions, including those from ultraviolet radiation, ionising radiation and oxidation. 
Defective DNA results in defective transcripts and an altered protein function. 
Malformed proteins are likely to have deranged functions and an inability to identify 
mismatches. (Burke, 1990, Bignami, 1994). Double msh2 knockout mice have been 
developed to further study the role of this gene in tumourigenesis (Wind et al, 
1995). Loss of this gene has been linked to the mutator phenotype and has been 
frequently observed in HNPCC (Kim et al, 1998, Mac Phee, 1995, Fishel et al, 
1993). 
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Recent work by Reznikoff and Fishel has used the mismatch repair deficient 
colorectal cell line EICT116 to show the importance of these genes to repair DNA 
damage following ionising radiation (IR). They have shown that these cells, 
deficient in MLH-1 protein, are able to cross the G2/M boundary following ionising 
radiation leading to a tolerance of DNA damage (Davis et al, 1998). 
1.5.2 Other Repair 
Over 50 genes have been discovered in yeast that are involved in different repair 
pathways. A number of known mechanisms exist in mammalian cells, these include: 
nucleotide excision repair which is capable of removing bulky adducts, such as 
pyrimidine dimers caused by UV, and covalent reactions induced by such 
carcinogens as benzopyrene; 
non-mismatch repair, 
abnormal precursor repair, 
base excision repair, and use of 06 —alkylguanine-DNA alkyltransferases. 
(King, 1996, Alberts, 1994, Ruddon, 1995). 
1.6 Genomic Instability 
The consequence of exposure to ionising radiation is an array of damage, which 
includes gene mutations, chromosome aberrations, cellular transformation and cell 
death (Kadhim et al, 1995). It has been thought that these changes occur rapidly 
after exposure and that their fixation or repair occurs equally rapidly. However, 
growing evidence suggests that cells initially surviving irradiation and capable of 
proliferation may produce descendants with new chromosome aberrations (Watson, 
et al, 1997, Kadhim et al, 1992, 1995, 1996,). Genomic instability (GI) is a new 
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term to describe the multiplicity of nuclear aberrations found in cells and whose 
accumulation appear to increase spontaneously over time. Many, if not all cancers 
exhibit the phenomenon, moreover many normal cells are thought to acquire this 
phenotype after genotoxic insult. This increase in mutations is thought to hasten the 
transformation process. Small colony formation (Sinclair, 1964) and an increased 
cell cycle time (Thompson and Suit et al, 1969) were some of the first characteristics 
of the differences between irradiated and control cells to be noted. Delayed lethal 
damage was later termed to describe the induction of lethal mutations arising in the 
offspring of cells surviving irradiation (Seymour et al, 1986, Gorgojo and Little, 
1989). A decreased cloning efficiency (Mendonca et al, 1989), decreased 
attachment ability (Little et al, 1991) and decreased ability to repair dsb (Little et al, 
1992) were also found to be characteristic of the phenotype. It appears that a 
multiplicity of cellular and molecular changes occur following exposure to radiation 
the formation of giant cells and abortive colonies which is indicative of failed 
cytokinesis (Chang et al, 1992, while non-clonal chromosomal rearrangements 
indicate de novo mutations (Little et al, 1997). Suzuki has summarised some of 
these and the elevated formation of micronuclei and chromosome bridge formation 
using embryo stem cells as a source of primary tissue (Suzuki et al, 1998). 
It is important to identify markers of instability so that those factors that may 
contribute to the phenomenon can be identified. Apart from the multiplicity of 
cellular alterations that occur in genomically unstable cells molecular 
rearrangements found in repetitive sequences of DNA have also been identified 
which may provide a rapid means of identify GI populations of irradiated cells. 
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1.6.1 Repetitive sequences 
Ubiquitous repetitive nucleotide sequences include microsatellites, minisatellites and 
Alu repeats, all can be highly polymorphic. These sequences can be thousands of 
basepairs in length with up to a million copies. Although their exact function is a 
mystery, they are thought to contribute to the mutator phenotype (Loeb, 1991) and it 
has been suggested that they play a role in the evolution of new extronic sequences 
(King, 1996). Originally discovered in the 1960s by S.R.J. Britten and D.E. Kohne 
through a method known as reassociation kinetics, several types of repetitive 
sequences have since been found. 
	
1.6.1.1 	 Microsatellites 
Microsatellites are dinucleotide repeats. Often they contain either TG or CA 
nucleotides repeated 10-60 times. Over 100,000 copies of these unique repetitive 
sequences have been found interspersed throughout the human genome. Variations 
in the number of repeats at known loci have been found to change over time. This 
variation has been linked to genomic instability. It is thought that variations with the 
fidelity of the repair and duplication process involved during cell division are 
responsible for these changes. Changes in these sequences are indicative of changes 
else where in the genome. 
	
1.6.1.2 	 Minisatelites or Tandem (VNTR) Repeats 
Minisatelites or Tandem (VNTR) repeats are similar to microsatellites but are 
clustered towards the ends of chromosomes and telomeric regions. Loss of these CA 
sequences results in the telomeres becoming susceptible to exonuclease digestion 
(Jeffreys et al, 1985). Variations in these sequences are also thought to be 
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contributory to telomere rejoining which is often found in chromosomes that have 
been damaged after ionising radiation. There is little difference between species. 
1.6.1.3 	 Alu and LINE repeats 
These repetitive sequences were originally able to be cut by Alul endonuclease. On 
average these are 300bp repeats of which 10E6 copies are interspersed around the 
human genome, accounting for some 6-8% of all genomic DNA. Each 300bp may 
have two similar regions connected by an adenosine rich spacer. The length of 
sequence varies, but a consensus sequence has been found which aids PCR 
amplification. LINE sequences are 6000-7000 Bp containing several coding 
proteins followed by a poly A site. LINE sequences are thought to account for 5% 
of the genome. Both these inserts are variable within a population, and even during 
an individuals lifetime (King, 1996, Lengauer et al, 1992). 
1.6.2 Oncogenes and Proto-Oncogenes 
Ionising radiation is thought to induce cancers through activating oncogenes. Proto-
oncogenes are found in all humans. These genes have a normal function until they 
are mutated and are then termed an oncogene, so as to distinguish them from there 
non mutated counter part. Oncogenes result from activating mutations that either 
raise the level of a protein in a cell or alter its function by mutation to the structural 
gene (Levine et al, 1994). Mutated forms of the gene result in a mutated protein 
structure and an abnormal function that may induce or encourage tumourigenesis 
Originally, oncogenes were discovered through investigations in cellular 
transformation using RNA oncogenic viruses (Ruddon, 1995, King, 1996). 
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Oncogenes are involved in all aspects of cellular growth and reproduction. Over 60 
oncogenes have been discovered, some of these will have an increased production of 
normal product while others still will have an altered gene product. The ras family 
of G-protein transducers is a group of oncogenes that include H, K and N-ras, all of 
which have been found mutated in a large number of neoplasms (King, 1996). 
Ionising radiation is known to induce a host of genes. Genes induced to transcribe 
shortly after exposure to ionising radiation (IR) are termed early response genes 
(Mallya et al, 1998). It is thought that these genes transcribe proteins, which are 
involved in the cell's response to DNA damage and will include; DNA repair 
induction, cell cycle arrest and the induction of apoptosis. Mechanisms have 
evolved in the cell to prevent DNA damage from being passed onto progeny. The 
single most important gene that has been found to prevent this process is p53. A 
careful understanding how this gene works to prevent the passage of damage has 
become central to cancer research. 
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1.6.3 Tumour Suppressors - p53 Guardian of the genome 
The tumour suppressor p53 (figure 1.2) is crucial for controlling the cell cycle after 
genotoxic damage (Cox and Lane, 1995). When DNA is damaged by ionising 
radiation cells react rapidly by arresting cell division until the damage is repaired. If 
the p53 gene is damaged than cell cycle arrest is prevented and mutated cells are 
able to traverse the cell cycle leading to the accumulation of mutations and 
eventually carcinogenesis. P53 is the most commonly mutated gene in human 
cancers. Originally it was found to be a host protein through its binding to the large 
T-antigen of the SV40 virus (Lane and Crawford, 1979). 
Figure 1.2 P53 interacting with DNA helix. (Modified from NCI Web site.) The 
purple regions of the diagram are those parts of the protein that have the most 
frequently mutated sites and in direct contact with DNA molecule. These regions are 
referred to as HOTSPOTS and are found between exons 5-8. 
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The p53 gene is found on the short arm of chromosome 17 at location 17p13.1 
(Levine et al, 1993). It contains 11 exons, (see figure 2.5) encoding a 393 amino 
acid phosoprotein of 53kD (Yamaizumi and Sugano, 1994) (see figure 1.3). Initial 
studies suggested that p53 could act as an oncogene (Eliayahu et al, 1984, 1989) as 
cells transfected with the gene were neoplastically transformed. However, as mutant 
forms of the gene were used in these experiments later work redefined its role as a 
tumour suppressor, as the wild type gene arrested cell cycling. 
Structural organization of p53 protein 
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Figure 1.3 Diagrammatic Representation of p53 — modified from NCI Website. 
The 3D structure of the DNA binding domain has been carefully studied and has 
been found to consist of three loops. Many mutations that have been found in 
tumours which are in the DNA binding region of the molecule between codons 112-
286. 
Codons 110-307 ranging over exons 5-8 have been termed HOTSPOTS. (Hollstein 
et al, 1991). Wild-type p53 is an anti-transformation factor that has been used in 
some gene therapies. However, some mutant forms produce proteins with half-lives 
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much longer than that of the wild type normal protein (Levine and Momand, 1990). 
Using these and other properties a number of immuno-histochemical assays were 
designed for screening purposes (Rodrigues et al, 1990). The gene itself is a 
tetramer composed of three functional domains. These domains are involved in the 
regulation of transcription, the binding of specific DNA sequences and the formation 
of dimers. The binding of mdm2 to the transcriptional domain inactivates normal 
p53 function (Picksley and Lane, 1994). Several domains of the p53 protein have 
been isolated using X-ray crystallography, NMR and partial proteolysis (Picksley 
and Lane, 1994). The diagram over gives the current understanding of the 
functional domains of the p53 protein. 
The frequency of mutations at a specific gene locus can be grouped together and 
frequently occurring mutations can be identified and compared in different tissues. 
This allows the identification of hotspots in mutation spectra. The work has 
identified the tissue specific mutations that lead to cancer. For studies investigating 
p53 the most frequent mutation is in codon 248, which codes for an arginine, this 
directly interacts with the DNA, whereas mutations of 249 have an indirect effect on 
binding. These studies have found for example that. Ovarian cancers show codon 
273 as an especially susceptible, whereas codons, 157, 248 and 249 are hotspots 
found in lung cancer (Hollstein, et al 1991). Reasons for these variations have been 
attributed to potential differences in a tissue's response to DNA damage as well as 
differing metabolic and repair capacities of the different cell and issue types 
(Hollstein, et a/, 1991). 
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P53 is known to mediate the Gl/S boundary of the cell cycle (Kastan et al, 1991). 
After exposure to IR transcription of p53 increases dramatically.(Kastan et al, 1992). 
The high levels of stabilised p53 in turn induce GADD45 and WAFI/Cipl (el-Deiry 
et al 1993) which mediates the Gl/S boundary of the cell cycle and can mediate cell 
cycle arrest, both these genes have also been implicated in base excision repair 
(Mallya et al, 1998). 
P53 has become of increasing interest in cancer research as 60% of all cancers can 
attribute loss of growth control to this gene (Levine et al, 1991, 1994). Over 90% of 
mutations in p53 are mis-sense and result in a malformed protein, which usually has 
an extended half-life. Of 252 mis-sense mutations found in one study 248 were 
found within this conserved region of the gene (Hollstein et al, 1991). These 
mutations can prevent the protein acting on down stream regulators of the cell cycle. 
Many mutations in p53 appear consistently in exons 5-8. This region of the gene has 
been conserved throughout evolution, with many divergent species having been 
found to have the same sequence. For example of the 200 mid-region amino acids, 
169 are the same in human, monkey, rat and mouse. 
P53 has been shown to be induced by double strand breaks (Lu and Lane, 1993) and 
has been found to bind to the ends of single strand breaks (Kastan, 1996). Though 
one of P53' s main post induction functions is to bind to the 21kDa Cipl/Wafl gene 
(p21) acting as a transcription factor for it (see figure 1.4). Cipl in turn binds to cdk 
and cyclin proteins blocking their function and thus arresting mitosis. Once the cell 
has been prevented from traversing through the cell cycle, multiple repair enzymes 
can be up-regulated to scan the DNA molecule for damage. Once damaged DNA 
36 
has been satisfactorily repaired, the blocking mechanism is removed. Alternatively, 
if the damage sustained is too great than the newly emerged cysteine proteases 
related to ICE (Interleukin-1 beta converting enzyme) and CED (C.Elgans) proteins 
are transcribed for initiation of apoptosis (Nicholson et al, 1996). 
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Figure 1.4 Functions of p53 — modified from King 1996. A large number of other 
proteins interact with p53, both upstream e.g. DNA PK, while others are 
downstream targets of the gene e.g. GADD45, mdm2 and the tumour suppressor 
p16. (Kastan et al, 1992, Oliner, 1993) 
Although much work has been has been done on p53's role as a transcription factor 
in response to DNA damage, relatively little work has investigated the mechanism of 
its regulation. Recent work by Woo et al suggests DNA PK and therefore possibly 
the Ku proteins found in DNA repair scaffold are involved in the binding of p53 to 
DNA (Woo et al, 1998). This work also suggests the DNA PK could be a link 
between DNA damage and p53 activation. P53 is probably the best known protein 
whose deficit leads to the accumulation of DNA damage as checkpoints are omitted 
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from the cell cycle. However, a number of other genes are now implicated in DNA 
repair. 
1.7 Radiation induced carcinogenesis. 
The opportunities to study the effects of radiation in man are rare. Exposure to high 
doses of ionising radiation is an uncommon event and generally restricted to 
accidental situations. In contrast, animal experiments can be performed under 
standardised conditions and can provide information on the dose response 
relationships for radiation carcinogenesis. How radiation, especially low doses, 
cause cancer is a question that appears can only be elucidated by help of in vitro 
cellular models. However, these early models generally relied upon animal cell 
systems. 
1.7.1 Animal Models of vitro transformation 
Reznikoff (1973) showed how a cloned mouse embryo cell line from C3H mice, 
later designated C3H10T1/2, could be used to test the effects of ionising radiation in 
growing populations of cells. Embryo cells were sensitive to the post-confluence 
inhibition of cell division and thus any transformants would appear as piled foci on a 
confluent monolayer (Reznikoff et al, 1973). Kakunaga, (1973) used a similar assay 
with BALB/3T3 cells to test the properties of chemicals for their ability to transform 
cells in vitro. 
With the advent of molecular biology and cloning techniques, a number of groups 
transfected known oncogenes into non-transformed cell lines, e.g. Shih used the 
mouse 3T3 line (1979). Transfected cells would be re-seeded into flasks and any 
transformed cells would pile-up forming foci, these could then be scored after 14-20 
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days (Shih et al, 1979; Cooper et al, 1980). Later experiments used different species 
of recipient and donor cells. It was found that this barrier was no obstacle for in 
vitro transformation. However, spontaneous foci were always present and had to be 
taken into account. Blair et al, extended this work in 1982 using nude mice to 
screen the foci produced from his transformation assay for the production of 
tumours. Molecular studies then allowed the confirmation that the human DNA 
transfected was present in the DNA of any of the transformants. The use of the 
G418 plasmid permitted antibiotic selection to confirm the transfection process and 
speed transformant selection which had previously been a time consuming and 
lengthy process (Wigler et al, 1979). 
During the late 1970s to mid 1980s the 10T1/2 and 3T3 assays were used 
extensively to investigate in vitro transformation. The studies analysed the effects of 
radiation qualities, dose-rate, fractionation, the effects of cell cycling, and many 
others variables. Little (1979) found an increased dose resulted in high cell kill and 
increased transformation, while an inverse dose rate effect for neutrons i.e. 
decreased dose-rate of neutrons resulted in a higher transformation was a key 
discovery by Hill et al, (1982). Hei in 1988 showed that high LET radiation was 
more damaging than low LET. Some of this work was extended to show that there 
was an enhanced transformation by low dose fractionation and enhanced cell repair 
by high dose fractionation (Miller et al, 1988, 1989). However, it was not until 1992 
that radiation induced neoplastic transformation was found to be cell cycle 
dependant (Miller et al, 1992). More recent work has shown that specific molecular 
lesions are responsible, at least in part, for transformation. C3H10T1/2 foci, type II 
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and III, formed after exposure to neutrons contain ras mutations which have been 
reported in about 25% of human tumours (Freyer et al, 1996). 
A number of other investigators have attempted to mimic in vivo carcinogenesis in 
vitro. In 1988 Paraskeva used a non-tumourigenic epithelial cells designated PC/AA 
as a model for a multistaged colorectal cancer HNPCC (Hereditary Non-Polyposis 
Colorectal Cancer). The cell line used had been derived from a large pre-malignant 
colorectal adenoma from a patient with the disease. The cells were immortal in 
culture and retained colonic characteristics, such as mucin secretion, while also 
keeping a normal karyotype (Paraskeva et al, 1988). By using chemical mutagens 
such as Sodium butyrate and the potent carcinogen MNNG (N-methyl-N-nitro-
nitrosoguanidine) it was hoped that the lines could be transformed into fully 
malignant cancers and any genetic changes dissected (Paraskeva et al, 1990). 
Specific abnormalities were noted in chromosomes 1, 6, 7, 13, 14, 17, 18, and 22. 
Later work showed that p53 mutations appeared as a late event in the transformation 
process and that Bc1-2 could be used as a possible sensor of nutritional stress that 
inhibits apoptosis and permits sub-lethal damaged cells to survive (William et al, 
1997, Singh and Paraskeva, 1998). 
The transformation of human cells is known to be complex multistage process and 
thus has proved difficult to induce using radiation. Some success using chemical 
carcinogens has been more fruitful (Chadwick et al, 1989 and Rhim et al, 1990). 
The use of hybrid or immortalised but non-transformed cell lines has been an 
approach to over come the difficulties of primary cell culture. (Redpath et al, 1987, 
1990). While not ideal its application is a compromise, which can still yield useful 
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information regarding the stages involved in the multistep pathway to cancer. Early 
phenotypic changes can be observed at length. Changes in growth characteristics 
such as plating efficiencies and cloning ability can be investigated. Molecular 
alterations can be found through DNA analysis and associated with the different 
phenotypic changes observed. 
1.7.2 Use of animals for screening purposes 
The creation of syngeneic animals such as the nude or athymic mice has meant that 
large numbers of irradiated cells can be screened for tumourigenecity. Inbred nude 
mice lack hair and the thymus gland which is critical for the production of T 
lymphocytes involved in cell mediated immunity (Payne et al, 1976). Thus, these 
mice are unable to reject foreign tissue or explants. The ability of agents or treated 
cells to be screened in nude mice has greatly advanced our understanding of cancer 
and allowed the production of human cancers to be studied under carefully 
controlled circumstances. 
1.7.3 Human transformation models 
Attempts to achieve neoplastic transformation of human cells by radiation have 
generally proven unsuccessful. However, efforts to investigate the progression of 
events that cause human cells to become neoplastic in response to ionising radiation 
have been aided by the development of cell and tissue culture systems of epithelial 
cells. Early work showed that certain phenotypic and later genotypic alterations did 
occur. An increased cell lifespan in culture following gamma radiation was reported 
by Watanbe et al, 1992 after using human embryo cells. Anchorage independent 
growth, indicative of a primary neoplastic event, was reported using human foreskin 
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fibroblasts (Sheela and Kennedy, 1986). Molecular alterations like point mutations 
(Rossi, 1991) as well as gene amplifications and changes in gene expression became 
commonly documented features of human cells exposed to ionising radiation (Garte 
and Burns, 1991). 
Human cancers are known to follow a stepwise progression. Human models that are 
able to mimic this would be invaluable in understanding the mechanisms involved. 
Though they would be equally useful in the screening of potentially transforming 
drugs e.g. Taxol (Hei and Hal, 1993). However, only with later work using human 
cells immortalised with viral constructs did it become possible to fully transform 
human cells so that they were able to form re-injectable tumours into nude mice (Su 
and Little, 1992). Cell lines produced from these tumours could then be studied in 
culture and later at the molecular level. 
Non-tumourigenic primary human keratinocytes transfected with SV40 virus 
(RHEK-1) were some of the first used (Rhim et al, 1990). These models used 
ionising radiation or the retroviral addition of known oncogenes to complete the 
transformation. A non-tumourigenic human epidermal keratinocyte cell line 
immortalised by adenovirus type 12 and simian virus 40 was transformed by 
exposure to x-ray irradiation (Thraves et al, 1990). These cell lines showed classic 
morphological differences from non irradiated controls cells. This included the 
ability to form anchorage independent colonies and the formation of tumours in nude 
mice. 
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Later work by Pazzaglia et al, 1994 used a human uroepithelial cell immortalised 
with SV40 to produce an in vitro multistep model of transformation. Their data 
suggests that cells exposed to radiation then chemical carcinogens produced a 
variety of tumour types. Phenotypes ranging from very aggressive, invasive high-
grade carcinomas to superficial low-grade indolent tumours were found. In addition, 
exposure of a low-grade indolent tumour, MC-T11, generated in this system to the 
same carcinogens, resulted in neoplastic progression as assessed by the production 
of high-grade aggressive cancers. 
Radiation induced neoplastic transformation of human cells using the re-expression 
of the HeLa tumour-associated cell surface antigen, p75-IAP (intestinal alkaline 
phosphatase) has recently been developed. Loss of tumour suppressor function in 
neoplastically transformed HeLa x skin fibroblasts (CGL1) human cell hybrids was 
found after gamma radiation. This particular cell system was later developed into a 
quantitative in vitro model. (Mendonca et al, 1995). Hei (1997) has extensively used 
a papillomavirus-immortalized human bronchial epithelial cell line as a model for 
lung carcinogenesis. Malignant transformation of immortalised human bronchial 
epithelial cells by asbestos fibres has been a particular useful application (Hei et al, 
1997). 
In summary, some of the earliest in vitro assays used bacteria to investigate the 
harmful affects of chemicals. However, the development of specialised media, 
which permits the growth of long-term cultures, has allowed investigations into the 
causes of cancer in eukaryotic cells to be studied. The treatment of cells with cancer 
causing agents have proved an effective method of dissecting some of the steps in 
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the path to the transformed cell, However, the use of animal cell systems has limited 
its application. More recently, work using viral constructs which immortalise 
human cells have proved successful. Although more useful these systems have 
intrinsic limitations. 	 Immortalised cell lines must be regarded as partially 
transformed which brings with the risk of spontaneous transformants. It is hoped 
that future cell lines such as those transfected with telomerase genes will overcome 
these problems. 
1.8 	 Development of immortalised cell lines. 
1.8.1 SV40 and Immortalisation 
Isolated in 1960 SV40 is a member of the papova family, this group of viruses are 
small non-enveloped DNA virus of 5243 basepairs which will induce a tumour in 
infected cells (Tse-Hua Tan et al, 1986, Bargonetti et al, 1991). 
The large T-antigen of the simian virus-40 binds to p53 (Levine, 1986). This 
inactivates the cell cycle arrest properties of the cell (Vogelstein, 1991). The 
process of transfecting cells with simian virus 40 effectively immortalises the cell 
line, (Lemoine, 1989) but in so doing may reduce its ability to repair damage. Under 
normal circumstances any damage sustained through chemical or background 
radiation would induce an arrest and initiate cell cycle repair processes. (Kastan et 
al, 1991). However, if cells are irradiated, p53 is induced and protein transcription 
initiated. Levels of the large T-antigen will bind to p53 and inactivate this arrest. If 
repair mechanisms are still functionally intact than repair will be started but cell 
division may continue. Damage may be mis-repaired or not repaired at all. This 
may lead to an accumulation of damage which if let unchecked could lead to 
enhanced transformation in vitro. Conceivably, this process could occur with out the 
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need for radiation and may account for the relatively small instances of apparently 
spontaneous transformation in vitro. 
1.8.2 HTori-3 
HTori-3 is a non-tumourigenic thyroid epithelial cell line. The cell line was 
developed by Levine et al, (1986) from tissue derived from a 35 year old female 
lobectomy patient. Tissue was treated with a mixture of digestive collagenases, and 
then filtered through a nylon mesh. The cells were then washed in Hanks calcium 
and magnesium free balanced salt solution (MISS). The follicular epithelium were 
then plated as a monolayer with 10% FCS and 0.1mU mi.' of bTSH (bovine Thyroid 
Stimulating Hormone). Transfection of 1ps of SVori- plasmid (which comprises of 
the 5.3 kb SV40 genome with a six base pair deletion that eliminated the Bgll site at 
the origin of replication cloned in pMK16) was performed using the strontium 
phosphate co-precipitation method (Brash et al, 1987). Confirmation of expression 
of SV40 was determined by an indirect immunoperoxidase procedure using 
monoclonal antibodies. Iodine trapping and a number of other variables including 
anchorage dependant growth and screening in nude mice was also confirmed. The 
two best cell lines HTori-3 and Htori-5 were then made available for general use. 
Levine states that these cell lines may be "very suitable for neoplastic reconstruction 
experiments" 
1.8.3 Tumour cell lines 
The HTori-3 cell line has previously been used in our laboratory for investigations 
into the effects of single and fractionated exposure of gamma radiation (Riches et al, 
1994) as well as single exposure to plutonium alpha particles in vitro (Riches et al, 
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1997). A number of alpha and gamma induced tumours were formed from these 
investigation which now been used in this present study. The human origin of the 
alpha and gamma tumours was confirmed by immuno-histochemistry, DNA 
fingerprinting and chromosome analysis. The experimental model used was thought 
to provide a suitable system to begin to study the molecular mechanisms involved in 
radiation carcinogenesis 
1.9 Chernobyl and the Thyroid gland 
The cells used throughout this investigation are HTori-3, thyroid epithelial cells. 
These cells are immortal in culture and are easy to maintain under standard 
conditions. It was anticipated that HTori-3 could be used as a model of in vitro 
transformation, not only thyroid tumourigenesis but epithelial carcinogenesis in 
general. In the wake of the Chernobyl disaster of 1986 no model of thyroid 
tumourigenesis existed. Thus it was anticipated that HTori-3 would provide an 
invaluable model that would aid research in the development and progression of the 
disease. 
1.9.1 The Thyroid Gland 
The human thyroid is a lobulated endocrine gland situated in the neck in front of the 
upper trachea. Embryologically it is derived from an epithelial down growth of the 
primitive oral cavity (Mansfield, 1949). The gland produces three hormones: 
1. 
	
	
Tri-iodo- thyronine (T3): Regulates basal metabolism, role in growth and 
maturation of nervous tissue. 
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2. Thyroxine (T4), converted to T3 once in general circulation. The hormone 
A.D.H., released from the anterior pituitary gland controls release of T3 and 
T4 
3. Calcitonin is a polypeptide hormone, which regulates blood calcium levels in 
conjunction with the para-thyroid hormones. The hormone lowers calcium 
levels by independently controlling the decalcification of bone by 
osteoclastic reabsorption. 
The thyroid gland is unique in that it stores large amounts of hormone in an inactive 
form. Iodine is absorbed through the diet and is soluble in the blood stream where 
upon it is sequested by the thyroid for hormone production. (Werner et al, 1957) 
Large quantities of radioactive iodine were released by the nuclear disaster at 
Chernobyl (Hillbrandt et al, 1996, Dubrova et al, 1996). Under these circumstances, 
the thyroid gland becomes a target for the accumulation of this radioactive isotope 
and a site for intracellular irradiation. Some of the youngest victims of the 
Chernobyl disaster were in utero but the thyroid gland is known to sequester iodine 
from 12-14 weeks gestation (Baverstock et al, 1992). Assays of the past have relied 
on murine or rodent cells. While useful, it is not always possible to extrapolate the 
results from these experiments to human or mammalian cells systems. The difficulty 
of culturing human cells has restricted their use in these types of experiments. A 
few isolated examples of in vitro transformation have been reported in the literature 
(Kakunaga, 1978, McCormick et al, 1988). More successful methods have been 
published using adenovirus or SV-40 (Lemoine et al, 1989). Thus, it was anticipated 
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that the use of HTori-3 cells would be a good model to study the in vitro effects of 
cellular irradiation and human tumourigenesis. 
1.9.2 Accident at Chernobyl 
Radiation induced tumours, especially of the thyroid gland, is a rare event and is 
generally restricted to accidental situations. However, when these accidents occur 
they provide an invaluable insight into the mechanisms involved in radiation 
carcinogenesis. In the Russian region of Belarus on the 26th April 1986 a breakdown 
in reactor number 4 leads to the release of a plume of radioactive material over 
Chernobyl. Gomel lies immediately north of the reactor and is known to have 
received a high level of radioactive fallout after the accident. (Baverstock et al, 
1992). Large amounts of radioactive iodine 131 were released into the cloud during 
the accident, which drifted over northern Europe for a number of weeks 
In 1990 a great increase in the frequency of thyroid cancer in children in Belarus is 
reported. A staggering 1500% increase on 1986 (Baverstock et al, 1986). Clinical 
investigations show that nearly all the thyroid tumours are of the papillary type, 128 
out of 131. These tumours are aggressive often metastasising to the lung. 
Spontaneous thyroid carcinoma were a rare event in the area surrounding Chernobyl 
prior to the accident, between one and two cases per year (Baverstock et al, 1992). 
The number of cases has double every year since the accident, with more than 50 
reported in 1991. The greatest increases were seen in the Gomel region,. Brest, and 
Grodno which also received high doses (Hillebrandt et al, 1995). 
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Children were the most vulnerable to the radioactive Iodine 131 as the thyroid is 
most active during adolescence in the control of growth and metabolism. Many of 
the children that developed tumours were tested for p53 mutations. The p53 
mutations found were located in three conserved regions of the gene that are 
involved in the binding of the large T-antigen of the SV40 virus (Ifillebrandt et al, 
1995). 
However, conflicting reports (Ito et al, 1993 and Zou et al, 1993) have been unable 
to give a clear indication as whether p53 or ras, another gene investigated, really are 
associated with radiation induced tumourigenesis. 
Although enhanced frequencies of p53 mutations are common and have been found 
in many spontaneous tumours (Levine et a/, 1994), Wright has suggested that p53 
mutations in thyroid carcinomas are rare. In a study of 20 spontaneous tumours 
from America and Germany only one p53 mutation was found in exon 7 (Wright et 
a/, 1991). Thus any thyroid tumours discovered in the wake of the Chernobyl 
accident that carried a p53 mutations could be used as a helpful diagnostic marker of 
radiation induced cancer (Taylor et al, 1994). It was hoped that radiation induced 
tumours could then be helped to be distinguished from spontaneous ones by their 
p53 status. 
1.10 Delayed effects of radiation 
Puck and Marcus were the first to measure the reproductive potential of single 
mammalian cells in vitro when exposed to ionising radiation. It became possible to 
measure the quantitative effects of radiation on the ability of cells to divide and form 
visible colonies in culture. In short, they demonstrated that human epithelial cells 
were far more radiosensitive then previously thought. Moreover, that ionising 
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radiation kills epithelial cells in a dose dependant manner probably by lethally 
affecting the "genetic apparatus" of the cell (Puck and Marcus, 1956). 
Further work demonstrated that survivors of a radiation exposure would either die 
within the first few rounds of division following exposure or they would survive to 
behave in a similar way to that of control cells (Elkind and Sutton, 1960, Elkind et 
al, 1963, Elkind and Whitmore, 1967). Even though other authors had shown that 
irradiated progeny formed smaller colonies then that of controls cells (Sinclair, 
1964), it had been presumed that this was due to an increased time to division 
(Gorgojo and Little, 1986) and not an enhanced level of cell death. 
1.10.1 
	 Delayed Lethal Damage 
It was not until 1986 that it was demonstrated that cells, which survived an exposure 
of ionising radiation, did not have the same proliferative ability as an unirradiated 
population. Survival experiments using primary and immortal cultured mammalian 
cell lines reported the provocative finding that cells which appeared in colony 
assays, following irradiation, were found lethally defective and unable to sustain a 
constant reproductive capacity. This phenomenon was termed delayed lethal death. 
(Alper et al, 1986). CHO-KI cells maintained in monolayer and primary sheep and 
human thyroid cells were irradiated in 6x25cm2 flasks per dose point. A 6°Co 
teletherapy unit was used to irradiate cells 6 hours after plating at a dose rate 
—1.5Gy/min at SSD. Enough cells were seeded into each flask so that approximately 
100 colonies would be expected. Immediately after irradiation, the flasks were 
returned to the incubator at 37°C for 7 days. Three of the six flasks were then 
stained with carbol fushin and colonies containing an average of 200-300 cells were 
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scored. The remaining flasks, corresponding to each dose point were maintained for 
three weeks, then each split at confluence into six fresh flasks labelled B flasks. 
Three of these B flasks were used to determine the plating efficiency in the usual 
manner while the remaining three were incubated until confluence was reached. 
These flasks were likewise handled as before and labelled C flasks. In all cases, 
confluent cultures yielded total cell numbers of the order of 4x106 (Alper et al, 
1986). 
Initially, it was shown that this state persisted for 15 population doublings after 
radiation (Seymour et al 1989). Though later work has shown the persistence of the 
DLD phenotype for 30-45 population doublings in many different cell lines 
(Mothersill and Seymour, 1987, Gorgojo et al, 1989, Redpath et al, 1989). 
The relationship between dose and cancer induction is of great importance. It is 
necessary to quantify the exact amount of cell kill for a given dose of radiation. The 
phenomenon of DLD affects this outcome. When the radiation response of 
epithelial cells is determined by colony assay, it is often characterised by an initial 
shoulder region at the lower doses. It has been suggested that this shoulder region is 
composed of cells which are lethally damaged and which will eventually die, but 
only after many divisions (Seymour and Mothersill, 1989), this has also been 
referred to as potential lethal damage (PLD). Thus, the number of cells that survive 
radiation may be overestimated and thus need to be corrected. 
An area, which had impact by these findings, was studies that investigated radiation-
induced neoplastic transformation frequencies, such as the 10T1/2 assay. These 
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frequencies are often calculated by dividing the number of foci produced many 
weeks post-irradiation with the originally number of cells in the population. 
Lethally damaged survivors which would have eventually died would have been 
included in the calculation resulting in an under estimation of the transformation 
frequency of certain radiation qualities and doses (Repath et al, 1989). 
Further work to investigate the pleomorphic changes in cells expressing DLD was 
attempted by Chang and Little in 1991. They extended the work of Marin and 
Bender, 1963 and Thompson and Suit in 1969 who used time lapse photography to 
form pedigrees of irradiated cells up to 6 doublings post-irradiation. Their work 
concluded that irradiated progeny had an increased cell cycle time. The mean 
control cells would take 20hours whereby DLD cells would take 23-31 hours. This 
appeared to confirm the work of Sinclair who had shown that irradiated cells 
produced smaller colonies than controls. Sinclairs V79-1 cells also showed a 
decreased PE during passaging, longer doubling times and increased radiosensitivity 
to subsequent X-irradiation. The work of Little went on to show that cells 
expressing DLD in addition had an enhanced frequency of giant cell formation and a 
reduced ability to attach to dishes. 
The delayed lethal damage phenotype has now been confirmed in a number of cell 
lines. CHO-K1, primary sheep thyroid cells, (Seymour et al, 1986, Seymour and 
Mothersill, 1989) 10TI/2 cells (Mothersill and Seymour, 1987), CHO and 
BALB/3T3 cells (Gorgojo and Little, 1989) as well as CGL1s (Mendonca et al, 
1989). It has also been reportedly induced through chemical but not by non-ionising 
radiation (Chang and Little 1992). The use of restriction endonucleases Hinff, which 
is able to induce cohesive double strand breaks in DNA, has been found to induce 
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the DLD phenotype. Though the use of the CHO mutant, xrs-5 which is defective in 
the repair of dsbs, could not be used to induce the phenotype following X-irradiation 
(Chang and Little, 1992). However, throughout all of this research little work, so 
far, appears to have been done on human cells. 
1.10.2 	 Chromosomal Instability 
Kadhim and Wright investigated the transmission of chromosomal instability after 
plutonium alpha particle irradiation (Kadhim et al, 1992). Using a clonogenic 
culture system murine haematopoietic stem cells were irradiated with 
environmentally relevant doses. Results showed a high frequency of non-clonal 
chromosome aberrations transmissible to progeny. This work highlighted the 
possible consequences of low dose exposure to high LET radiation. Later work 
suggested that delayed apoptotic cell death was also evident after both X and alpha 
irradiation. Moreover, that the type of genomic instability was dependent on the cell 
type, its genetic susceptibility and the type of irradiation exposure (Kadhim et al, 
1995). Radiation induced genomic instability in murine haematopoietic stem cells 
may be due to an elevated oxidative stress (Clutton et al, 1996). Moreover, that 
pathways for oxidative species production are elevated in irradiated cells and may 
explain why cells displaying genomic instability appear to have a "memory" of the 
initial irradiation insult. Little in 1997 published evidence that cells expressing 
DLD, a slowing growing phenotype, selected sub-population of chromosomally 
unstable cells. (Little et al, 1997). 
Evidence presented in 1998 went onto suggest that clones from the same population 
of irradiated cells, which expressed DLD, not only had different phenotypes but also 
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genotypes. Previous experimenters had used high LET radiation to induce DLD. 
However, eloquent experiments by Suzuki using low LET X-rays and primary 
human embryonic cells confirmed evidence of DLD in human cells. Expression 
lasted for over 40 population doublings, the presence of giant cells, chromosome 
bridges and an elevated frequency of micronuclei were also documented. They also 
provided evidence that genetic instability induced by low LET radiation resulted in a 
decreased efficiency at the rejoining of broken chromosome ends. (Suzuki et al, 
1998). 	 Suzuki hypothesised that DLD may be the result of unscheduled 
recombinational events instigated by radiation induced dsb. Fragile chromosome 
sites which may include telomere regions which have been associated with bridge-
breakage-fusion cycles are thought to result in potentially unstable chromosome 
regions that may explain the phenomenon of DLD and such indicators as elevated 
colony micronuclei levels. 
Work by Seymour and Mothersill have provided evidence that a cytotoxic substance 
released into the media from irradiated cells is also responsible for cell death. 
Moreover, the secreted substance can be used induce immediate and non-recoverable 
cell death in unirradiated cultures. This bystander effect occurs independent of 
whether gap junctions are opened or closed, whether cells are in cell-cell contact 
with doses as low as 0.5Gy inducing the effect. Possible candidates for this 
substance are AIF (Apoptosis inducing factor) and 1L8 (Mothersill and Seymour, 
1997). 
Some of the latest work on delayed cell death and genomic instability has transferred 
purely in vitro assays to the more realistic in vivo systems. Preconceptional paternal 
irradiation has been implicated as a causal factor in childhood cancer e.g. incidences 
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of childhood leukaemia clusters in the vicinity of nuclear installations. The system 
of Luke et al was based on a transgenic mouse model, employing a lambda shuttle 
vector that following irradiation (0.1-4.0 Gy) allowed mutations in the lad gene to 
be identified from murine bone marrow. Results showed a two fold increase from 
2.39 x le to 4.26 x10-5 in the rate of mutations and suggest that a route for the 
transgenerational transfer of genomic instability exists (Luke et a/ 1997). Other 
authors have shown that the children of the cleanup workers after the Chernobyl 
accident have a higher frequency of chromosome aberrations in peripheral blood 
lymphocytes including HPRT mutations (Vorobtsova et al, 1995, 1997). 
In the late 1990's the subject of delayed lethal death was reopened with the 
application of more sophisticated molecular techniques. Radiation induced genomic 
instability in murine haematopoietic stem cells may be due to an elevated oxidative 
stress (Wright et al, 1996). Moreover, that pathways for oxidative species 
production are elevated in irradiated cells and may explain why cells displaying 
genomic instability appear to have a "memory" of the initial irradiation insult. Little 
in 1997 published evidence that cells expressing DLD, a slowing growing 
phenotype, selected sub-population of chromosomally unstable cells. (Little et al, 
1997). 
1.10.3 	 Quantification of the Delayed Lethal Death Phenotype 
Evidence presented in 1998 went onto suggest that clones from the same population 
of irradiated cells, which expressed DLD, not only had different phenotypes but also 
genotypes. Previous experimenters had used high LET radiation to induce DLD. 
However, eloquent experiments by Suzuki using low LET X-rays and primary 
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human embryonic cells confirmed evidence of DLD in human cells. Expression 
lasted for over 40 population doublings, the presence of giant cells, chromosome 
bridges and an elevated frequency of micronuclei were also documented. They also 
provided evidence that genetic instability induced by low LET radiation resulted in a 
decreased efficiency at the rejoining of broken chromosome ends. (Suzuki et al, 
	
1998). 	 Suzuki hypothesises that DLD may be the result of unscheduled 
recombinational events instigated by radiation induced dsb. Fragile chromosome 
sites which may include telomere regions which have been associated with bridge-
breakage-fusion cycles are thought to result in potentially unstable chromosome 
regions that may explain the phenomenon of DLD and such indicators as elevated 
colony micronuclei levels. 
Work by Seymour and Mothersill have provided evidence that a cytotoxic substance 
released into the media from irradiated cells is also responsible for cell death. 
Moreover, the secreted substance can be used induce immediate and non-recoverable 
cell death in unirradiated cultures. This bystander effect occurs independent of 
whether gap junctions are opened or closed, whether cells are in cell-cell contact 
with doses as low as 0.5Gy inducing the effect. Possible candidates for this 
substance are AIF (Apoptosis inducing factor) and IL8 (Mothersill and Seymour, 
1997). 
	
1.10.4 	 Preconceptional paternal irradiation 
Some of the latest work on delayed cell death and genomic instability has transferred 
purely in vitro assays to the more realistic in vivo systems. Preconceptional paternal 
irradiation has been implicated as a causal factor in childhood cancer e.g. incidences 
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of childhood leukaemia clusters in the vicinity of nuclear installations. The system 
of Luke et a/ (1997) was based on a transgenic mouse model, employing a lambda 
shuttle vector that following irradiation (0.1-4.0 Gy) allowed mutations in the lad 
gene to be identified from murine bone marrow. Results showed a two fold increase 
from 2.39 x 10-5 to 4.26 x10-5 in the rate of mutations and suggest that a route for the 
transgenerational transfer of genomic instability exists (Luke et al 1997). Other 
authors have shown that the children of the cleanup workers after the Chernobyl 
accident have a higher frequency of chromosome aberrations in peripheral blood 
lymphocytes including HPRT mutations (Vorobtsova et al, 1995, 1997). 
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Chapter 2 
MATERIALS AND METHODS 
2.1 Cell and Media 
2.1.1 Cell culture conditions: HTori-3 
All cell culture and transformation experiments performed used the human thyroid 
epithelial cell line HTori-3. Professor Wynford-Thomas of the University of Wales 
College of medicine kindly donated the original cell line to Dr Riches laboratory in 
1989. 
HTori-3 was created by transfecting primary thyroid cells removed from a 35-year-
old female patient with the replication defective SV40 virus. The SV40 genome is 
5.3kb and contains a 6 base pair deletion that inactivates the Bgll site at the point of 
replication, (Lemoine, 1989). The virus encodes two important antigens: the large 
and the small T-antigen, (Lane and Crawford, 1979). It is the large T antigen that 
binds to free p53 protein, (Vogelstein, et al 1991), inactivating it and thus preventing 
cellular arrest. The resulting phenotype of the cell is immortal. The cell has 
unlimited reproductive capacity. 	 However, karyotype analysis shows the 
chromosome compliment to be polyploid with no mode. Southern blotting proved 
the singular integration of a single copy of the SV40 genome, (Lemoine, 1989). 
The cells were cultured under standard conditions in a variety of Nunc tissue grade 
flasks. The most common was the T80 flask with an 80 cm2 surface area, though the 
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T25 and T180 were also used. The cells were incubated with Dulbecco's modified 
Eagles medium and Hams F12, supplemented with 5% foetal calf serum (FCS) and 
5% glutamine, 100 units/ml penicillin and 1001.1g/m1 streptomycin. Cultures were 
gassed with 5% carbon dioxide in air, sealed and kept at a constant 37 °C in a warm 
air incubator. 
2.1.2 Freezing Cells 
A subconfluent flask of cells would be trypsinised and counted using an electronic 
Coulter counter (ZM model). Cells were then spun at 1000 rpm in a cryocentrifuge 
for 10 minutes. The supernatant was discarded and the pellet resuspended in a 
volume of antibiotic free media supplemented with 10% FCS. A volume of 
suspension that gave approximately 1.0x106cells/ml, certainly no less than 7.5x105 
and no greater than 1.25x106 was used in addition to 10% dimethyl- sulphoxide (or 
100µ1) to prevent the formation of ice crystals which would rupture the cells during 
the freezing process. Later it was discovered the cells recovered more promptly if 
they were frozen in pure FCS. At Berkeley a Nicool was used to gradually reduce 
the temperature at the rate of 1°C/min over a period of 90 minutes until the vials 
were at -80°C. Up to 8 cryovials could be suspended in a rack over an insulated 
bowl of liquid nitrogen. A fan at the top of the unit drew cold air over the vials at the 
predetermined rate. Once frozen the vials could be placed directly in liquid nitrogen 
or a minus 170°C freezer. At St Andrews the vials were prepared as before, with cell 
line, date, passage number, initials and cell concentration clearly labelled. But cells 
were placed into a top tray of the cryostat. These upper trays were not in direct 
contact with the liquid nitrogen but the vapour is sufficiently cold that over a period 
of several hours a freezing rate equating to approximately 1°C per minute is reached. 
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Once frozen the vials could be placed into the desired cryostat cheese and recorded 
in a logbook. 
2.1.3 Thawing Cells 
For thawing vials, an 80cm2 tissue culture flask was prepared with 20m1 of pre-
warmed / pre-gassed media. Though later it was found a T25 flask produced a better 
recovery. The vial was rapidly thawed in a 370C water bath, until a pellet the size of 
a small pea remained. The vial was sterilised with 70% alcohol and then pipetted 
down the back of the flask to minimise any osmotic shock. Details labelled on the 
outside of the vial were transferred to the flask. E.g. passage number and date. 
2.1.4 Passaging 
All the media is removed from the flask and a volume of warmed trypsin sufficient to 
cover the bottom of the flask was added and used as a wash. A further volume is 
added and the flask is incubated at 370C. Once the cells begin to lift off a volume of 
warmed media equal to or greater than the volume of trypsin is added to neutralise its 
effects. Adherent cells can be encouraged into suspension by gently tapping the side 
of the flask. A volume of cell suspension can be returned to a freshly labelled flask, 
and 1 added to the number of passages made. At Berkeley flasks had vented caps 
and were placed into Perspex gassed boxes in hot rooms kept at a steady 37°C. At St 
Andrews all flasks had to be individually gassed using a 5% CO2 and airline with a 
sterile Pasteur pipette pushed onto the end on the line. Each flask would take 20-30 
seconds to gas. The line would have to swab each time it was used and a fresh pipette 
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used for each flask. Once gassed the flasks could be returned to a 37°C warm air 
incubator. 
2.2 HTori-3 Characterisation 
2.2.1 Growth Curve 
Exponentially growing cell were harvested and seeded at appropriate concentrations 
into small petri dishes. Dishes were incubated @ 37°C for up to three weeks. Two 
replicate dishes were counted daily and media changed after one week of growth. 
Counting the cells involved removing all media and adding a trypsin wash of a 
couple of mis. This was replaced by a further 2mls and the dishes were returned to 
the incubator for 5-10minutes. Lightly tapping the dish resulted in adherent cells 
being released from their substrate, these were pipetted up and down to ensure a 
single cell suspension resulted. Then, 500p,1 of this suspension was diluted in 
19.5mls of isotonic solution giving a 1:40 dilution. Four Coulter counts would be 
taken per dish, 500p1 was sampled by the Coulter on each count, so the sum of these 
counts equated to 2mls or 1120th of the total, multiplying the result by this factor gave 
the cellularity per ml of original suspension. 
2.2.2 Plating Efficiencies 
Plating efficiencies can be used to determine the number of cells that survive any 
cytotoxic insult. For example, it may be necessary to determine the percentage of 
cells that survive following passaging or a dose of irradiation. A sub-confluent S-
phase flask is harvested and a number of cells, proportionally to one cell per cm2, are 
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re-plated into a new flask. After two weeks of incubation, the media is decanted and 
the cells are stained. All the cells that were able to reproduce formed colonies and 
were termed viable cells; i.e. they have reproductive integrity. These cells are 
counted and divided by the number of cells originally plated. The value obtained is 
the percentage of viable cells able to survive following the experiment. When 
determining the plating efficiency for given doses of radiation cells die not only from 
the re-plating but also directly from the radiation. Thus, both types of cell death have 
to be accounted for before the surviving fraction can be calculated. All cultures are 
kept in Perspex boxes gassed with 5% carbon dioxide in air and keep at a constant 
temperature of 370C. Below are the equations used to calculate the above variables: 
PE = Mean / Actual number of cells plates 
VC = Actual number of cells plated x Plating Efficiency 
SF = Mean / Viable Cells 
PE =Plating Efficiency 
VC =Viable cells 
SF =Surviving Fraction 
2.3 Radiation Protocols 
2.3.1 X-Ray Irradiation 
The X-ray room at Berkeley contained a shielded Phillips 250 kVp X-ray Unit. 
Only authorised personnel were allowed to use this apparatus. Prior to irradiations 
the unit was warmed using a number of sequenced programs. Cells were plated in 
pre-warmed, pre-gamed media at 2x105 cells/per ml the day before irradiations and 
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allowed to settle. For collecting survival data a series of dose points were selected 
and the cells irradiated. 
	
2.3.1.1 
	 Acute irradiations 
Acute irradiations required the highest dose rate of 2 Gy/miiii. The flasks were 
placed in Perspex holder called a phantom, which was pre-warmed to 37°C in the hot 
room's overnight. A 1.2mm Aluminium and 0.3mm Copper (No2) filter was placed 
over the aperture of the X-ray tube and the phantom and flask is placed at position 
(No6) 50.2cm for the correct dose rate. Pre-programmed set-ups were used at 
1.31mA and 420kVp. Post-radiation the cells were again harvested and replated at 
an expected survival, taking into account cell death from the radiation. The cultures 
were left in the hot room for two weeks for the formation of cfu's (colony forming 
units). They were then stained with 15% Giemsa v/v or 50% methylene blue in tap 
water and counted under a light box. The survival and other variables could then be 
calculated. 
	
2.3.1.2 
	 Chronic irradiation 
Chronic irradiations used a 1.2mm Aluminium, 0.3mm Copper and 0.65mm Tin 
(No4) filter, the phantom was placed in position No12 (105.3cm). The chronic dose 
rate is 1Gy / hi''. The required doses were calculated by converting the dose into 
mGy and using a conversion table for the number of mA required. The current was 
set at 250kVp. 
63 
2.3.2 Strontium Irradiations 
2.3.2.1Yittrium/strontium-90 
Two Yittrium/strontium-90 sources were available at Berkeley Centre, which had 
nominal activities of 20 and 140 mCi (30/10/85). Handling of these sources was 
kept to a minimum while the culture dishes were placed in the units. Dosimetry 
estimates performed on the 21.11.94 show the low activity source to be 9.8Gy/hr-I 
and the high activity source to be 65.5 Gy/hr hr-1 From this it is possible to 
calculate the doses required for survival experiments. The protocol for this 
experiment followed the same procedure as for collection of plating efficiency data 
but included the irradiation of the flask of cells prior to their seeding. 
2.3.2.2 Hot Particle Irradiation 
Hot particle irradiations were performed at the Physics and Astronomy Department 
of Birmingham University. 30mm petri dishes were irradiated on a continuous, non-
uniform, strontium 60 point source. The dishes were harvested on return to Berkeley 
Technology Centre and replated at the appropriate concentration. A comparison of 
these survivals can be seen in the result section. 
2.3.3 Gamma Irradiation 
All gamma irradiations were performed at the Bute medical buildings at the 
University of St Andrew. Except for the making of feeder layers all irradiations were 
performed with the cells in suspension using the 137Cs IBL 437 y-irradiator at a dose 
rate of 4.6 Gy /min. Once trypsinised cell were kept on ice for the duration of the 
experiment, irradiated and then returned to ice. 
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2.4 Cellular Transformation Assay 
HTori-3 cells previously irradiated and frozen in liquid nitrogen at Berkeley 
Technology Centre (BTC) were now thawed and passaged in vitro. Initially cultured 
in a single T80 flask until sub-confluent, the flask was split into 5 further flasks, 
which were then kept separate for the duration of the in vitro period. The flasks 
were again grown to subconfluence, and passaged once a week for six weeks. Cells 
were then harvested at approximately 80% sub-confluence and around 1 million 
cells were injected sub-cutaneously into nude athymic mice for screening of a 
transformed clone. 
The athymic mice used for all injections were born at the St Andrew animal house, 
though the originally MF1 parental stock nu/nu were purchased from Charles River 
and sons in July 1998. The mice were kept under aseptic conditions being fed and 
watered three times a week and bedding changed weekly. An ambient room 
temperature of 22.3°C was maintained with a 12-hour diurnal fluorescent light cycle 
being automatically maintained. Outside air was filtered and warmed before being 
vented to the room. 
The cells to be screened were harvested using standard trypsination protocol. The 
cells were re-suspended in a 30m1 universal tube containing 10mls of media. 500µ1 
of the stock was counted in 19.5mls of Isoton using a ZM series electronic Coulter 
counter. The required volume to give 1.0 x 10 6 cells was calculated and removed to 
a fresh universal. The vial was the spun at 10,000 rpm in a cryo-centrifuge for 10 
minutes. The supernatant was discarded and the pellet resuspended in the residual 
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media (approximately 250µ1). The concentrated cell solution was sucked into a 
sterile lml syringe with a 21-gauge needle ready for injection. The procedure was 
repeated for each flask. The syringes and their content were removed from the tissue 
culture laboratory to the animal house ready for injection. The mice, which were 4-6 
weeks old and were of both sexes were individually swabbed on their backs with 
70% alcohol and immediately inoculated with the entire volume of the syringe. 
Approximately one million cells. The mice were returned to their boxes and checked 
twice weekly for tumour formation, any swelling was graded with the use of steel 
ball (Riches and Thomas 1970) bearing as a comparison. The sizes were recorded on 
data sheets and used to plot tumour growth and volume over time. Once the 
swellings had reached grade 5 or 6, approximately 1 cm, the mice were sacrificed by 
cervical dislocation and the lump excised. Half the volume was placed on a small 
strip of filter paper and placed into a volume of formal saline (1:19 formaldehyde 
and NaCl2) in a universal tube. This was promptly sent for histological examination 
and the remaining prepared for return to in vitro tissue culture. 
2.4.1 Establishment of Tumour cell lines 
Mice that had grown tumours of grade 5 or greater were suitable for the tumour to be 
excised and established in vitro. The mice were sacrificed by dislocating the cervical 
vertebrae. A pinching technique was employed while the mice were stretched on the 
cage lids. The tumours were swiftly dissected after death and any connective tissue 
was trimmed away in a petri dish. On occasion the dermal tissues were adherent, 
these were left in situ for histological examination. The tumour, roughly the size of a 
pea, and crunchy when sliced were first cut in half using a sterile scalpel. One half 
for histology the other half was for establishment of the cell line. This second half 
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was cut into small cubes, approximately 1mm3, these were placed into a universal 
with a few drops of standard HTori-3 media. Taken to a laminar flow hood a T25 
flask was pre-warmed and pre-gassed with 5mIs of media. The cubes of tumour 
tissue were sucked up using a sterile Pasteur pipette and rubber bulb. This permitted 
the cubes to be carefully placed inside the bottom of the flask. 
Once all the pieces had been arranged the flask was carefully placed into a 37°C 
incubator to allow the explants to adhere and infiltrate to the floor of the flask. 
Initially the flask was left untouched for seven days, though observed daily for any 
signs of infections. After this time the flask could be viewed under a platform 
microscope for signs of growth. If the explants showed signs of growth then the 
media could be changed. After 2-3 weeks of incubation subconfluence would be 
reached and the cultures could be passaged into larger flasks. Chromosome banding 
and metaphase spreads were then performed to correctly identify the tumours as 
HTori-3 in origin. Eventually, stocks of the cells could be frozen and stored in liquid 
nitrogen for future use. 
2.4.2 Identification of tumour cell lines 
To confirm that the tumours grown in the nude mice were derived from the irradiated 
HTori-3 cells injected, karyotype analysis of metaphase spreads was performed. The 
protocol for metaphase spreads is as follows. Glass slides are cleaned to remove any 
traces of dirt or grease. The are immersed in 1M HCI for 1 hour and then rinsed in 
molecular grade water and finally dipped in 100% ethanol and stored at 4°C. Log 
phase cells are treated with 0.04µg/ml of colcemid and left for 4 hours to arrest the 
cells in metaphase. Colcemid prevents the formation of microfilaments, so as cells 
progress through the cell cycle the chromosomes condense but once they reach 
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metaphase they are prevented from progressing any further. Cells are trypsinised as 
usual and then pelleted at 2,000 rpm in a cryocentrifuge chilled to 4°C. The 
supernatant is discarded and the pellet re-suspended in the residual volume. 5mIs of 
0.075M KCI (0.55g/100m1) solution is then added dropwise to the centrifuge tube 
and then left for up to 5minutes to incubate at room temperature. This solution is 
hypotonic to the cellular environment and results in the influx of water by osmosis; 
the cellular compartment expands and eventually ruptures. The suspension is spun 
again and the pellet of nucleolei is washed with Carnoy's fixative or lml of 3:1 
ethylalcohol: glacial acetic acid. The procedure is repeated and then remaining pellet 
is re-suspended in a small volume of fixative. The nucleolei are then draw up into a 
clean Pasteur pipette and dropped onto the cooled slides. The slides are held at an 
angle of 45° increasing the shearing force upon the nucleolei as they impact; this 
improves the chance of complete rupture of the nuclear matrix and favourable 
deposition of the metaphase chromosomes. Slides are air dried for 15minutes @ 
37°C then stained with 5% giemsa in tap water v/v. Once rinsed and air-dried the 
slides were viewed using oil immersion at x 100 magnification using a light 
microscope. 
2.5 	 Cellular Characterisation of Tumour Cell Lines 
2.5.1 Apoptosis — DNA Fragmentation Detection Kit 
Delayed colony assays performed over 6Gy showed the expression of delayed cell 
death. This was exemplified by 
1. Decreased numbers of colony units and /or 
2. Small colony formation 
The reasons for this phenomenon were not clear. There were two possible reasons; 
68 
There had been an increase in the cell cycle time resulting in fewer cell divisions 
throughout the incubation time. 
The duration of the cell cycle was unchanged but there could be an increase in the 
levels of apoptosis. 
Initially, growth curves were produced, these showed that the cells expressing the 
DLD appeared to have fewer cell division as the growth curves showed a trend down 
and to the right of the control cultures. However, it was possible that the levels of 
cell division were similar in both cultures but that there was a higher frequency of 
cell death in those cells expressing DLD. To prove this hypothesis a DNA 
fragmentation protocol was employed to investigate differences in the levels of 
apoptosis between the two cultures. 
Although cell death has been shown to occur through necrosis and apoptosis, it has 
been assumed that necrotic cell death would have occurred almost immediately in the 
post-irradiated cultures. As necrosis will only occur through structural and 
mechanical damage resulting in gross deformities and cell lysis, of which the cell has 
no control over. Whereas apoptosis is a controlled process which occurs over a 
period of hours with specific stages and is part of normal developmental process 
involved in cellular differentiation and control of cell numbers. A number of 
molecular cascades are involved which includes the cleavage of DNA into 
oligonucleosomes detectable through pulse field gel electrophoresis. 
2.5.1.1 Principle of Tunel 
Terminal deoxynucleotidyl transferase (TdT) binds to exposed 3'-OH ends of DNA 
fragments which catalyses the addition of biotin-labelled and unlabeled 
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deoxynucleotides. Biotinylated nucleotides are then detected using a streptavidin-
horseradish peroxidase (HRP) conjugate. Diaminobenzidine reacts with the labelled 
sample to generate an insoluble coloured substrate at the site of DNA fragmentation. 
Counter-staining with methyl green aids the morphological evaluation and 
characterisation of normal and apoptotic cells. 
2.5.1.2 Materials Supplied 
Proteinase K 2mg/m1Proteinase K in 10mM Tris pH 8.0 
5X TdT Equibration buffer 1mM Sodium Cacodylate, 0.15M Tris, 1.5mg/mi BSA, 
3.75 mM CoCl2, pH 6.6 
TdT labelling reaction mix - 3 vials of labelled and unlabelled deoxynucleotides 
TdT Enzyme Terminal Deoxynucleotidyl Transferase 
Stop Buffer 0.5M EDTA, pH 8.0 
Blocking Buffer 4% BSA in PBS 
50X Conjugate Peroxidase streptavidin conjugate 50-fold concentrated solution. 
DAB tablets 3,3' Diamionbenzidine (0.7mg/tablet) 
H202/Urea tablets - H202/urea (0.6mg/tablet) 
Methyl green counterstain 0.3% methyl green 
Control Slides: HL60 promyelocytic leukaemia cells and HL60 cells incubated with 
0.5µg/m1 actinmycin D for 19 hours to induce apoptosis; 2 slides per kit. 
2.5.1.3 Extra Materials 
1 X Phosphate Buffered Saline 
4% Formaldehyde (in 1 X PBS) 
10mM Tris pH 8.0# 
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Distilled water 
Coplin jars / glass slide holders 
Wash bottle for rinsing slides 
Humidified chamber 
Glass cover slips 
Mounting media 
Microscope 
Pipettes 
Microcentrifuge and tubes 
Parafilm and wipes 
Ice 
2.5.1.4 Recommendations 
All reagents should be kept at —20°C and should be pulse spun prior to use. 
DAB is a potential carcinogen and Cacodylic acid is toxic and a carcinogen 
2.5.1.5 Suggested Protocol 
The protocol can be broken into these stages: 
1 	 Preparation and pelleting of cells 
2 	 Cytospin cells 
2 	 Permeabilization of specimen 
3 	 Inactivation of endogenous peroxidases 
4 	 Equilibration and labelling reaction 
5 	 Termination of labelling reaction 
6 	 Detection 
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7 	 Counterstain 
1. Trypsinise and pellet cells, 2-3x10E6, then cytospin cells onto slides. To fix the 
specimen, immerse the slides in 4% formaldehyde (in 1X PBS) for 15 minutes at 
room temperature. Dry, then immerse in 1X TBS for 15 minutes at room 
temperature. Mark specimen on slide from underside. 
2. To permeabilse the cellular membrane dilute 2mg/m1 proteinase K 1:100 in 
10mM Tris pH 8.0 (mix 10 of 2mg/m1 Proteinase K plus 99µ1 10 mM Tris per 
specimen). Cover entire specimen with 50-1000 of 20µg/proteinase K. 
Incubate at room temperature for 10 minutes. (Do not over incubate.) 
3. Dip slides 2-3 times into a beaker of IX TBS. Gently tap off excess liquid and 
carefully dry the slide around the specimen. 
4. To inactivate endogenous peroxidases dilute 30% H202 1:10 in methanol (mix 
10µI 30% H202 with 90111 of methanol per solution) 
5. Cover entire specimen with 100µ1 of 3% H202. Incubate @ room temperature 
for 5 minutes. Do not over incubate. Then rinse slide with 1X TBS 
6. For equilibration of labelling of reaction dilute 5X TdT equilibration buffer 1:5 
with d1120 (mix 201.d 5X buffer with 80p1 of dH2O per specimen). 
7. Cover entire specimen with 100111 of lx TdT equilibration buffer. Incubate at 
room temperature for 10-30 minutes while preparing end labelling reaction 
mixture. Alternatively slides can be immersed in a Coplin jar containing 1X 
TdT. 
8. Preparation of the TdT labelling reaction mixture is as follows: Lightly vortex 
contents of the TdT labelling reaction mix tube, pulse spin the TdT enzyme tube 
in a microcentrifuge prior to opening, transfer to a fresh tube for each specimen 
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57 µI TdT labelling enzyme reaction mix and 3µI of TdT enzyme, mix gently and 
keep on ice. 
9. Carefully blot the lx TdT equilibration buffer from the specimen, taking care not 
to touch the specimen. Immediately apply 60µ1 of TdT labelling reaction 
mixture (prepared above) onto each specimen and cover with a coverslip and 
then with parafilm cut larger than the specimen 
10. Place the slides in a humidified chamber and incubate @ 37°C for 1.5 hours 
11. To terminate the labelling reaction remove the parafilm and coverslip and rinse 
the slide in 1X TBS, however if a precipitate is present first prewarm the Stop 
Buffer @ 37°C for 5 minutes. Cover the slide with 1000 of Stop Buffer and 
incubate @ room temperature for 5 minutes. Rinse the slide with lx TBS and 
gently dry around the specimen. 
12. For the detection phase cover the specimen with 100µI of Blocking Buffer and 
incubate for 10 minutes at room temperature. Then dilute the 50X conjugate 1:50 
in Blocking Buffer (min 2111 50X conjugate with 98µI of Blocking Buffer per 
specimen.) 
13. Carefully blot around the specimen and immediately add 100111 of diluted 1X 
conjugate to the specimen. Place the slides in a humidified chamber and incubate 
for 30 minutes. 
14. Five minutes prior to the incubation prepare DAB solution by dissolving one 
tablet of DAB and one tablet of H202/Urea in 1ml of tap water. This yields 
enough Dab solution for 10 specimens. Tap water contains metal ion which aids 
the staining. 
15. Rinse slides with 1X TBS, tap and dry around specimen and cover slide with 
100111 of DAB for 10-15mintes before rinsing with distilled water. 
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16. To Counterstain add 100µl of the methyl green counterstain solution and 
incubate for 3 minutes. 
17. Press edge of slide against absorbent paper and dip slide 2-4 times in 100% 
ethanol 
18. Blot and repeat with fresh 100% ethanol 
19. Blot and repeat with xylene, wipe away excess from back of slide and mount a 
coverslip over the specimen. 
2.5.1.6 Interpretation of Results 
A dark brown DAB signal indicates an apoptotic cell while shade of blue-green to 
greenish tan signifies a non reactive / normal non apoptotic cell. Morphology as well 
as the degree of stain can be used to interpret the degree of apoptosis in a cell 
population. Many apoptotic cells are pyknotic (dark bodies), a blebbing and budding 
cell membrane morphology is common. Apoptosis is asynchronous and members 
will be randomly distributed throughout the slide whereas necrotic cells will tend to 
occur in-groups. Cytoplasmic and diffuse staining is often seen in necrotic cells due 
to loss of membrane integrity. 	 Oncogene Research Products: TdT- 
FragEL Tm 
2.5.2 MTT Cell Attachment Assay 
MTT reduction assay is a widely used technique for the measurement of cell viability 
(Mosmann, 1983). It is a rapid colourmetric assay for cellular growth and survival 
and has application to proliferation and cyto-toxicity assays. 
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MTT is a water soluble tetrazolium dye that is reduced by living but not dead cells to 
a purple formazan product that is insoluble in aqueous solutions. The assay has been 
shown to give the same results as the standard colony assay. Cells are incubated in 
square, flat-bottomed microtitre plates. Once the cells are adherent to the substrate, 
usually this takes no more than a couple of hours, 50111 of MTT can be added to each 
well using a multichannel pipette. Plates are wrapped in aluminium foil and 
incubated in the dark for a minimum of 4 hours and maximum of 8. After the 
appropriate incubation time the media is removed from the plate with a flicking 
action into a sink. The water insoluble MTT-formazan crystals are dissolved in 
DMSO and adjusted to pH 10.5 with Sorensen's Buffer. The optical density of each 
well are quickly read in an ELISA plate reader. 
2.5.2.1 Materials 
microtitre plates (Flat bottomed) 
Growth Media 
Ependorf Tips 
Petri dishes 
Trypsin 
Sorensen's glycine buffer (0.1M glycine, 0.1M NaC1 adjusted to pH10.5 with 1M 
NaOH) 
MTT (3-(4-5-dimethyliazol-2-yl)-2,5-diphenyltetrzolium bromide 50mg/m1 (Sigma) 
Multichannel pipette (Costar) 
Dimethyl Sulphoxide (DMSO) 
ELISA plate reader (BioRad, ICN—flow) 
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2.5.2.2 Suggested Protocol 
1. A sub-confluent Nunc T80 flask of cells is harvested using the routine method. 
2. A sample is counted and the remaining pelleted @1000rpm for 5 minutes 
3. The pellet is resuspended in fresh media and serial dilutions are made so that 
each well contains 200111 of media and cell suspension. 
4. All plates are placed in a warm 37°C wet incubator to permit attachment. 
5. After a couple of hours the plates are removed from the incubator and a fresh 
aliquot of 501,i1 of MTT is added to each well using a multichannel pipette 
6. The microtitre plates are then wrapped in aluminium foil and replaced in the 
incubator for a minimum of 4 hours. 
7. Remove the media and add 2001..d of DMSO then 25µ1 of Sorensen's buffer and 
read immediately, absorbency is recorded at 570nm 
8. The first and last wells in the plate are used as blanks and just contain media. 
2.5.2.3 Interpretation of Results 
All plates were scored using an ELISA plate reader programmed with the appropriate 
details of plate size and wavelengths and other variable. Plates were automatically 
shaken for 15 seconds to enhance the distribution of the blue colour produced by the 
reduction of the MTT dye by the active cells. The plates were then read with the 
photospectrometer and results printed out for each well. This assay has application 
for the determination of cellular radiosensitivity as well as the screening of cytotoxic 
and metabolic drugs in the use of predictive testing e.g. for cancer therapies. 
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2.6 Molecular Characterisation Techniques 
2.6.1 DNA Extraction Protocol 
DNA is extracted from samples using puregene reagents. A sub-confluent flask is 
harvested and centrifuged at 13000g (14000rpm) for 5 seconds to pellet the cells. 
The supernatant is discarded and the pellet re-suspended in the residual media by 
vigorously re-suspending it using a vortex. 0.6m1 of lysis agent is added. This can be 
added directly to the flask without trypsination. The samples are stable in lysis 
solution for up to 18 months. 0.03m1 of RNAse solution is added and incubated for 
15-60 minutes at 37°C. 0.2ml of protein precipitation solution is then added and 
vortexed for 20 seconds and centrifuged at 13000g for 3 minutes. The protein pellet 
is discarded and the DNA supernatant is washed twice with 0.6mls of isopropanol. 
The sample is inverted 50 times until the DNA threads appear. The sample is then 
re-spun at 13,000g and washed in 0.6mls of 70% ethanol. This is decanted and the 
pellet air-dried. 0.1m1 of DNA hydration solution is added to allow the DNA to 
rehydrate, either overnight or for lhr at 65°C in an oven. DNA concentration was 
calculated using a spectrophotometer at Berkeley. 
2.6.2 Polymerase Chain Reaction: PCR 
The first PCR reaction was performed by Saiki et al (1985), though others had 
previously described the reaction in the 1970s. The principle of PCR relies on the 
intrinsic properties of DNA its ability to form single strands and the properties of the 
thermal stable polymerase enzyme Taq. The reaction can be split into four distinct 
stages. 
1. 	 Denaturing @ 95°C 
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2. Annealing @ 55°C 
3. Polymerisation @ 72°C 
4. Final extension @ 72°C 
The Polymerase Chain Reaction is a rapid and relatively simple way to amplify 
genes. Small amounts of DNA, down to nanogram quantities can be used. 
Primarily, the sample is denatured by heating to 95°C; double stranded DNA is split 
into its single stranded form. Short sections of single stranded DNA analogous to the 
starting and finishing sequences of the gene of interest, called primers, are then used. 
Primers can be purchased commercially on a per base basis. The reaction is cooled to 
50-60°C the temperature at which the primers will bind to any complementary 
sequence. In the presence of excess nucleotides, Mg" and the polymerisation 
enzyme Thermus aquaticus (Taq) the temperature increases to 72°C to permit 
polymerisation from the site of the primer. 
Extension occurs continuously along the strand of DNA until the temperature is 
increased to 95°C and the reaction is arrested. These first copies of the gene will 
extend beyond the site of the complementary primer; there is no limit to amount of 
polymerisation on the original template. 
	 However, in subsequent cycles 
complementary primers bind to the newly polymerised strands as readily as the 
original template. The next new sequences will have a finite length; i.e. will only 
polymerise as far as the end of the strand. These shorter strands will also act as 
template for the next round of replication and will predominate exponentially in the 
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reaction. Far fewer copies of the longer original template will be copied in 
comparison to these shorter gene sequences. 
Through this series of heating and cooling steps the double stranded DNA is broken, 
primers anneal and polymerisation occurs. In this way a gene sequence may be 
duplicated many millions of times. At the end of 30-40 cycles the amplified product 
can be finally extended for 5 minutes at 72°C for double stranded DNA to reform 
(see table 2.1 and 2.2). The product can then be cooled to ambient and run on a 2-
3% agarose gel and its size determined. 
2.6.2.1 PCR of p53 gene 
All components were rapidly thawed in the hand and pulsed in a microcentrifuge 
prior to being pipetted onto the side of a clear 1000p,1 thin walled reaction tube. 
Thin walled reaction tubes permit rapid temperature exchange to the inside of the 
reaction vessel and thus its contents. All amplification reactions were placed into 
the 96 well block of a Techne Gene E thermocycler, a heated lid which prevented 
excessive evaporation. 
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Table 2.1 Listed are the components required for PCR amplification of gene 
fragments amplified from genomic DNA template. Included is the stock 
concentration as well as the final reaction concentration. The sequence in which 
each component is added is also included. 
Component [Stock] Volume [Final] 
Order of 
addition 
PCR Buffer 10X 10n1 1X 2 
dATP stock 10mM 24.11 200pM 3 
dCTP stock 10mM 2p1 200µ1V1 4 
dGTP stock 10mM 2µ1 200µM 5 
dTTP stock 10mM 2µ1 200u1V1 6 
MgC12 25mM 4µ1 1mM 9 
Primer A 0.04nm 5p1 400nM 7 
Primer B 0.04nm 5µi 400nM 8 
DNA template 1 ug/101.11 10p,1 1p,g/100µ1 10 
Taq 5 Units/p1 0.5p,1 2.5U/100µ1 11 
H2O - 57.5p1 1 
TOTAL 100µ1 
When making up a reaction it became helpful to make master mixes where all the 
reagents were pipetted into a single ependorf. The required volume was removed 
into a fresh reaction vessel and the separate primers for each exon of the gene were 
pipetted individually. 
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Table 2.2 Example of Cycling Constraints. Each pair of primers requires its own 
cycling constraints. These can be determined in part from equations pertaining to the 
base sequence of the primer. The size of the fragments is also important in 
determining the correct ramp rate. 
Initial 
Denature Denature Anneal Extend 
Final 
Extension 
Time lmin lmin 30 Sec 30 Sec 30 Sec 
Temperature 94°C 94°C 55°C 72°C 72°C 
# Cycles 1 30 30 30 1 
Figure 2.1 Below is the entire DNA sequence of the amplified regions of the p53 
gene and the Alu repeat sequence. Each pair of primers is coloured red and the 
amplified section is blue. The size of each exon in base pairs is listed next to DNA 
fragment. P53 sequences were amplified to test for the presence of DNA mutations, 
while the Mu repeat sequence was amplified to compare changes in the length of 
repeat sequence between the different tumour cell lines 
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Amplified Exon Regions of p53 Gene 
12061 ccccggacga tattgaacaa tggttcactg aagacccagg tccagatgaa gctcccagaa 
12121 tgccagaggc tgctccccgc gtggcccctg caccagcagc tcctacaccg gcggcccctg 
12181 caccagoccc ctuctggccc ctgtcatctt ctgtcccttc ccagaaaacc taccagggca 
12241 gctacggttt ccgtctgggc ttcttgcatt ctgggacagc caagtctgtg acttgcacgg 
12301 tcagttgccc tgaggggctg gottccatga gacttcaatg cctggccgta tccccctgca 
12361 tttcttttgt ttggaacttt gggattcctc ttcaccctta ggcttcctgt cagtgttttt 
12421 ttatagttta cccacttaat gtgtgatctc tgactcctgt cccaaagttg aatattcccc 
12481 ccttgaattt gggcttttat ccatcccatc acaccctcag catctctcct ggggatgcag 
12541 aacttttctt tttettcatc cacgtgtatt cottggcttt tgaaaataag ctectgacca 
12601 ggcttggtgg ctcacacctg caatcccagc actctcaaag aggccaaggc aggcagatca 
12661 cctgagcccc aggagttcaa gaccagcctg ggtaacatga tgaaacctcg tctctacaaa 
12721 aaaatacaaa aaattagcca ggcatggtgg tgcacaccta tagtcccagc cactcaggag 
12781 gctgaggtgg gaagatcact tgaggccagg agatggaggc tgcagtgagc tgtgatcaca 
12841 ccactgtgct ccagcctgag tgacagagca agaccctatc tcaaaaaaaa aaaaaaagaa 
12901 aagctcctga ggtgtagacg ccaactctct ctagctcgct agtgggttgc aggaggtgct 
12961 tacacatgtt tgtttctttg ctgccgtgtt ccagttgctt tatcLgttca cttgtgccct 
13021 gactttcaac tctgtctcct tcctcttcct acagtactcc cctgccetca acaagatgtt 
13081 ttgccaactg gccaagacct gccctgtgca gctgtgggtt gattccacac ccccgcccgg Exon 5 
13141 cacccgcgtc cgcgccatgg ccatctacaa gcagtcacag cacatgacgg aggttgtgag 274 Bp 
13201 gagctgcccc caccatgagc gctgctcaga tagcgatggt gagcagclgg ggctggagag 
13261 acgacagggc tggttgccca gggtccccag gcctctgatt cctcactgat tgctcttagg 
13321 tctggcccct cctcagcatc ttatccgagt ggaaggaaat ttgcgtgtgg agtatttgga Exon 6 
13381 tgacagaaac acttttcgac atagtgtggt ggtgccctat gagccgcctg aggtctggtl 199 Bp 
13441 tgcaactggg gtctctggga ggaggggtta agggtggttg tcagtggccc tccgggtgag 
13501 cagtaggggg gctttctcct gctgcttatt tgacctccct ataaccccat gagatgtgca 
13561 aagtaaatgg gtttaactat tgcacagttg aaaaaactga agcttacgag gctaagggcc 
13621 toccctgatt ggctgggcgc agtggctcat gcctgtaatc ccagcacttt gggaggccaa 
13681 ggcaggcgga tcacgaggtt gggagatcga gaccatcctg gctaacggtg aaaccccgtc 
13741 tctactgaaa aatacaaaaa aaaattagcc gggcgtggtg ctgggcacct gtagtcccag 
13801 ctactcggga ggctgaggaa ggagaatggc gtgaacctgg gcggtggagc ttgcagtgag 
13861 ctgagatcac gccactgcac tccagcctgg gcgacagagc gagattccat ctcaaaaaaa 
13921 aaaaaaaaag gcotcccctg cttgccacag gtctccccaa ggcgcactgg cctcatcttg 
13981 ggcctgtgtt atctcctagg ttggctctga ctgtaccacc atccactaca actacatgtg Exon 7 
14041 taacagttcc tgcatgggcg gcatgaaccg gaggcccatc ctcaccatca tcacactgga 193 Bp 
14101 agactccagg tcaggagcca cttgccaccc tgcacactgg cctgctgtgc cccagcctct 
14161 gcttgccgct gacccctggg cccacctctt accgatttct tccatactac tacccatcca 
14221 cctcttatca catttccggc gggaatctcc ttactgctcc cactcagttt ccttttctct 
14281 ggctttggga cctcttaacc tgtggcttct cctcccacct cctggagctg gagcttaggc 
14341 tccagaaagg acaagggtgg ttgggagtag atggagcctg gttttttaaa tgggacaggt 
14401 aggacctgat ttccttactg catcttgctt ctcttttcct atcctgagta gtggtaatct 
14461 actgggacgg aacagctttg aggtgcgtgt ttgtgcctgt cctgggagag accggcgcac Exon 8 
14521 agaggaagag aatctccgca agaaagggga gcctcaccac gagctgcccc cagggagcac 223 la 
14581 taagcgaggt aagcaagcag gacaagaagc ggtggaggag accaagggtg cagttatgcc 
14641 tcagattcac ttttatcacc tttccttgcc tctttcctag cactgcccaa caacaccagc 
14701 tectotaccc agccaaagaa gaaaccactg gatggagaat atttcaccct tcaggtacta 
14761 agtcttggga cctcttatca agtggaaagt ttccagtcta acactcaaaa tgccgttttc 
14821 ttcttgactg ttttacctgc aattggggca tttgccatca gggggcagtg atgcctcaaa 
14881 gacaatggct cctggttgta gctaactaac ttcagaacac caacttatac cataatatat 
14941 attttaaagg accagaccag ctttcaaaaa gaaaatagtt aaagagagca tgaaaatggt 
15001 tctatgactt tgcctgatac agatgctact tgacttacga tggagttact tctgataact 
15061 cgtcgtaagt tgaaatattg aaatattgta agttgaaaat ggatttaata cacctaatct 
15121 aaggaacatc atagcttagc ctagcctgct tttttttttt tttttttttt ggagacagag 
15181 tctcactctg ctacccaggc tggagtgcag tggcgggatc tcggctcact gcaacctccg 
15241 ccttctgggt tcaagcgatt ctcctgcctc agcccactga gtagctggga ttacaggcac 
15301 ctgccccgac gcccagctaa ttttttgtta tttatttcct ttttttttag tagagataga 
15361 atttcaccat gttggccagg ctagtctcga actcctgacc ttgtgatctg cctgccttgg 
15421 cctcccaaag tgctgggatt acaggcgtga gccaccgcac ctggcctgcc tagcctactt 
15481 ttattttatt tttaatggag acagcatctt gctctgttgc ccaggctgga ttacagtgat 
15541 gtgatcatag ctcattatac cctcctgggc tcaagcaatc cccctaactc tgcctoccca 
15601 gtagctagga ccacaggcat acaccaccat acccagctaa tttttaaaat tttttgtaga 
15661 tagatagagt ctcactatgt tgcccaggct ggtctctagc ctactttttt gagacaaggt 
15721 cttgctctgt cacccaggct ggatagagtg cagtagtgca gtcacagctc actgcagcct 
15781 ccacctecca ggctccatcc atcctcccag ctcagcctcc caagttgctt caactacagg 
15841 cctgcaccac catgcctggc taatttttat ttatttattt ttattttatt ttattttatt 
15901 ttttgagact cagtctcact ctgtcgoctt aggctggagt gcagtggcat gatctcggct 
15961 cactgctaac ctctgcctcc tgggtttcaa gtgattctcc tgcctcagcc tcccgaatag 
16021 ctaggactac aagcgcctgc taccacgccc ggctaatttg tgtattttta gtagagacag 
16081 ggtttcacca tgttggccag gctggtctcg aacttctgac catgtgatcg ccgoctaggc 
16141 ctcccaaagt gctgggatta caggtgtgag ccaccacgcc cggctaattt ttatttattt 
16201 atttaaagac agagtctcac tctgtcactc aggctagagt gcagtggcac catctcagct 
16261 cactgcagcc Ltgacctccc tgggctccgg tgatttcacc ctcccaagta gctaggacta 
82 
Mu repeat Polymorphism of p53 gene 
7141 aaaaaaaaaa aaaaaaagga aagaaaaaaa ataacgatta gaaaggaaga aatcaaacac 
7201 attcacagcc agtatgattc tatacataCC atggtcctaa tggggCcagg cgtggtggct 
7261 catgctgtaa tcctagcact tttaggaggc tgaggcaggt ggcttccctg ggaccagctg 
7321 gccaacatgg tgaaacccca actctaataa aaatacaaaa aatcagccag gcgtggtgag 
7381 ggcacctcta atcccagcta ctcaggaggc tgaggcagga gaattgcttg gacctcaggag 
7441 gcagaggttg cagtgagccg agatcgcgCt attgcactcc agcctgggca acaagagtga 
7501 aactccggca gggtgtggtc ttacgcctgt aatcccagca cttcgggagg ctgaggcagg 
7561 ccgatcacct gaggtcagga gtttgagacc aacctaacat ggtgaaaccc Cgtotatact 
7621 aaaaatacaa gaattagctg ggtgtagtgg tgggcgcctg taataccagC tacttgggag 
7681 gctgagacag aagaattgct tgaacccagg aggtggaggt tgcagtgagc tgagatCatg 
7741 ccattgcaca ccacgccggg caacagagcg agattccgtc tcaaaaaaaa aaaaaagatg 
7801 aaactctatc tcaaaaaaaa aaaaaagtcc taatggaaaa tccataaaaa gctaccaaaa 
7861 ctaataaata aatatagcag ggttgcaggt tacagggCaa tatagttatc cctotatctg 
7921 taggggcttg gttctgggac tcctcacaca ccaaacccac agatgtctaa gtcccatata 
7981 taagacggaa tagtatttaa cctacacata tcctcccata tagtttaaat tatctagatt 
8041 acttacatta cccccataca atgaaaatgc taatgtacat gcaagtatgt atgtaagtac 
8101 ttgtactata ttgtttaggg aatcactgga Cagataggcc ttcaagactg ataccagcag 
8161 ccactgttaa gattctggtc aggectgccc ctgtttgggg tctcagttga tctcattgcc 
8221 ttcccaccca gccaagggca cctgcattte tcttggctcc ctggccattt ggaaggCCta 
8281 gttcagcctg gcacatttgt atcctggccc aCtgatgctg gtacCaCtgg gaaggtcctg 
8341 ctctgaaaaa cacggagatt ttagttgcta ctgaagattt gagagataaa gacagggaga 
8401 cctgtctgta gacctgtgtc cctccaagtg ggattgagac tttgggcccc ccatttcagg 
8461 acagcacctc ctggcctgtt gactgaatag atccctgaag gaggtgtagt tgcattttag 
8521 gagtgggggt gggagcagta ccactgatcc gcactaacaa tcacacagtt ctctctagaa 
8581 taataatata gaacaagtga aatagaacaa ttgcagaaag agctaacctt tgttgagctc 
8641 ttactgtgtg cccagcactt tcctcaactc tacatttccc ataatacata gagtactagg p53ivsla 
8701 taggcgaggc ttgagggctC acgcctgtaa tcccagcact ttaggaggcc aaggggggtg 
8761 gatcacctga ggtagggagt tCaagaccag cctgactaac atggtgaaaC cccgtctcta 
8821 ctagaagtac aaaattagcc aggtgtggtg gcacatgctt gtagtcctag ctactcagca 
8881 ggctgaggca ggagaatcat ttgaatccgg gaggaggttg cagtaagcgg agatagtgcc ALE3 
8941 actgtactcc agcctgggCa ataagagctg agactccgtc tcaaaataaa ataaaataaa 
9001 ataaaataaa ataaaataaa ataaaaaaag aaaagagcct gccattaaag gagctgtttg p53ivalb 
9061 gtaggggatg ttttgtcagt gcaaacaaca gaaaagtggg ctgggcacag tggttcatgc 
9121 ctgtaatccc agcactttgg gaggccaagg cgggaggatc acctgaagtt gggagttcaa 
9181 gaccagcctg accaatatgg agaaaccccg tctctactaa aaatacaaaa ttagccgggc 
9241 gcagtggccg atgcctgtaa tcccagctac tcgggaggct gaggcaggag aatcgcttga 
9301 acctgggagg cagaggttgc ggtgagccga gatcgcacCa ttacactcca gcctggacga 
9361 gagcaaaact ctgtctcaaa aaaaaaaaaa aacagaaaag tgtaacaaac acttacagta 
9421 ggcatgtttc ttagcaaatc tgatgacaaa tttggcataa agaaagagag catccctgaa 
9481 aaaaaaaaaa aaaaaaaaaa agagagcatc ctgcctgggc aacatagtga aaccctgcct 
9541 ctacaaaaaa actcaaaaat tggccgggtg cagtggctca cacctgtaat cccagcactt 
9601 tgggagtcgg aggegggagg atcacctgaq gtcaggagtt cgaaaccagc ctggccaaca 
9661 tggcaaaacc ccatctctac taaaaataca aaaaattaat caggcgcatt ggtgggcgcc 
9721 tgtaatccca gctactcagg aagttgaggc aagaggatcg cttgatactg ggaggtggag 
9781 gttacagtga gtcgagatca caccactgca ctctagcctg ggtqacaggg cgagactccg 
9841 tctccaaaaa aaaaaagaaa aagaaaaaga ctaaaaaatt agccaggcag gcctctgtgg 
9901 tcccagctac ttgggaggct gaggcaggag aatcactgag cccaggagtg gcaggctgta 
9961 gtgagccatg attgcaccac tgtaccctag Ottaggcttg aaagcaagac cctgcctcaa 
10021 aagaaaaaag aaagaaagaa agaacatggc gggccaggca cagtggctca cacctgtaat 
10081 cccagcgctt tgagaggccg aggcaggtgg atcacaaggt caggagttcc acaccagcct 
10141 ggccaacatg gtgaaaccct gtctctacta aaaatacaaa aaatcagcag gcagggtggt 
10201 aggggcctgt aatcccagct actcgggagg ctgaggcagg agaattgctt gaaaccagaa 
10261 ggcagaggtt gcagtgagcc tagactgcac cactgcactc cagcctgggc gaaaagagcc 
10321 aaactccatc tcaaaaaaaa aacaaaaaaa caaaacaaaa aaaaacatgg cagcctttga 
10381 aagcttgtct gggagaaggt gcgatgatgg ttgcataact tcgtgcaaga tgctggtcca 
10441 cacaggggct gccccttgct ctttctcgct ctcttaacct ctcatataac aggcttgtgt 
10501 gttatgcaca tttattgagc ccaagcaggt gcaaggcatt gtgatctaat actttggtca 
10561 gcaagacaac aagatagatc actgccctgc ccttaggaag tgtatatgct attagaggaa 
83 
2.6.3 RFLP - Restriction Fragment Length Polymorphism 
RFLP is useful technique that can be used to identify mutations in a known gene 
sequence. A number of enzymes are available which will restrict DNA at specific 
nucleotide sequences. DNA is isolated from irradiated cells and then using PCR the 
gene sequence of interest can be amplified. Then restriction endonucleases can be 
used to digest the product. A mutation at a known site will prevent restriction and a 
variance in DNA length compared to a control sample will result when run on an 
agarose gel. To identify the exact site of the mutation the gene usually has to be 
sequenced. 
2.6.4 DNA Fragment determination and purification by agarose 
gel electrophoresis 
To find the molecular weight of a DNA fragment, especially those amplified by PCR 
agarose gel electrophoresis is the simplest method. To produce a 3% high definition 
gel, electrophoresis grade agarose e.g. MetaphorTM is weighed on a balance and 
dissolved in an appropriate volume of molecular grade water. For example 3g of 
agar dissolved in 100m1of 1X TBE buffer = 3% gel (see table 2.3). A conical flask 
heated in a microwave oven, though sealed and then pierced with paraffin wax film 
provides a safe and rapid way to dissolve the agar. Swirling the flask every 20-30 
seconds helps prevent boiling the agar. Once dissolved and cooled, 50p1 of ethidium 
bromide can be added which will later intercalate with the DNA and permit it's 
resolution when fluoresced under 290nm ultra-violet light. The next step is the 
casting of the gel into the gel tray. Prior to this step the tray and buffer tank must be 
thoroughly cleaned with detergent and wiped down with 70% alcohol and the 
appropriate size comb inserted. Once the gel has become hot to the palm it can be 
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rapidly cast into the tray on a flat surface. Any bubbles can initially be removed by 
gently tapping the tray, if this proves unsuccessful lml Gilson can be used to remove 
them so long as the gel has not begun to set. When the gel has firmly set, bearing in 
mind the higher the % of agar the quicker and more firmly the gel will set, it can be 
covered in saran-wrap and moved to the lower compartment of a refrigerator. Once 
the gel has been chilled to 4°C it can be placed in the buffer tank and immersed in 
pre-chilled lx TBE buffer. The comb can be removed and any bubbles removed 
with a Gilson. Pre-running the gel will help remove any concentrated ions from the 
wells and should ensure a clean run. Once mixed with loading dye (0.25% 
bromophenol blue in 40% sucrose w/v) samples could be loaded at the electrically 
positive end of the rig and the gel run at 100 volts for an absolute minimum of 90 
minutes to permit differentiation of the bands. itiX174 was always accompanied when 
running samples so as to permit the correct determination of the fragments being run. 
Table 2.3 	 Agarose Gel Electrophoresis. Below are listed the requirements for 
correctly casting and running agarose gels for the separation of PCR fragments 
amplified from the PCR reactions. 
Type Agarose (High melting point) 
Concentration 2.7-3.0% 
Format Horizontal 
Length 200mm 
Width 5mm 
Buffer 1X TBE (Stock of 10X ) 
Maximum loaded volume 251.11 
Voltage 100 (4.5V per cm) 
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Temperature 	 > 37°C 
Stain 	 0.5% Ethidium Bromide 500/100m1) 
2.6.4.1 DNA extraction from agarose gels 
After using PCR to amplify your gene of interest (YOGI) is possible to dissect the 
desired band from the standard agarose gel and purify it with the appropriate 
reagents. Purified genes products can then be used for direct DNA sequencing. The 
QlAquick reagents are stored at room temperature (20-25 °C). The protocol is 
designed to purify single or double stranded DNA PCR products ranging from 
100bp to 10kb. 
2.6.4.2 Contents and buffers supplied: 
Spin columns and collection tubes 
Buffer QG — solubilses the agarose gel and provides conditions suitable for the 
binding of DNA in addition it also contains a pH indicator. 
Buffer PB — Permits the efficient binding of small DNA strands and the removal of 
primers up to 40 nucleotides 
Buffer PE — Ethanol wash 
Buffer EB — Elution buffer (10mM Tris Cl, pH 8.5),100% Isopropanol 
2.6.4.3 Protocol 
1. Using a sterile scalpel blade the band of interest is cut from the agarose gel 
2. The slice is weighed and QC buffer in the proportion of 100mg ge1/100µ1 of 
buffer is added 
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Gel is incubated @ 50°C for 10 minutes or until the slice has completely dissolved 
in a column 
3. Checking that the colour is orange/violet i.e. pH 7.5. (Otherwise add 100 of 3M 
sodium acetate) 100tt1 of 100% Isopropanol is added in the same ratio as before. 
The column placed in a collection tube and spun at 10,000g (13,000rpm) for 1 
minute 
4. 5000 of the QG buffer is then added and spun for 1 minute 
5. 7501.11 of PE buffer is added, and spun for 1 minute 
6. Flow through is discarded and column is placed in clean collection tube 
7. To elute DNA 501.11 of EB buffer is added to the centre of the tube and spun for 1 
minute. 
8. The flow through is concentrated DNA. 
2.6.5 Polyacrylamide gel electrophoresis 
Preparation of the glass plates is crucial. Both were washed in detergent and warm 
water for 10-15 minutes and then allowed to dry. Then sprayed with 70% ethanol 
and wiped clean. A couple of mis of bind saline were first applied to the short glass 
plate and wiped in long vertical motions over the entire surface of the plate. The 
same procedure was repeated using sigma coat on the glass buffer tank plate. Once 
dry a soft tissue swabbed in 100% methanol was used to wipe away any residues on 
either of the plates. Once dry the plates were sandwiched together with spacers and 
the comb inserted upside down, the rig was now clamped together. The same rig 
was used for denaturing DNA sequencing gels, for ingredients see table 2.6 and non-
denaturing SSCP gels, for ingredients see table 2.3. 
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Table 2.4 Preparation of SSCP non-denaturing acrylamide gel. Ingredients for 
the preparation of SSCP non-denaturing acrylamide gels. Gels were cast at a variety 
of concentrations and with a number of additives, as subtle changes in a bands 
conformation and mobility can be achieved. 
Acrylamide (30%) 22m1 
Bis-acrylamide (3%) 6.75m1 
5X TBE buffer 15m1 
Molecular grade water 97.75m1 
Glycerol 7.5m1 
Ammonium persulphate (10%) 0.8ml 
TEMED 0.1m1 
2.6.5.1 TBE Buffer 
• 5X —54g Tris 
• 27.5g Boric acid 
• 20m1 0.5M EDTA pH 8.0 
2.6.5.2 PCR dilution solution: 
• 0.1% SDS and 10mM EDTA 
2.6.5.3 Loading buffer: 
• 10m1 formamide 
• 0.2m1 0.5M EDTA @pH 8.0 
• 10mg Bromophenol blue and 10mg Xylene cyanol green 
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2.6.5.4 Sample: 
• 90µ1 of dilution solution, 
• 6-101 of loading solution 
• 10 1 of PCR reaction solution 
2.6.6 Silver Staining PAGE gels 
This protocol is used for the silver staining of DNA and or RNA in polyacrylamide 
gels (see table 2.4). When the gel was finished running the rig was carefully 
dismantled and the buffer discarded. There are huge suction forces binding the 
buffer tank to the glass plate so a wedge was gently tapped between the plates to 
help relieve this pressure. When the plates were pulled apart the gel was adherent 
solely to the thin glass plates. The plate was now lowered into the first buffer. 
During the incubation the gel was gently agitated. All buffers were prepared an hour 
or so before the end of the running time of the gel. It was especially important for 
the developer containing the sodium borohydride. 
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Table 2.5 	 Silver Staining buffers. All buffers were made from the following 
ingredients. While some buffers could be stored e.g. buffer A and others reused e.g. 
buffer B others had to be made fresh prior to staining. 
Effect Constituent Volumes Incubation Time 
Buffer A 
Stop 10% Ethanol 
0.5% Acetic acid 
100m15mIs 
895m1ddH20 
3 min 
2x10 sec ddH2O 
Buffer B Stain 0.1% AgNO3  lg in IL 10 mins 2 washes 
Buffer C Developer 1.5% NaOH 
0.01% NaBH4 
0.015%Formaldehyde 
15g in 1L 
0.1g of 
4mIs ddH2O 
20 mins 
Buffer D Fixer 0.75% NaCO3 7.5g in 1L 10 mins 
A white AgC12 precipitate may form in gels where heavy concentrations of sodium 
chloride are present. This leads to heavy silver staining of the background. The 
precipitate can easily be redissolved by: 
1. Washing gel for 30 seconds in ddH2O 
2. Incubate the gel in 2.5% Ammonium 
3. Wash the gel twice for 30 seconds with ddH2O 
4. Incubate the gel with buffer a for 3 minutes 
5. Continue staining protocol at buffer B 
• lOg of NaC12 was added to the filtered buffer B. A grey silver chloride 
precipitate would form which could be then filtered or allowed to settle out with 
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gravity. The purified water could then be disposed of and the Silver waste safely 
collected. 
2.6.7 DNA sequencing 
Automated DNA sequencing was attempted using DNA purified from bands run in 
agarose gels (500ng of DNA +66ng 20mer primer in 1411 water). This proved 
unsuccessful as the number of bands that were un-resolvable and designated "x" 
made the technique inappropriate for further use. Instead manual sequencing using 
the chain termination method proposed by Sanger was attempted. 
2.6.7.1 Dideoxy DNA sequencing — Chain Termination Method 
Sequencing DNA involves the amplification of the sequence of interest in four 
separate reactions (see table 2.5). Each reaction includes the normal PCR reagents 
but also includes one dideoxy nucleotide, A, T, G or C. The dideoxynucleotides will 
incorporate into the extending strand at the same rate as any of the other nucleotides, 
but they will arrest polymerisation once incorporated. At the end of the reaction each 
tube will contain amplified fragments of all possible lengths, each tubes fragments 
will terminate in either an A, T, C, or G depending on which ddNTP was added at 
the start of the reaction. Samples from each reaction can then be run on 
polyacrylamide gel (PAGE). Four lanes each with numerous bands can then be 
stained. The smallest and faintest bands will be at the bottom of the gel as these will 
be the fragments that have migrated the furthest. The darker heavier bands will be 
those fragments, which were terminated last and have moved more slowly through 
the gel. 
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Table 2.6 Reaction contents for a two step genomic DNA sequencing reaction. 
The second reaction used exactly the same as primers as the first. 
	 11.1I of 
concentrated PCR reaction was used as the template for this second stage. Four 
reaction tubes were used, one for each ddNTP 
Contents Volumes 
Buffer 5µl 
DNA 1µI 
Primer 5µI 
Water 16µ1 
DideoxyNTPs (ddNTP) 2i_d each 
Taq 1µ1 
Table 2.7 Preparation of Sequencing denaturing acrylamide gel. 
	 Manual 
sequencing required a two step PCR reaction followed by electrophoresis using a 
denaturing polyacrylamide gel 
Acrylamide (18%) 18ml 
Bis-acrylamide (1%) lml 
10X TBE buffer 12ml 
Molecular grade water 47m1 
Glycerol 0 ml 
Ammonium persulphate (10%) 0.8ml 
TEMED 0.05m1 
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2.7 MATERIALS 
2.7.1 Cell Culture 
Dulbecco's Modified Eagles Medium + Hams F12 basal medium (Gibco Life 
Technology) 
200mM L-Glutamine (Gibco Life Technology) 
Fetal Calf Serum (PAA) 
50mg/m1 Gentamicin (Gibco Life Technology) 
Trypsin-EDTA ).25% trypsin with 0.25% EDTA (Imperial Laboratories) 
Dimethyl Sulphoxide (DMSO) 
Laminar Flow Hood 
Isoton (Coulter Euro Diagnostic Isoton II) 
Geimsa stain (BDH) 
Methylene Blue stain (BDH) 
Tissue culture flasks 25cm2, 80cm2, 175cm2 (Nunclon) 
35mm x 10mm Tissue culture petri dishes (Corning) 
2.7.2 Chemicals 
Methanol / Ethanol (Sigma) 
Acetic acid (Sigma) 
Silver nitrate (Sigma) 
Sodium hydroxide (Sigma) 
Sodium Borohydride (Sigma) 
Formaldehyde (Sigma) 
Ethidium bromide (Sigma) 
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Cybergreen (Flowgen) 
Methylene Blue (BDH) 
2.7.3 Equipment 
Nicool LM 10 freezing apparatus (Jencons Scientific Ltd) 
Cyrostat (Jencons Scientific Ltd) 
Philips 420kVp X-ray machine (Ago Installations Ltd) 
Caesium 137 IBL 437C gamma irradator (CIS UK Bio International) 
Class II Microbiological Safety Cabinet (Envair Ltd) 
Coulter Counter (Coulter scientific Instruments), ZM model 
PCR Machine (Scotlab GeneE) 
Sequi Gene DNA sequencer (BioRad) 
Diaphot Microscope (Nikon) 
Wifug centrifuge Model 500E 
Perspex gas boxes (5% CO2 and air) maintained @ 370C. 
2.7.4 Reagents and Kits 
Puregene DNA extraction kit Puregene 
QlAquick PCR purification kit 
Micro-FastTrack kit 
cDNA Cycle Kit 
Cat#D-5000A 
Qiagen Cat # 28104 
Invitrogen Cat# K5632-01 
Invitrogen Cat# K1520-02 
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Chapter 3 
RESULTS 
3.1 Transformation HTori-3 Cells 
3.1.1 Experimental Procedure 
Exponentially growing HTori-3 cells were exposed to single doses of a range of X-
rays and beta particles. Doses included: 0.25, 0.5, 0.75, 1.0,2.0, 3.0, 4.0, 5.0, 6.0, 7.0 
and 8.0 Gy. Five flasks were seeded following radiation. Little or no growth was 
observed in the higher doses of irradiated cells following radiation, however after 
this initially period, cultures recovered well and grew very rapidly and required only 
a 1/40 split to sustain the flask. The flasks were passaged independently once 
weekly for six weeks. All flasks were prepared for injection at a concentration of 
lx10E6 cells per flask/per mouse. The three columns below represent the three sets 
of screenings that were performed: 
X-ray Acute 2.0Gy 
	 X-ray Acute 1.0Gy 	 X-ray Acute 0.5Gy 
X-ray Chronic 2.0Gy 
	 X-ray Acute 0.75Gy 	 X-ray Acute 0.25Gy 
Strontium 2.0Gy 	 X-ray Chronic 1.0Gy 
	 X-ray Chronic 0.5Gy 
X-ray Chronic 0.75Gy 	 X-ray Chronic 0.25Gy 
Strontium 1.0Gy 	 Strontium 0.5Gy 
Strontium 0.75Gy 
	 Strontium 0.25Gy 
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3.1.2 The Results 
All but one group developed tumours, while two tumours were found in the second 
screening control group. A z-test gives a p value of less than 0.001 and thus 
confirms that there is a significant difference between the radiation treated and the 
unirradiated control groups. However, due to tumours being found in the control 
mice this statistic must be viewed with caution. No particular trend was observable, 
other than that the radiation source was able to produce tumours in all of the 2 Gy 
treated group, moreover these appeared progressively from the date of injection. 
Immediately after injection (19th September 1997) a soft swelling was observed at 
the site of injection, this disappeared after the first week. The first tumour appeared 
in the Strontium group on day 56 with others following soon after (23 days). This 
first tumour grew progressively until day 109 when it was excised and made into a 
tumour cell line (TCL), using the method previously described. The remaining mice 
were kept until 27th February 1998. While two mice had no observably tumours a 
grade 2 and grade 3 were present in the remaining mice. The grade 3 tumour was 
also made into a TCL. The first tumour was designated ST-1, while the second ST-
2. ST-2 was bulked up and frozen for storage, while ST-1 was passaged in vitro 
until it was re-injected on 17 March 1998. 
On day 79 the first X-ray acute tumour was found. This grew progressively in just 
30 days until its excision at grade 4 on day 109. The remaining 4 mice in this cohort 
were checked weekly until 1 April 1998, 194 days since injection. Two of the mice 
had no noticeable tumours, while the remaining two had small grade 1 tumours. The 
first and largest tumour was re-introduced in vitro and made into a tumour cell line. 
96 
The cell line was designated XA-1 and was passaged weekly until it too was re-
injected on the 17th March 1998. 
Three tumours were found in the X-ray chronic cohort. Although injected at the 
same time as the other group the time taken for these to form suspected tumours was 
greatly increased. It was over 4 months before the first tumours were seen. Two 
mice with no observable tumours were killed 30 March, the remaining three all of 
which had good sized tumours were kept until 12 May 1998 when then they were 
culled with tumours grade 4, 3 and 3. All were made into TCLs and the best of these 
was designated XC-1. 
All new tumour lines were sent for histological examination (see figure 3.3) and 
stocks of the newly formed cell lines were frozen in nitrogen for storage. In addition, 
chromosome analysis (see figure 3.4) was performed on the first tumour from each 
group so as to confirm the human nature of the cell line. A dose response was 
plotted and the cells then used to look for the expression of delayed lethal damage at 
set times post-irradiation. At the end of this period the DNA was extracted and used 
for molecular biology. 
Of the mice in the control group, none were found to have tumours after 192 days 
since injection. On 30th March they were culled, one mouse was killed on 19th 
January due to suspected gastro-enteritis. Figure 3.1 gives the tumour grow rates in 
the nude mice throughout the screening period. The tumour incidence can be 
viewed in table 3.1 and table 3.2. 
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3.1.3 Statistical Analysis of Tumour Formation 
A Z test was used to test the hypothesis that there was a statistically significant 
difference between the total number of tumours found in the controls compared to 
the treated groups. An estimator of the variance was calculated assuming a common 
population variance. A Z-test is used when n is high i.e. greater than fifty, with an n 
value less than 50 a t-test would have been more appropriate. Data collected from 
tumour formation experiments n=80. 
Z value 
crAAI (1/ni + 1/n2) 
Where, x1 and x2 are the mean number of tumours from each sample population crA 
is the estimator for variance and 1/n1 and 1/n2 are the reciprocals of n for each 
sample where n is the number of values for each sample. 
The estimator is calculated thus, 
CYA = (n1 x S12)+ ( n2 x S22) / ni + n2 - 2 
At a 95% confidence interval a critical value (2 tailed) of 1.96 is estimated, at a 99% 
confidence interval a critical value (2 tailed) of 2.58 is estimated. From the tumour 
data collected from this study a Z test value of 5.619 is calculated which lies well 
beyond the critical value interval even at a 99%a C.I. Thus, a significant difference 
can be confirmed between the two mean data values. 
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Figure 3.1 Tumour growth curves after transplantation into athymic nude mice. Normal HTori-3 cells injected were treated with different 
doses of chronic (1Gy/hr-1) or acute (120 Gy/hr-1). X-rays doses ranging from 0.25 Gy to 2 Gy. One strontium irradiation @ 2Gy was also 
screened. 
17th March 1998 a second screening of irradiated HTori-3 cells was performed. On 
this occasion, doses below that of the previous screening were selected to see if a 
threshold was present. Two doses were selected from the X-ray acute and X-ray 
chronic groups; 1 Gy and 0.75Gy. 
The first tumours appeared in the X-ray acute group in less than a month. By the 
end of June three suspected tumours were present in the 1 Gy set, while four were 
present in the 0.75 Gy. These were designated )CA-2 and XA-3 respectively. 
However, two tumours of similar size were found in the controls. Contamination 
during the culture process was suspected. Extra control mice were injected so as to 
confirm the non-tumourigenic nature of the parental cell line HTori-3 . In the X-ray 
chronic three large suspected tumours were found, two variable tumours were seen, 
these appeared up to a size 2 but then disappeared. The largest of the other three 
suspected tumours was made into a TCL and designated XC-2. In the lowest 
doserate set; 0.75Gy over 8 hours size 3 tumours were observed, one of these was 
made into a TCL and designated XC-3. None of the control mice for this group had 
any tumours throughout the experimental period. 
On 14th July 1998 the last group of X-irradiated cells were injected for screening 
purposes. The group included 0.5Gy and 0.25Gy chronic and acute, these were the 
lowest dose available, with greater than a 100-fold difference in their doserate. 
Extra controls were added into this group to ensure that the induction of tumours in 
the controls was not due irradiation independent transformation in vitro. 
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Table 3.1 Table of combined tumour incidence in HTori-3 cells for all doses of 
radiation screening in nude mice. Included are the tumour incidences of secondary 
tumours formed after cells derived from primary tumours were reinjected. 
Dose Radiation 
Source 
Primary 
Tumours 
Incidence Secondary 
Tumours 
2 Gy X-ray Acute 2/5 40% 2/5 40% 
2 Gy X-ray Chronic 3/5 60% 1/5 20% 
2 Gy Strontium 3/5 60% 5/5 100% 
Controls None 2/10 20% 
1 Gy X-ray Acute 4/5 80% 
1 Gy X-ray Chronic 3/5 60% 
0.75 Gy X-ray Acute 3/5 60% 
0.75 Gy X-ray Chronic 2/5 40% 
Controls None 3/10 30% 
0.5 Gy X-ray Acute 1/5 20% 
0.5 Gy X-ray Chronic 0/5 0% 
0.25 Gy X-ray Acute 3/5 60% 
025 Gy X-ray Chronic 3/5 40% 
Controls None 1/5 20% 
Total controls 6/25 26% 
Total Tumours 27/55 49% 
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3.1.3 Re-injection of derived tumour cell lines 
On 6th April 1998 the first two cell lines XA-1 and ST-1 were reinjected to confirm 
their tumourigenecity. With 3 weeks all ST-1 mice had grade four tumours, all were 
killed 1st May and sent for histology. By the 12th June 2 out of 5 mice in the group 
XA-1 had grade 5 tumours. The X-ray chronic tumour line was reinjected sometime 
later but surprisingly no tumours appeared and the mice were culled after 4 months. 
3.1.4 Latent Period 
Latent period can be defined as the interval between injection and the appearance of 
the first primary palpable tumours (see figure 3.2). In the experimental group some 
of the tumours grew progressively from the date of injection e.g. XC 1.0. However, 
from those tumours that had latent periods before tumour growth the shortest was 56 
days for the 2Gy strontium-irradiated cells. Zero latency was observed when these 
cells were reinjected. The only group of cells screened that did not produce 
tumours, was the X-ray chronic 0.5Gy. These cells were screened for 143 days, with 
no visible tumours at the end of the incubation process the mice were culled. 
3.1.5 Conclusion 
• Gamma radiation can enhance the rate of transformation of thyroid epithelial cell 
• All tumours derived are confirmed as from the human thyroid epithelial cell line 
• Latent period appears to have no effect on the time to tumourigenesis 
• The time to tumourigenecity may be indicative of the rate of instability 
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Figure 3.2 Graph of latency of tumour development in athymic nude mice after transplantation of strontium, x-ray acute and x-ray chronic 
irradiated thyroid epithelial cells after a range of radiation doses. Graph shows all tumours colour coded from each group irradiated, colour 
coded for appearance of tumours in individual mice. 
Figure 3.3 	 Histological appearance of a primary XA-1 (2Gy) tumour at low power (x100) and at high power (x400). Data confirms 
anaplastic nature of all tumours with little differentiation. Scale bar on left equals 1001.tm, scale bar on the right equals 25µm, approximately. 
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Figure 3.4 	 Chromosome spreads of the non-tumourigenic parental control cell line HTori-3 (Panel A). Tumour chromosomes are 
derived from HTori-3 cells after screening 2 Gy irradiated cells in nude mice. Panel B, X-ray Acute tumour (XA-1), Panel C, X-ray 
Chronic tumour (XC-1) and Panel D, STrontium tumour (ST-1). Data confirms that all tumours derived from athymic nude mice were 
human HTori-3 cells and not murine spontaneous tumours. 
Table 3.2 	 Summary of all Tumours produced during this study, including those tumours from the first tumour screening that were 
reinjected to confirm tumourigenecity 
Screenings for Tumourigenecity 
First Screening  
Group 1 ST 2 XA 2 XC 2 Control 
Dose 2 2 2 0 
Dose Rate Gythr-1 2.286 240 0.25 0 
No. of mice 5 5 5 5 
Cage 1 3 males 3 males 3 males 3 males 
Cage 2 2 males 2 males 2 males 2 males 
Passage 5 4 4 10 
Date Injected 19.9.97 19.9.97 19.9.97 19.9.97 
No of Tumours 4 2 3 0 
Grade of Tumours 1234 14 344 0 
Day. in vivo 196 194 237 192 
Date Excised 3.4.98 1.4.98 12.5.98 30.3.98 
Line Name ST-1 XA-1 XC-1 N/A 
% Tumourigenecity 80% 40% 60% 0% 
Second Screening of First Printery Tumours 
Cell Line ST-1 XA-1 Control XC-1 
Passage 4 4 4 4 
Date Injected 6.4.98 6.4.98 6.4.98 10.8.98 
No. of mice 5 5 5 5 
Cage 1 3 males 3 females 3 males 3 males 
Cage 2 2 males 2 males 2 males 2 females 
No of Tumours 5 2 2 1 
Tumour Sizes 4 4 4 4 4 55 55 3 
Days In vivo 21 78 78 57 
Date Excised 1.5.98 7.8.98 7.8.98 6.10.98 
% Tumourigenacity 100% 40% 40% 20% 
Second Screening  
Group 2 XA 1 XA 0.75 XC 1 XC .75 Control 
Dose 1 0.75 1 0.75 0 
Dose Rate Gylhr-1 2.286 2.286 0.125 0.09375 0 
No. of mice 5 5 5 5 5 
Cage 1 3 males 3 females 3 females 3 females 3 males 
Cage 2 2 males 2 females 2 females 2 females 2 males 
Passage 7 7 10 10 8 
Date Injected 17.3.98 17.3.98 173.98 17.3.98 17.3.98 
No of Tumours 4 3 3 2 1 
Grade of Tumours 3 2 1 1 553 144 54 3 
Days In vivo 143 143 143 143 143 
Date Excised 7.838 7.8.98 7.8.98 7.8.98 7.8.98 
Line Name XA -2 XA-3 XC-2 XC-3 N/A 
%Tumourigenecity 80% 60% 60% 40% 20% 
Third Screening 
Group 3 XA 0.5 XA 0.25 XC 0.5 XC 0.25 Control 
Doira 0.5 0.25 0.5 0.25 0 
Dose Rate Gylhr-1 2.286 2.286 0.0625 0.03125 0 
No. of mice 5 5 5 5 5 
Cage 1 3 males 3 males 3 females 3 females 3 females 
Cage 2 2 females 2 males 2 females 2 Females 2 females 
Passage 9 10 10 10 11 
Data Injected 14.7.98 14.7.98 9.7.98 9.7.98 147.98 
No of Tumours 1 3 0 3 1 
Grade of Tumours 2 321 0 363 2 
Days In vivo 89 93 94 94 89 
Date Excised 7.12.98 7.12.98 7.12.98 7.12.98 4.12.98 
Line Name XA-4 XA-5 XC-4 XC-5 N/A 
% Tumourigenecity 20% 60% 0% 60% 20% 
3.2 Growth and Survival 
3.2.1 HTori-3 Growth Curves 
Growth curves for the HTori-3 cell line were the first to be undertaken in an attempt 
to understand the kinetics and dynamics of the cells reproductive cycle in culture. 
	
3.2.1.1 	 Experimental Procedure 
Plates for the growth curve were prepared in duplicate to cover the experimental 
period. Each was filled with 2mls of culture medium. Each dish was seeded at a 
total concentration of 12,000 cells. Cells were incubated for 72 hours with two 
dishes being sampled daily. Repeat experiments were staggered to account for 
weekends. 
	
3.2.1.2 	 Results 
As the cells recovered from the plating procedure, an initial lag period, characteristic 
of all growth curves was observed which lasted for 2-3 days (see figure 3.5, 3.6 and 
3.7). Steady growth was then observed over the next 10-14 days. If media was 
withheld after one week in culture a characteristic nutrient plateau was observed 
similar to that seen in cultures at confluence. Eventually, the surface area of the 
dishes became carpeted in cells and confluence was reached. Growth in cultures of 
tumour cells would also eventually arrest, though cells became highly concentrated 
and tightly packed. Little or no piling of cells occurred so contact inhibition is likely 
to have contributed to their arrest. An estimated doubling time could be made from 
the gradient of the exponential phase of growth; for HTori-3 cells this was around 22 
hours per cell division. 
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Figure 3.5 	 Growth curve of HTori-3 cells in vitro culture, with an average 
doubling time of 22 hours. 
An initial lag period is observed over the first few days as the cells recover from the 
plating procedure. Exponential growth is then observed throughout the next 10 days 
until day 12. Even after feeding on day 7 the cells were unable to continue 
exponential growth indefinitely. Saturation is reached after day 12 and the cells 
begin to senesce as confluence is reached. 
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3.2.2 Tumour Growth Curves 
Ten and fourteen day growth curves were made for selected alpha and gamma 
tumour cell lines. These tumour cell lines had previously been derived in our 
laboratory from alpha and gamma irradiation of HTori-3 cells (see appedix). These 
lines were now characterised by exposure to gamma particles (Riches et al, 1994, 
1997). The first X-ray acute, X-ray chronic and strontium tumour cell lines were 
also included in this study. Normal tumour cell growth curves were compared 
against those expressing the characteristics of the delayed lethal damage (DLD) 
phenotype. These data could then be directly compared to that of the parental cell 
line HTori-3. 
3.2.2.1 Experimental procedure 
The cell line of choice was seeded at a concentration of 6x103 cells per ml. A total 
of 2mls of cell suspension in standard Dulbecco's media was added into a small 
8cm2 Nunc dishes.. Duplicate dishes were seeded, e.g. 20 dishes for a 10-day 
growth curve. Over time, three repeats were made at staggered intervals. 
3.2.2.2 The Results 
On the whole, normal HTori-3 cells grew faster then any of the newly derived X-ray 
tumour lines (see 3.6 and 3.7). However, no significant difference was noted for any 
of the cell lines when compared in the exponential phase of the cell cycle. However, 
general trends could be noted: 1) The new X-ray and Strontium tumours had growth 
rates below that of HTori-3 .2) Tumours that expressed DLD after 8Gy of gamma 
radiation had an apparent growth rate less than their parental tumour. 3) The long 
established tumours G4 and A9 appeared to have a faster rate of growth. 
109 
2000000 
1800000 
1000000 
1400000 
1200000 
10=00 
800000 
800000 
400000 
200006 
0 
HTod-3 
—04(«,» 
-4-04 Rey) 
2 3 4 6 8 7 8 9 10 
Time Pro) 
0 1 2 3 4 5 6 7 8 9 10 
Una (Owe) 
Figures 3.6 Comparison of in vitro growth curves of HTori-3 control cell and the 
tumour cell lines; A9 and G4. Growth rates of the tumour cell lines were compared 
to the same tumour expressing the DLD phenotype. Both are plotted with 
comparison to the HTori-3 cell line. Cell cycle times was calculated as 22 hours per 
cell division. An initial lag period was observed during the first few days, this lead 
to the exponential growth phase which lasted over a week until confluence was 
reached. 
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Figures 3.7 Comparison of in vitro growth curves of HTori-3 control cell and the 
tumour cell lines; XA, XC and ST. All lines were also compared to their DLD 
expressing counterparts which had previously been irradiated with 8Gy and cultured 
for 4 weeks. 
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3.3 	 Dose Response of HTori-3 and Tumour Cells Lines. 
These experiments were initially used to investigate the relative radiosensitivity of 
the different cell lines. Later they were used to collect cells to investigate the 
expression of Delayed Lethal Damage (DLD) after a variety of doses of gamma 
radiation. 
A series of dose response experiments were performed using 9 alpha, (see figure 
3.9), 12 gamma (see figure 3.10), one x-ray acute, (see figure 3.11) one x-ray 
chronic (see figure 3.12) and one strontium tumour cell line (see figure 3.13). The 
dose response of HTori-3 cells irradiated with 1311 can be seen in figure 3.14. 
3.3.1 Experimental Procedure 
An exponentially growing culture (T80cm2 sized flask) was harvested and re-
suspended in a universal tube with an equal or greater volume of media. This 
volume was then split into separate universal tubes, labelled with the appropriate 
dose of radiation they were to receive; 0, 2, 4, 6, or 8 Gy. All tubes were then placed 
on ice and taken to the radiation room were the Cs 137 gamma source was housed. 
Irradiation times were calculated and programmed into the source. Each universal 
was placed inside a special container and irradiated before being placed immediately 
back on ice. The tubes were returned to the laboratory and serially diluted at the 
appropriate concentrations so to yield 50 colonies per plate. 
112 
• 
• 
• w IF' 
a 
1. 
3.3.2 Results 
All cells lines showed a clear dose response to gamma irradiation. Direct 
comparisons of the surviving fraction at SF8 (8Gy) have been made (see table 3.3). 
Not only are there obvious differences between the individual tumour cell lines dose 
response but differences in colony size were clearly noted, as can be seen below. 
Figure 3.8 	 Photograph of the variations found in colony sizes. All 90cm2 petri 
dishes had previously been filled with 10m1 of Dulbecco's media and had been pre-
warmed and pre-gassed in a 5% CO2 incubator. 
Once seeded dishes were returned to the CO2 incubator for 14 days to allow for the 
formation of colonies. After this time dishes were stained with giemsa and counted. 
At the same time fresh flasks were seeded at 10X the plating dose to study the 
effects of delayed lethal damage phenotype (DLD). These flasks would be then be 
used to investigate plating efficiencies at T=2, T=4, T=8 and T=12 weeks post-
irradiation. Cells were also collected during this stage for the micronucleus and 
apoptosis assays. Clear differences can be observed between the control plate on the 
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left and the DLD expressing dish on the right. The scoring of colonies was 
subjective and open to some interpretation. However, as a rule, colonies over 50 
cells were termed reproductively viable and were scored. 
Figure 3.9 Comparison of the radiation dose-response of the alpha tumours Al-A9, 
all tumours were derived from the parental cell line HTori-3 after different doses of 
alpha radiation. Each tumour cell line is derived from the explant of the primary 
tumour that grew in the nude mice. 
114 
2 	 4 
Dose (Gy) 
6 8 
- c1  
-C6 
- G7 
- C8 
- 03 
- 010 
- G11 
- 012 
013 
om I 
0 
U 
LL 
00.10 
to 
Figure 3.10 Comparison of the radiation dose-response of the gamma tumours GI - 
G13, all tumours were derived from the parental cell line HTori-3 after different 
doses of gamma radiation. Each tumour cell line is derived from the explant of the 
primary tumour that grew in the nude mice. 
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Figure 3.11 The mean radiation dose-response of the X-ray tumours XA- I , the 
tumour was derived from the parental cell line FITori-3 after a 2 Gy dose of X-ray 
radiation. Each tumour cell line is derived from the explant of the primary tumour 
that grew in the nude mice. Dose points for dose-response curve included: 0.25, 
0.50, 0.75, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0 Gy 
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Figure 3.12 The mean radiation dose-response of the X-ray tumours XC-1. The 
tumour was derived from the parental cell line HTori-3 after a 2 Gy dose of X-ray 
radiation. Each tumour cell line is derived from the explant of the primary tumour 
that grew in the nude mice. Dose points for dose-response curve included: 0.25, 
0.50, 0.75, 1.0, 2.0, 3.0 ,4.0, 5.0, 6.0, 7.0, 8.0 Gy 
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Figure 3.13 The mean radiation dose-response of the strontium tumour ST-1, the 
tumour was derived from the parental cell line HTori-3 after a 2 Gy dose of X-ray 
radiation. Each tumour cell line is derived from the explant of the primary tumour 
that grew in the nude mice. Dose points for dose-response curve included: 0.25, 
0.50, 0.75, 1.0, 2.0, 3.0 ,4.0, 5.0, 6.0, 7.0, 8.0 Gy 
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Figure 3.14 The mean radiation dose-response of HTori-3 cell irradiated with 
Iodine 131. Intra-cellular irradiation with iodine 131 was hoped to induce tumours 
and mimic cellular response similarities to those observed from the radiation induced 
tumours from children surrounding Chernobyl. (Combined data from Dr Clare 
Peddie). 
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Table 3.3 A comparison of the surviving fraction after 8Gy of all turnouts analysed 
for dose responses and plating efficiencies after gamma radiation. While some 
tumour cell lines reacted well to the radiation, being relatively radio-resistant e.g. 
ST-1, G13 and A7. Others reacted poorly, being more sensitive to the damage 
sustained e.g. G11, A4 and A6. 
Cell Line Mean SF8 Cell Line SFS Cell Line SF8 
HT 0.09 G1 0.02 Al 0.17 
G2 0.023 A2 0.06 
XA1 0.118 G3 0.08 A3 0.11 
XC1 0.101 G4 0. 02 A4 0.01 
ST1 0.281 G5 0.03 A5 0.00 
G6 0.02 A6 0.00 
G7 0.01 A7 0.12 
G8 0.02 A8 0.07 
G9 0.02 A9 0.04 
G10 0.07 
Gil 0.03 
G12 0.09 
G13 0.17 
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3.4 Studies into the expression of the delayed lethal 
death phenotype 
Plating efficiencies measure reproductive integrity following a given procedure. 
The ability of a culture to adhere to a surface and form a visible colony of 50 cells or 
more is used as confirmation. Measurement post-irradiation gives an insight into the 
cells ability to repair or pass on a defective karyotype to its progeny over time. 
3.4.1 Experimental Procedure 
Initially, HTori-3 cells were used for the standard colony assay, later this assay was 
extended to include all tumour cell lines. Doses of 2, 4, 6, and 8 Gy were chosen to 
give a broad range of response. Later some of the repeats included doses up to 16 
Gy where cell survival was greatly reduced. Time intervals of two weeks from the 
date of irradiation and up to 8 weeks post-irradiation were chosen to observe the 
cells delayed response to an ionising insult. Repeats were performed with a control 
at the 8 Gy dose; as this was the dose at which the induction of DLD was most 
clearly observed. 
3.4.2 The Results 
All cell lines tested expressed the DLD phenotype as detailed by Alper et al, 1989. 
A dose dependant decrease in cell survival and therefore colony forming potential 
was observed with all cell lines (see figures 3.15, 3.16 and 3.17). The extent of 
recovery in all lines was found to increase over the study period. At 8 weeks post-
irradiation, colony forming potential in 8Gy irradiated HTori-3 cells was equal to 
that of their control, i.e. the cultures could be termed reproductively recovered. 
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The in ability of the cells to prevent the passage of defective material into progeny is 
termed "Genomic Instability" and was used as a measure of delayed lethal death. 
Figure 3.18 plots the ratios of normal to DLD expressing plating efficiencies of all 
the tumour cell lines (see also table 3.4). 
3.4.3 Conclusions 
• Using a decreased plating efficiency as an indicator, all tumour cells lines 
investigated confirmed the expression of the DLD phenotype 
• Doses of 6Gy and above were required to induce DLD expression 
• An incubation period of around four weeks was required 
• Recovery of the PE appeared after 8-12 weeks post radiation 
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Figure 3.15 HTori-3 plating efficiency at two weekly intervals post irradiation. There appears to be a dose dependant decrease in plating 
efficiency at T=O.. An effective recovery is apparent at 2 weeks post-irradiation. Although there is a slight decrease in plating efficiency over 4 
and 8 weeks from cultures irradiated at doses over 6 Gy the HTori-3 cell line can not be said to express the DLD phenotype as expressed in the 
tumour cell lines. 
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Figure 3.16 Plating efficiencies of all 13 gamma tumour cell lines. Each control line is compared to the 8Gy irradiated DLD expressing group 
that had been irradiated four weeks earlier and passaged in vitro. 
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Figure 3.17 Plating efficiencies of all 9 alpha tumour cell lines. Each control line is compared to the 8Gy irradiated DLD expressing group that 
had been irradiated four weeks earlier and passaged in vitro. 
Table 3.4 	 The plating efficiencies from the all the in vitro colony assay 
experiments can be converted into ratios so to clarify the observed differences 
between the control and the treated tumour cell lines (TCL). i.e. The plating 
efficiency of each cell line at T=4 weeks was divided by its own control plating 
efficiency at T=0 weeks. The larger the ratio, the greater the difference in plating 
efficiency. While some lines appeared to recover well, back to near control levels 
e.g. A5. Others showed a marked decline in colony forming ability during the 
experimental period, e.g. ST-1, XA-1, G13, Al A3 and A7 showing the most 
dramatic loss of colony forming ability. 
Cell Line Ratio Cell Line Ratio 
Al 0.48 G1 0.77 
A2 0.49 G2 0.44 
A3 0.75 G3 0.67 
A4 0.64 G4 0.65 
A5 0.32 G5 0.28 
A6 0.85 G6 0.79 
A7 0.53 G7 0.11 
A8 0.81 G8 0.41 
A9 0.53 G9 0.11 
XA-1 0.69 G10 0.72 
XC-1 0.68 G11 0.79 
ST-1 0.85 G12 0.58 
HP 0.98 G13 0.57 
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Figure 3.18 Ratios of the delayed plating efficiency at 4 weeks (T=4) post-irradiation, compared to each control PE. Graph includes 
the new tumour cell lines XA, XC, ST as well as the 13 gamma and 9 alpha tumour cell lines previously established from our 
laboratory. 
3.5 	 Molecular Analysis of Tumour Cell Lines 
3.5.1 Experimental Procedure 
DNA was extracted from all the x-irradiated cell lines including XA-1, XC-1 and the 
strontium tumour ST-1. Using a p53 database the most commonly mutated alpha 
and gamma cell lines, (which had previously been sequenced) were also selected to 
confirm their p53 mutational status. Primers were prepared to amplify exons 5-8 of 
the human p53 gene using each tumour DNA as an independent template (see 
figures 3.19, 3.20 and 3.21). 
Exon 5= 282 Bp 	 Exon 6 = 207 Bp Exon 7 = 193 Bp 	 Exon 8 = 231 Bp 
A HaCaT cell line, known to be a p53 positive mutant in exons 5 and 8 was also 
grown in culture. DNA from the HaCaT cell line was extracted and used as a 
template to amplify its mutant exons, this was used as a positive control. When this 
sample was run with others of unknown status, a characteristic double band 
appeared which helped identify unknown samples. 
3.5.2 Results 
Initially the PCR-SSCP technique yielded no positive mutants (see figure 3.24). 
However, when the work was extended and hetroduplex analysis was used (see 
figures 3.22 3.23 and 3.25), apparent mutations were found in XA-1 tumour exon 7, 
XC-1 tumour exon 7 and the fast growing ST-1 tumour in exons 5 and 7. 
Confirmation of the p53 mutations in the most commonly mutated alpha and gamma 
tumours could not be verified by sequencing. 
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3.5.3 Conclusions: 
• p53 mutations are likely to contribute to genome instability but moreover the 
expression of the DLD phenotype. 
• Variations in the length of Mu repeat sequences in tumour cell lines may be 
indicative of genome instability and contributory to the expression of the DLD 
phenotype. 
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Figure 3.19 PCR amplification of p53 tumour suppressor gene, using HTori-3 DNA 
as template. Confirmation that all exons were successfully amplified. The bands 
were excised, purified, and used for re-amplification and mutation analysis. 
Lane 1: 4X174 marker. 	 Lane 2: Exon 5. 	 Lane 3: Exon 6. 
Lane 4: Exon 7. 	 Lane 5: Exon 8. 	 Lane 6: (1)X174 marker 
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Figure 3.20 PCR amplification of exons 5-8 of the p53 tumour suppressor gene 
from a number of different tumour DNA templates. Amplified exons 5-8 of each of 
the tumour lines was stored for later use in mutation analysis assays. 
Top gel:: Lane 1: OX174 marker, Lanes 2-5: XA Exons 5-8. Lanes 6-9: XC tumour 
DNA template Exons 5-8. Lanes 10-13: ST tumour DNA template. Bottom gel: 
Lane 1: 430C174 Marker. Lanes 2-5: XA-8 Exons 5-8. Lanes 6-9: XC-8 tumour DNA 
template Exons 5-8. Lanes 10-13: ST-8 tumour DNA template. 
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Figure 3.21 Confirmation of the amplification of the most frequently mutated exons 
of the alpha and gamma tumour cell lines. Each product could be isolated and used 
to look for mutations within the individual exon. 
Lane 1: X174 Marker, 
Lane 2 A3 Exon 5, 	 Lane 3: A3 Exon 7 Lane4: A4 Exon 7, 
Lane5: A4 Exon 5, 	 Lane 6: A5 Exon 8 Lane 7: G13 Exon 5, 
Lane 8: G1 Exon 8, 	 Lane 9: G2 Exon 7 Lane 10: G9 Exon 7, 
Lane 11: G10 Exon 7, 	 Lane 12: Markel-0174 
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Figure 3.22 Hetroduplex analysis of p53 gene. Included are amplified exons 5-8 of 
DNA from HTori-3 control cells and HTori-3 cells expressing the DLD phenotype. 
Selected exons from alpha and gamma tumour DNA templates are also included. 
Gel confirms that the p53 status is not altered between normal and DLD expressing 
templates. Any mutants would appear as a double band, e.g. positive control lane 3. 
No mutants were found. 
Lane 1: 40C174 Marker, 	 Lane 2: HaCaT Exon 8, Lane 3: HaCaT Exon 5, 
Lane 4: HT Exon 8, 	 Lane 5: HT Exon 7, 	 Lane 6: HT Exon 6, 
Lane 7: HT Exon 5, 	 Lane 8:HT-8 Exon 8, 	 Lane 9: HT-8 Exon 7, 
Lane 10: HT-8 Exon 6, 	 Lane 11: HT-6 Exon 5, 	 Lane 12: Alpha lExon 6, 
Lane 13: Alpha 4 Exon 7, 	 Lane 14: Alpha 9 Exon 6, Lane 15: Gamma 13 Exon 5 
Lane 16: Gamma 9 Exon 6. 
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Figure 3.23 Hetroduplex analysis of p53 gene, exons 5-8 on a high resolution 
spreadex gel. Mutant hetroduplexes form an extra band(s) and are usually retarded 
in the gel. No mutants were found. 
Lane 1: 0X174 marker, Lanes 2-5: HT template, exons 5-8. Lanes 6-9: XA tumour 
DNA template, exons 5-8. Lanes 10-13: XC tumour DNA template, exons 5-8. 
Lanes 14-17: ST tumour DNA template, exons 5-8. Lanes 18-21: ST tumour 
expressing DLD phenotype, exons 5-8. 	 Lanes 22 and 25: HaCaT positive 
controls, exons 5 and 8. Lane 22-24 negative controls, exons 6 and 7. 
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Figure 3.24 SSCP gel of p53 exons 5-8 of HT and tumour templates XA, XC and 
ST. Possible mutations were found in lane 8, lane 12, lane 14 and lane 16. However, 
due to the high number of background bands it is difficult to confirm these as true 
mutants without sequencing. 
Lane 1: 0X174, 	 Lane 8: XA Exn 7, 	 Lane16: ST Exn 6, 
Lane 2: HT Exn 5, 	 Lane 9: XA Exn 8, 	 Lane 17: ST Exn7, 
Lane 3: HT Exn 6, 	 Lane 10: XC Exn 5, 	 Lane 18:ST Exn 8, 
Lane 4: HT Exn 7, 	 Lane 12: XC Exn 6, 	 Lane 19: HaCaTExn 5 
Lane 5: HT Exn 8, 	 Lane 13: XC Exn7, 	 Lane 20: 0X174. 
Lane 6: XA Exn5, 	 Lane 14: XC Exn 8, 
Lane 7: XA Exn 6, 	 Lane 15: ST Exn 5, 
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Figure 3.25 Alpha and gamma tumour template hetroduplex analysis of p53 exons 
5-8 including positive controls. No mutants were found. 
Lane 1: 0X174 marker 	 Lane 2: HT Exn 5, 	 Lane 3: HT Exn 6, 
Lane 4: HT Exn 7, 	 Lane 5: HT Exn 8, 	 Lane 6: GI Exn 7, 
Lane 7: G2 Exn 8, 	 Lane 8: G9 Exn 7, 	 Lane 9: GIO Exn 7, 
Lane 10: A3 Exn 7, 	 Lane 12: A4 Exn 7, 	 Lane 13: A5 Exn 8, 
Lane 14: A6 Exn 6, 	 Lane 15: A9 Exn7, 	 Lane 16: GIO Exn 7, 
Lane 17: HaCaT Exn 5, 	 Lane 18: HaCaT Exn 8, Lane 19: blank 
Lane 20: Blank. 	 Lane 21: 0X174 marker. 
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Figure 3.26 Alu repeat polymorphism on 8% acrylamide gel. 406 Bp products all 
appear the same size. Any variation in product size may indicate genomic instability 
within each cell line tested. No variation was found at this resolution. 
Lane 1: 4X174 marker. 	 Lane 2: HT Mu 	 Lane 3: XA Mu 
Lane 4: XC Mu 	 Lane 5: ST Mu 	 Lane 6: XA-8 Mu 
Lane 7: XC-8 Mu 	 Lane 8: ST-8 Mu 
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Figure 3.27 High resolution spreadex gel of Mu repeats. Includes normal and 
DLD phenotypes for new tumour cell lines. Each band represents a 406 base pair 
product from an early intronic sequence of p53. Up to 5 bp variations could be 
resolved, possibly indicating genomic instability. 
Lane 1: Marker 0X174 
Lane 2. HT 	 Lane 6.XC 
	 Lane 10. A3 Exn 5 
Lane 3.HT-8 	 Lane 7.XC-8 	 Lane 11. A4 Exn 7 
Lane 4. XA 	 Lane 8.ST 	 Lane 12. GI Exn 8 
Lane 5.XA-8 	 Lane 9.ST-8 	 Lane 13. G2 Exn 7 
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3.6 Investigations into the delayed induction of 
Micronuclei 
Micronuclei are small distinct fragments of nucleus that may be used to measure the 
effects of radiation damage and therefore the induction of genomic instability. In 
these experiments, micronuclei are scored immediately after irradiation (72 hours 
permitted for colony formation) or at intervals of four weeks post-irradiation. 
Scoring colonies of cells grown on slides overcomes the limitations associated with 
cytochalasin block that only permits the scoring of binucleated cells, as described by 
Fenech et al, 1985. 
3.6.1 Experimental Procedure 
For analysis of immediate, (T=0) and delayed, (T=4) formation of micronuclei, 
tumour cells were harvested either immediately following irradiation and/or 
following four weeks of in vitro incubation. 
Cells were seeded onto coverslips and incubated for 72 hours to permit the 
formation of colonies. Irradiated cultures were seeded at 10X the dose of controls to 
compensate for radiation induced cell killing. Following incubation, dishes were 
giemsa stained and mounted on glass slides ready for evaluation. 
Selected alpha and gamma tumour lines were selected on either being highly or 
poorly transforming. X-ray and strontium lines were also included to provide a 
range of data covering a variety of radiation transforming qualities. Cell colonies 
from 4-16 were scored and the number of micronuclei per cell within each colony 
was scored. Binuclear and pyknotic cells were also scored. 
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3.6.2 The Results 
Micronuclei formation was found in all cell lines tested. Figure 3.28 shows a typical 
colony of HTori-3 cells and a high power picture of a micronucleus. All cell lines 
tested at T=0 gave a characteristic dose response. 
However, data were collected from those cells expressing the DLD phenotype at 
four weeks post-irradiation produced more diverse results. While the gamma 
tumour cell line G2 appeared relatively radioresistant to the formation of 
micronuclei G1 did not. It must be remembered that although each TCL was 
originally transformed with either alpha or gamma or x-rays each was then irradiated 
with a Cs137 gamma source to induce the DLD phenotype. As such, it is difficult to 
find trends between the different radiation sources used. However, in all cases cells 
irradiated were never able to recovery to levels observed in control cultures. 
HTori-3 cells scored at 72 hours post-irradiation showed that a dose of 8 Gy was 
able to induce the highest frequency of micronuclei. At T=4 an elevated frequency 
of micronuclei formation was observed that remained dose dependant and elevated 
above that of its control (see Figure 3.29). Figure 3.30 represents the micronuclei 
frequency in selected tumour cell lines. It is interesting to note that the new tumour 
cell lines XA-1 and ST-1 have the highest frequencies of micronuclei when 
compared to the well established alpha and gamma tumour cell lines. Intra-colony 
variations were noted and are displayed graphically in Figure 3.31. 
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3.6.3 Conclusions 
• Dose dependant increase in micronuclei formation is observed immediately after 
irradiation 
• Levels of micronuclei remain elevated upto 4 weeks after irradiation 
• Fluctuations in the frequency of colony size and micronuclei numbers at up to 6 
Gy may be indicative a generalised genome instability. 
• At doses above 6 Gy most cells are lethally damaged and are unable to form 
colonies. Those 8 Gy irradiated cells that form colonies are true survivors and 
thus plate/divide normally with reduced frequency of micronuclei. 
• Enhanced levels of colony micronuclei may contribute to the expression of the 
DLD phenotype and may be a good indicator of cellular instability post-
irradiation. 
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Figures 3.28 Panel "A" shows a low power (x400) HTori-3 colony as observed when scoring micronuclei. High power micronuclei within a 
single cell (x800) can be seen in panel "B". The non-clonal distribution of micronuclei observed suggests de novo mutations arising in the 
population independent of colony size. This is indicative of an unstable population. 
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Figure 3.29 Comparison of micronuclei formation in HTori-3 cells immediately following radiation (blue bars) and in those cells cultured for 4 
weeks after the radiation dose and then tested (red bars). Although both show a dose dependant increase, the levels after 4 weeks in culture 
remain elevated above that of the control. 
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Figure 3.30 Frequency histogram of micronuclei found in HTori-3 control cells, selected alpha and gamma lines as well as a strontium and x-ray 
acute tumour cell lines were examined. All but A5 show an elevated frequency of micronuclei at 4 weeks post-irradiation. 
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Figure 3.31 Colony micronuclei frequencies in HTori-3 cells as a function of colony size over a range of doses. Eight cell sized colonies are 
the most frequently recorded due to 72 hr incubation period. A high level of odd number sized colonies indicate high levels of instability, as not 
all cell divisions are being completed successfully. 
3.7 Analysis of Attachment Ability in radiation 
transformed cells 
The HTori-3 cell line and the radiation induced thyroid tumours derived from it were 
examined for their ability to attach to a substrate at two weekly intervals post-
irradiation. Variations in the cells' ability to attachment to a plastic surface could be 
a sign of early transformation events and skew any colony assay data. It may also 
implicate cell surface attachment proteins in the DLD phenotype. 
3.7.1 Experimental Procedure 
Initially, the parental HTori-3 cell line and HT cells expressing DLD after 8Gy and 
two weeks incubation were chosen, designated HT and HT-8 @ T=2 (see figure 
3.32). Shortly after the experiment was developed to include the tumour cell lines 
XA, XA-8 and XC, XC-8. These were tested at time intervals of T=2, T=4, T=8 and 
T=12 weeks post radiation (see figures 3.33 and 3.34). 
Each cell line to be tested was passaged at sub-confluence and then serially diluted 
from a stock of 200,000 c/ml. The following concentrations were made: 40,000 
c/mi; 20,000c/ml; 15,000c/ml; 10,000c/ml; 5,000c/ml; 2500c/ml; 1250 c/ml and 
625c/ml. All concentrations were seeded in a volume of 200111 per well, in a 96 well 
flat bottom microtitre plate. Each cell concentration had eight replicates per dish 
and each dish was repeated three times. Each experiment was completed within the 
minimum time constraints allowed, to prevent dividing cells having an influence on 
the outcome. 
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3.7.2 Results 
An small decrease in attachment ability was observed over the lower range of cell 
concentrations used at four weeks post-irradiation(see figure 3.32). The data 
collected indicates that at low cell concentrations attachment ability may play a 
contributory factor in the expression of delayed lethal damage phenotype up to four 
weeks post irradiation. However, after this time and at high cell concentrations the 
cells' ability to attach to a surface appears to diminish or becomes uncertain. 
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Figure 3.32 HT and HT-8 attachment ability as measured through the MTT dye 
exclusion assay at four weeks post-irradiation. 
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3.7.3 Conclusion: 
• Anchorage independence may be expressed in the DLD phenotype and help to 
explain the decreased plating efficiencies in colony assays. 
• Lack of cell surface adhesion in DLD expressing cell lines could be investigated 
at the molecular level by looking for mutations in known genes involved in the 
attachment process. 
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Figure 3.33 MTT mean attachment ability for XA and XA-8 tumour cell lines after 2, 4, 8 and 12 weeks of in vitro incubation post irradiation. 
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Figure 3.34 MTT mean attachment ability for XC and XC-8 tumour cell lines after 2, 4, 8 and 12 weeks of in vitro incubation post irradiation. 
3.8 Measurement of Apoptosis and Necrosis in 
anchorage dependent and independent cells 
Apoptosis has been implicated as a cause of the delayed lethal death phenotype in 
non-tumourigenic cells but not tumour cells (O'Reilly et al 1994, Mothersill, et al 
1995, 1996). It has been suggested that DLD is a "cleansing mechanism" signalled 
externally and used to eradicate lethally damaged cells before they become 
tumourigenic. This author wanted to investigate if the radiation induced thyroid 
tumours produced in this study were also expressing a delayed form of apoptosis. 
3.8.1 Experimental Protocol 
Adherent and non-adherent cells were collected from exponentially growing cultures 
of the parental, non-tumour, cell line HTori-3 and the tumour line XA-1, these were 
designated FIT and XA. To induce the DLD phenotype, cells were irradiated with 8 
Gy of gamma rays and passaged for 4 weeks in vitro, these cells were designated 
HT-8 and XA-8. 
The media was decanted and spun for the collection of floating cells, while the 
culture flask was passaged and samples of adherent cells aliquoted. All cells were 
diluted to 20,000 c/m1 and then a single drop of dye was added (acridine 
orange/ethidium bromide). 
3.8.2 Results 
Distinction between transformed and non-transformed, floating and adherent could 
be made. As expected, the relative percentage of necrotic cells in the floating 
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fraction was higher than that of the adherent population in both groups. However, 
levels of apoptosis appeared higher in the cells expressing delayed lethal damage. 
The tumour cell line had an increased percentage of apoptotic cells over the non-
tumour line (See table and figure 3.35). Internucleosmal degradation could be 
subdivided into early apoptotic, late apoptotic, early necrotic or late necrotic 
(Compton et al, 1992, Eastman, 1995). 
3.8.3 Conclusions 
Although it is likely that apoptosis may play a role in the expression of DLD and 
explain the decrease in plating efficiency found in tumour cell line colony assays the 
data presented here is insufficient to confirm these findings. There are always 
uncertainties in scoring apoptotic and necrotic cells, as such an alternative assay 
would be required to confirm these results e.g. TUNEL. 
Table 3.5 	 Fraction of apoptotic and necrotic cells in floating and adherent 
fractions of non-tumour and tumour cell populations 
Non Tumour HT 
Adherent 
HT 
Floating 
HT-8 
Adherent 
HT-8 
Floating 
% Apoptotic 3 4 4 5 
% Necrotic 5 8 6 9 
Tumour XA 
Adherent 
XA 
Floating 
XA-8 
Adherent 
XA-8 
Floating 
% Apoptotic 5 7 6 7 
% Necrotic 7 9 8 10 
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Figure 3.35 X-ray acute tumour (control) cells can be seen in panel "A", while panel "B" shows the same tumour cell line that expresses the 
DLD phenotype (i.e. previously irradiated with 8Gy and incubated in vitro for 4 weeks). An enhanced frequency of necrotic cells are present in 
panel "B" with an elevated apoptotic population. Green cells are viable, orange are necrotic. Apoptotic cells are green but with eclipse shaped 
chromatin. 
Chapter 4 
DISCUSSION 
4.1 General Discussion 
Transformation of human cells in vitro has proven difficult. Models of the past have 
relied on murine and rodent cell lines. The HTori-3 system hoped to overcome these 
problems with the use of an immortalised human epithelial cell line. An advantage 
of this type of system was, not only could cells be cultured indefinitely, but any 
tumours produced could be directly correlated with the non-transformed parental cell 
line. Phenotypic and genotypic comparisons could then be made. It was anticipated 
that this model would be more relevant than other animal cell systems and permit the 
correlation of in vitro carcinogenesis more closely with that of human 
carcinogenesis. 
The use of nude mice allows the screening of large numbers of cells from different 
experimental procedures in a relatively short time period e.g. 3-6 months, compared 
to human carcinogenesis of 30-40 years. It becomes experimentally feasible to 
produce tumours using a variety of ionising radiation sources and directly compare a 
number of variables e.g. the effects of dose, cell number, passage. 
The importance of developing a model of thyroid carcinogenesis is clear. The 
ability to understand the mechanisms involved would impact both on cancer 
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research and radiation biology. The major findings from this work will now be 
discussed in the light of the work of other key authors. 
4.1.1 Major Findings 
The human thyroid epithelial cell line HTori-3 has been transformed by ionising 
irradiation. These newly derived tumour cell lines have been used in a number of 
assays to test for the expression of the delayed lethal death phenotype. 
The colony assay has shown the induction of this phenotype after doses of gamma 
radiation above 6 Gy and after four weeks but not two weeks of incubation in vitro. 
The colony micronuclei assay has been used as an alternative assay for measuring 
the same biological endpoint. This method has shown that levels of micronuclei, 
giant cell formation and pyknotic bodies remain elevated many weeks after the 
initial radiation insult. 
Using the MTT cell attachment assay it has been shown that although it is likely, 
that cell adherence and apoptosis may also play an important role the expression of 
the DLD phenotype it is difficult to confirm this with the data presented here. It is 
likely that all the endpoints tested in this thesis do play a critical role in the 
expression of genomic instability and assist in the expression of transformation. 
However, further detailed investigations would be required to define their roles 
conclusively. 
4.2 Transformation Studies 
The results of this study show that the human thyroid epithelial cell line, HTori-3 
can be transformed by a single exposure to low LET radiation. Moreover, that 
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comparison of this induction can be made between the chronic and acute delivery of 
the radiation and over a range of low doses. 
In culture, the tumour cell lines (TCLs) grew in a similar fashion to the parental 
HTori-3 cell line forming continuous monolayered sheets of cell. Morphological 
appearances were identical though when growth rates were measured clear 
differences in some tumours growth curves were noticed. Experiments were 
performed to compare the radiation response of HTori-3 cells a variety of low LET 
radiation sources. These included chronic and acute x-rays, beta particles from both 
a strontium/yttrium uniform and strontium particle source as well as gamma rays 
from the Cs137 source. 
The data presented clearly shows that irradiated thyroid epithelial cells express 
genomic instability in several forms after exposure to radiation e.g. decreased 
plating efficiency. Genetic changes have undoubtedly occurred in exposed cells, 
which directly affect their ability to repair DNA damage and thereby complete stable 
divisions. Moreover, these cells are more capable in forming tumours than 
unirradiated control cells. It seems likely the expression of the genomic instability in 
the form of the delayed lethal death phenotype and the formation of tumours are 
directly related and dependent. 
All cultures exposed to radiation were passaged once weekly for six weeks. This 
step has been regarded as indispensable for the fixation of damage (Borek & Hall, 
1966; Borek & Sachs, 1967; Reznikoff et al, 1992). Whether this period is required 
for the expansion of the transformed cell(s) is unlikely, as it would mean that 
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transformation occurs almost instantaneously or within the short period of time that 
the cells are passaged in culture. It is more likely that this period of passaging 
provides time for the fixation of damage. Damaged cells are then able to replicate 
and accumulate more mutations, which makes cells increasingly unstable. It is a 
high concentration of unstable cells, which are then screened in mice. Selection, 
which has occurred to an extent in vitro, is likely to continue in vivo. 
However, other reports have shown that this step may not be necessary. Some 
suggest that the effects of radiation may linger for some time after the initial delivery 
of the dose Clutton et al, 1996). Persistent oxidative stress and the release of stored 
free radicals from the cytoplasmic endoplasmic reticulum have all contributed to this 
theory, (Clutton et al, 1996; Kadhim et al, 1995, 1996, 1998; Watson 1997). 
A relationship for the radiation dose delivered and the subsequent transformation in 
vivo can be made. Although a range of low doses were screened for their tumour 
forming potential they do not show a dose response, tumours were found in all but 
one group. This data is consistent with other reports (Borek and Hall, 1973). 
Moreover, the single transforming dose is also supported by others (Martin et al, 
1993 and Hei et al, 1994). 
To expand, all groups of cells screened, except the X-ray chronic 0.5 Gy, produced 
progressively growing tumours. Although a few tumours were found in the control 
groups these remain insignificant when tested statistically. The reasons for control 
tumours maybe the result of a general instability within the HTori-3 cell line. This is 
difficult if not impossible to control for. The original paper by Lemoine in 1989 
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provides data on the unstable karyotype of the cell line. Data from studies in our lab 
shows an increase in chromosomal aberrations with passage number. Indeed as the 
cell line has been immortalised with the SV40 virus the p53 protein status is 
uncertain. As such it is not known whether the cells are able to induce a G2 or even 
a G1 arrest. There may well be an accumulation of damage over time in HTori-3 
cells, which remain unexposed to experimental doses of radiation. It is possible that 
background levels of radiation could conceivable induce a mutator phenotype along 
the lines of that suggested by Loeb (1991). HTori-3 must be regarded as a partially 
transformed cell line thus the work described in this thesis has used several related 
cell and molecular endpoints e.g. plating efficiency, micronuclei, formation, cell 
adherence, gene mutations as indicators of genomic instability. These variables 
were first studied in the parental cell line HTori-3 to provide a definitive background 
level of spontaneous genomic instability. Samples of cells were then irradiated and 
screened for their tumourigenic potential in nude mice. Tumours derived from these 
experiments were then used to further investigate and compare the levels of 
instability with controls 
It is likely that the tumours created in this study have defective repair pathways. In 
humans lack of these pathways have been found in a number of hereditary diseases, 
these syndromes predispose individuals to higher rates of stabilised damage and an 
increased risk of cancer. The genetic diseases that result include xeroderma 
pigmentosum which is characterised by extreme sensitivity to sunlight, ataxia 
telangiectasia which predisposes individuals to elevated sensitivity to x-rays with 
immune and blood vasculature abnormalities. Others include Fanconi's anaemia, 
Bloom's and hereditary retinoblastoma and the germline p53 minus syndrome Li- 
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Fraumeni. Underlying all these genetic diseases and syndromes are mutations; 
hereditary mutations, mutations induced by ionising radiation or any other 
deleterious sources. 
This study demonstrates that human thyroid epithelial cells can be transformed by 
exposure to chronic or acute x-rays as well as strontium beta particles. It is likely 
that the SV40 immortalisation of these HTori cells is a crucial first step along the 
path to transformation. Not only does SV40 immortalised cells and permit indefinite 
cell cycling but as p53 function is compromised, it is likely to lead to an 
enhancement in the accumulation and stabilisation of mutations. The cell, primed by 
the radiation becomes incapable of preventing the further accumulation of 
mutations. This multi-step hypothesis is supported by several authors (Reznikoff et 
al, 1992, Rhim, 1990, Loeb, 1991) 
4.2.1 Characterisation of Tumour Cell Lines 
The production of tumour cell lines (TCL) was a primary concern after irradiated 
HTori-3 cells formed tumours in nude mice. Once TCLs were established it was 
crucial to confirm their human phenotype. Previous studies have highlighted the 
importance of confirming the nature of derived tumours from in vitro experiments. 
In vitro assays of this kind can easily be contaminated with other cell lines which out 
compete the growth of the original leading to erroneous results and conclusions 
(McCormick et al, 1988). 
Half of each tumour was sectioned and taken for histological analysis. The paraffin 
embedded sections revealed that the tumours were anaplastic and classified as 
undifferentiated anaplastic carcinomas. Reports after the Chernobyl disaster 
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indicated that papillary thyroid tumours dominated the childhood cases, (Baverstock 
et al 1992). Of the primary tumours retransplanted in to nude mice, all formed 
progressively growing secondaries from the time of injection with significantly 
reduced latent periods. Growth rates were much faster and the time to excision of 
the tumour was greatly reduced, thus confirming their tumourigenecity. This is 
confirmed by the work of Reznikoff (1992). Karyotype analysis of selected tumours 
was performed by preparing giemsa stained chromosome spreads. Although the 
number of chromosomes varied considerably and chromosome aberrations were 
frequently encountered the human nature of all spreads was unmistakable. 
Dose response curves from the different tumour cell lines created showed an initial 
shoulder region characteristic of low LET radiation. Gamma and x-irradiation is 
relatively sparsely ionising and thus relatively ineffective at killing cells at low 
doses. The intrinsic repair capacities of the cell are able to overcome the damage 
sustained, especially during chronic irradiations. However, the results presented in 
this thesis show how latent damage can lead to cell death many generations after the 
initial dose response. 
4.2.2 Dose Response Data 
To compare the parental dose response with that of the other TCLs survival curves 
were constructed. Where appropriate the linear quadratic, model which assumes that 
there are two components to cell killing by radiation was used. While some of the 
lines appeared relatively radiosensitive e.g. A9 others showed an elongated shoulder 
region suggestive of increased radioresistance e.g. A3. A similar pattern was 
observed for the gamma tumour dose response. While G10 appeared radiosensitive 
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G13 dose response up to 8Gy was more suggestive of a relatively radioresistant cell 
line with an extended shoulder region. 
To investigate this further a number of comparison were made to see if any patterns 
could be observed between the cell lines dose response and a number of collected 
variables which could characterise each cell line as an individual. Unfortunately, no 
substantial correlation could be drawn between the cell lines p53 status, mutation 
type, passage number, doubling time or growth in culture. While some of the cell 
lines grew extremely rapidly others were relatively slow growers, this could not be 
correlated with either the irradiation regime, radiation quality or the cell lines 
subsequent dose response. 
4.2.2 Radiation Induced Tumourigenesis and the Mutator 
Phenotype 
It has been suggested that p53 mutations may be indicator of radiation induced 
tumourigenesis (Taylor et al, 1994). Cancer progression is thought to be a multistep 
process (Rhim, 1990). Certain cancers e.g. HNPCC have rate limiting steps 
involving 6-12 key rate limiting genes that directly or indirectly affect cell 
proliferation. Loeb (1991) has predicted that the known mutation rate in somatic 
body cells = 10E7 per cells per generation. This rate is inadequate to account for the 
large number of chromosome rearrangements found in some cancer cells. Thus, the 
chance of a single cell accumulating six or more mutations in its lifetime are very 
unlikely. Yet carcinogenesis occurs and chromosome spreads of tumour cells 
derived from this study show an array of chromosome abnormalities. 
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However, Loeb's early calculations did not take into account an increased mutation 
rate. Such an increase could be induced by a single mutation in genes that repair 
damage. Under these circumstances a mutator phenotype could be induced, 
hastening the chances of a transformation. One indication of a cell with a mutator 
phenotype is the appearance of variations in microsatellite sequence lengths. Losses 
at specific gene loci, which are not matched on the complementary strand, are 
termed LOH or loss of hetrozygosity. Thus an Mu repeat sequence from the early 
intronic region of the p53 gene (Lengauer et al 1992) was used in the current study 
as a potential marker of a) mutator phenotype b) presence of genomic instability. 
However, it is more common for other types of repetitive sequences to be used in 
these types of studies, such as mini or microsatellite. 
4.2.3 P53 and Mu repeats 
The Alu repeat sequence was amplified using the PCR technique and then size was 
determined by electrophoresis. Results indicate that the size of Mu repeat sequence 
does vary in the tumour lines investigated. Moreover a precedent for variations by 
Dubrova et a/ (1996) confirms that the human minisatellite sequences do vary after 
exposure to ionising radiation. The mutation rate in the area surrounding Chernobyl 
was measured using a tandem repeat minisatellite was found to be twice that of the 
control group. 
Estimates of doses received after the Chernobyl accident have been calculated at 
about 0.185 Gy per person (Dubrova et al 1996). It has been suggested that these 
low chronic doses of radiation are more effective in the induction of tumourigenesis 
and enhancing the mutation rate (Dubrova et al 1996). Suggestions of how radiation 
161 
can induce alterations in the mutation rate have been linked to mutator phenotype. 
The initiating lesion includes the loss of regulatory repair pathways. 
In this study PCR amplified DNA from selected alpha and gamma, strontium and x-
ray radiation induced TCLs were tested for the presence of p53 mutations. Exons 5-
8, known to be hotspot regions involved predominately in the DNA binding domain 
were amplified. DNA extracted from XA TCL exon 8, XC exon 7 ST exon 5 and 
ST exon 7 appeared to have mutations, though DNA sequencing would be required 
to confirm this. No mutations were detected in any of the selected alpha and gamma 
TCLs previously established in this laboratory. There are conflicting reports on the 
association of p53 mutations in thyroid carcinogenesis Ito et al (1992) reported 
mutations at exon 5 and 8, suggesting that p53 mutations have an important 
contribution in the development of thyroid cancer. However, Wright et al, (1991) 
appears to conflict with this argument after investigating p53 mutations in primary 
thyroid cell lines. However, as only a small sample of cell were tested for mutations 
it is difficult to come to a firm conclusion regarding its role in the pathogenesis of 
thyroid carcinogenesis. 
4.2.3 Repair Pathways and Genomic Instability 
The mismatch repair and polymerase genes sustain the careful balance between the 
need for replication and restoration of the DNA helix. If either of these genes which 
code for the proteins of this mechanism are damaged then the likelihood of other 
sequences being disrupted are increased. This in turn leads to the phenomenon of 
the mutator phenotype (Loeb et al, 1991), whereby a positive feedback loops which 
results in the increased accumulation of mutations. 
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If a cell loses mismatch control and checkpoint control e.g. loss of p53, the mutation 
rate would raise dramatically, increasing the chance of uncontrolled cell division. 
As the frequencies of un-repaired mutations rise the likely hood of one arising in 
other important genes may also rise exponentially. Cahill et al, (1998) has shown 
how mutations in genes controlling the mitotic spindle apparatus that prevent 
chromosome attachment will accelerate the formation of aneuploidy and or 
polyploidy cells. 
Under normal circumstances, chromosomes are attached by their kinetechore to the 
microtubule spindle apparatus. Chromosomes poorly attached will produce a signal 
that induces a checkpoint preventing the transition to anaphase until the correct 
alignment is achieved. The genes responsible for this signal, which were initially 
found in yeast, have now been identified in humans. Three BUB (budding 
uninhibited by benomyl) and 3 MAD genes (mitotic arrest-deficient) and the protein 
kinase Msplp also has a contributory function. A mutation in these genes results in 
chromosome instability and acquired aneuploidy. 
The tenet of much cancer research is based on the belief that if mutant alleles of a 
gene are consistently detected in tumours, than these mutations are likely to confer a 
selective advantage on cancer cell clones and progression of the disease. In this 
study, PCR amplification of a number DNA transcripts for possible mutations 
proved largely unsuccessful. From the few possible mutations found in the 
strontium and x-ray lines it is difficult to conclude the effectiveness of p53 
mutations as a potential instigator of the later phenotypic changes. However, there 
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is little doubt that radiation is able to induce a specific phenotype change, which can 
be studied in detail in using this thyroid model. 
4.2.4 Correlation with Chernobyl 
After the Chernobyl accident the incidence of childhood thyroid tumours increased 
dramatically (Baverstock et al 1992) and as previously mentioned so did the 
mutation rate (Dubrova et al 1996). Many of the childhood tumours were screened 
for mutations found in normal adult tumours e.g. ras and p53 mutations. The results 
of that study showed that less than 20% of childhood thyroid tumours analysed had 
p53 mutations (Hilldebrandt et al, 1996). However, this data correlates with the lack 
of p53 mutation found in this study. In a recent paper by Suchy et al, 1998 none of 
an additional 34 children sampled for mutations in these genes proved positive 
either. They conclude, "ras or p53 mutations do not play a role in childhood thyroid 
carcinogenesis after Chernobyl". Results presented in this thesis confirm this result 
as both Iodine 131 and gamma particles were used throughout this study and should 
produce effects similar to those found after the release of radiation from the 
Chernobyl accident. 
Other data from childhood thyroid tumours after the Chernobyl disaster states that 
most were papillary carcinomas or PTC, solid and follicular variants predominated 
(Palle and Salomaa, 1994). Any adult tumours found after the Chernobyl accident 
were mostly undifferentiated, anaplastic variants. In this study the largest tumour 
from each group of each screening was excised. Half was used to produce a new 
tumour cell line (TCL), while the other half was taken for histological purposes. 
The sections showed that all the tumours were anaplastic in nature, showing little 
sign of their tissue of origin. Occasionally, a section would show signs of 
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differentiation i.e. the formation of small follicular areas but these were sparse. The 
larger tumours showed signs of vascularisation. 
High frequencies of stable and unstable aberrations in lymphocyte of people exposed 
to Chernobyl fallout have been reported (Salomaa et al, 1997) and chromosome 
painting techniques using primary thyroid tumours (Lehmann et al, 1996) have 
revealed translocations on chromosomes 1, 4 and 12. However, only a high 
incidence of RET rearrangements have been reported in thyroid tumours of children 
from Belarus. Mutations commonly observed in adult thyroid tumours are of the 
cRET/HGF receptor gene (diRenzo et al 1992) and activating ras mutations (Bos, 
1989). Ito et al, (1993) has shown that these rearrangements can be induced in vitro 
in a human thyroid cell line but very high doses are required, in excess of 50Gy. 
Screening current tumour lines for RET rearrangements would be able to confirm 
their presence in tumours induced in vitro and confirm their importance in thyroid 
tumourigenesis. 
cRET encodes a receptor type tyrosine kinase whose ligand is unknown, it is a 
proto-oncogene that becomes oncogenic in one of three intronic splice variants with 
the unknown H4 gene or ubiquitously expressed ELE 1 gene. Two thirds of 
childhood PTC tested showed RET rearrangements, this is very high when compared 
with adult PTC. Possibly a time dependant mutation is occurring whose expression 
is reduced over time and whose expression may vary with age, it is possible that 
RET rearrangements are only active during childhood. It is hoped that RET 
mutations maybe a radiation induction mutation signature of papillary thyroid 
tumours, especially in children. 	 Screening current tumour lines for RET 
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rearrangements would be able to confirm their presence in tumours induced in vitro 
and confirm their importance in thyroid tumourigenesis. 
So it can be concluded that although the Chernobyl tumours found in children are 
now thought to be radiation induced, the specific lesions original anticipated to be 
involved e.g. p53 are now not thought to play a role in their pathogenesis. However, 
other genetic markers such as variations in minisatelites and Alu repeat sequences as 
well as other genes e.g. RET involved in growth regulation are being investigated. 
Moreover, this study has been able to produce a model of radiation induced 
tumourigenesis and provide a valuable source of radiation induced tumours cells 
which are required to continue investigations in this area of radiobiology. 
4.3 Delayed Lethal Damage 
The original premise in early sixties was that radiation induced damage would result 
in cell death within the first few population doublings; And that radiation survivors 
were indistinguishable from unirradiated cells (Elkind and Whitmore, 1967). Work 
by Nias (1965) and Grote (1981) attempted to explain the reduced growth rates in 
radiation cell survivors in terms of an increased cell cycle time and this author would 
agree that this is a contributory factor. Variations found in colony sizes in this 
study and growth curve data suggest that cells expressing DLD have an elongated 
cell cycle time. However, OReilly, (1994) believed that the failure of irradiated 
cells to produce viable colonies was in a proportion of the cells failing to produce 
two viable progeny, rather than this elongated cell cycle time. 
However, work published principally by Seymour and Mothersill proposed that the 
reasons for a reduced ability for a successful reproductive life could include: 
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1 	 Damage to a Mutator gene 
2 	 Damage to a Lethal mutation gene 
3 	 Induced form of apoptosis 
Their experiments for the reassessment of cloning efficiency (delayed plating 
efficiency) in post-irradiation cultures allowed the correction of survival curves 
resulting in a new residual curve, i.e. a fraction of cells originally termed 
reproductively viable at the first plating efficiency are subsequently lost from the 
population when the plating efficiency is reassessed sometime after the initial 
radiation dose is received. 
Loss of the initial shoulder resulted in a series of experiments to investigate the 
effects of repair (Mothersill et al, 1989). An inhibitor of repair (sodium arsenate, 
which reduces levels of ATP) was added to cultures post-irradiation. It was found 
that inhibition of repair prevented the expression of DLD, as all lethality occurred 
with the first few population doubling. It was only repair occurring in the first 2 
hours after irradiation that lead to the expression of DLD (Seymour and Mothersill, 
1989) i.e. that is a subpopulation of sub-lethally miss repaired cells is what leads to 
the expression of the DLD phenotype. 
The increased frequency of chromosome aberrations found in irradiated HTori-3 
cells would tend to support this hypothesis. Experiments by Alper, (1988) and 
Chang and Little, (1992) proved that double strand break repair deficient cell lines 
e.g. xrs-1 mutants did not express DLD. Fractionation of dose resulted in reduction 
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of DLD and the first dose proved the most important in DID induction. Metabolic 
inhibitors or dsb inducers would lead to DLD, while cytotoxic agents like cisplatin 
did not (Mothersill, 1991). However, Mothersill states that lethal mutations are 
either reduced or do not exist in tumour cell lines. Lastly the irradiation of cells with 
gap junctions for extracellular communication resulted in fewer lethal mutations 
than single cells without (Mothersill, 1997). 
Further work by Mothersill has shown the release of a chemical into the media of 
irradiated cells that can be added to unirradiated cultures resulting in the effective 
expression of DLD. This work suggests that although gap junctions may prevent the 
transmission of a secreted substance preventing the induction of increased cell death 
unirradiated cells can still be induced into cell death. 
All these results suggest that fast but defective repair of dsb was the main cause of 
DLD, which this author agrees with. In this study delayed cell death has been 
shown to predominate, but not exclusively from apoptosis, this is also supported by 
(Mothersill and Seymour, 1997). 
Thus, apoptosis is an important process involved in the expression of DLD. 
Investigations into the processes involved in apoptosis have shown that the active 
prevention of programmed cell death is caused by the upregulation of the anti-
apoptosis gene Bc12. Evidence suggests that rather than cells dying from a p53 
mediated apoptotic pathway, it is the reduction in the levels of Bc12 in the progeny 
many divisions after the initial radiation that finally allows the cells to die of 
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apoptosis. As p53 function is undetermined in HTori-3 cells, this method of cell 
death may be a mechanism active in HTori-3 tumours. 
Mothersill et al, have been shown that the levels of Bc12 fall to 50% at 10-15 
population doublings after irradiation and this correlates well data presented in this 
thesis, (Seymour and Mothersill, Unpublished). The expression of DLD appears to 
be independent of p53 status as mutant human keratinocytes, which are p53 mutants 
are still able to express DLD. Again, this correlates well with lack of observed p53 
mutants found in this study. 
However, Mothersill et al 1996 claim that lethal mutation are only found in the non-
tumourigenic cell lines. The DLD phenotype is induced only to act as a "mechanism 
for ridding the population of unstable cells rather than being an expression of 
instability" (Mothersill et al 1996, page 719). On the basis of the work presented in 
this thesis, this author would fundamentally disagree with this hypothesis. Instead, I 
propose that delayed lethal damage is an expression of de novo genomic instability 
induced by ionising radiation. Results in this thesis also suggest that the presence of 
micronuclei and cellular adherence are also factors. 
In addition, reports by Mothersill et al express terminal differentiation in the form of 
giant cell formation, formation of vacuoles and lipid accumulation and even, some 
senescence. Giant cell formation was found to be a common feature in the post-
irradiation cultures in this present study. In vivo it is likely that a complex 
combination of these processes all contribute to the expression of the DLD 
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phenotype. This study sets a precedent in that the DLD phenotype has been induced 
in thyroid tumour cell lines using a broad range of radiation qualities. 
During the current studies I have attempted to induce tumour cell lines through a 
variety of ionising radiation sources. Having established their tumourigenic 
potential I wanted to investigate if the DLD phenotype could be expressed. The 
results from the series using tumour cell lines support the hypothesis that delayed 
lethal death phenotype is the expression of genomic instability induced through 
doses of low LET radiation. 
4.4 	 Further Work 
Further work that would like to have been undertaken was to investigate the 
mismatch repair genes MSH2 and MLH1 using the reverse transcriptase PCR 
method to look at protein transcripts. Loss of mismatch repair and MIN would be a 
good indication of why these cell lines express DLD. Repeats of these assays using 
a non partially transformed cell line would also be advantageous. 
Multiple roles have been discovered for mismatch repair genes. In addition to 
correcting the genetic anomalies that occur during normal cell replication, these 
genes fix environmentally induced DNA damage and have also been implicated in 
regulating the cell cycle. Mismatch repair proteins are known to repair a variety of 
environmentally induced lesions, including those from ultraviolet radiation, ionising 
radiation and oxidation. Defective DNA results in defective transcripts and an 
altered protein function. Malformed proteins are likely to have deranged functions 
and an inability to identify mismatches. (Burke, 1990, Bignami, 1994). 
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Any lack of proof reading and mismatch repair is crucial and potentially lethal to the 
cell. Transcripts are at a far higher risk from environmental free radical and other 
base damage attack than at any other event of the cell cycle. 
Work with mutant MLH-1 has shown that neither cell cycle arrest nor repair will 
occur without it. It is believed that the important implications for this work are the 
refinement of chemotherapy regimes. For example, HNPCC patients often do better 
than others because the damage induced by the drugs are hampered by the lack of 
mismatch repair genes and thus more cells die. (Hoguen, Kim et al, 1998). 
Mismatch repair errors can in vivo through replication errors, hetroduplex formation, 
deamination of 5-methicytosine and the presence of DNA adducts, such as those 
induced by U.V. Cells cope with this damage by the recruitment of specialised 
proteins able to recognise, excise and correctly match mismatched bases. In addition 
to this, mismatch repair genes have been implicated in cell cycle arrest, 
microsatellite instability and proto-oncogene instability. (Hoguen Kim, et al, 1998, 
Wind,- et al, 1995, Mac Phee, 1995 and Modrich, 1994). Of the many genes found 
four have been directly implicated. hMSH2, hMLH1, hPMSI and hGTBP hMSH2 
and hGTBP form a dimer that is able to recognise mismatched base pairs and 
directly bind to the region, hPMSI and hMLII1 are able to recognise the 
DNA/protein complex and also bind. Once the protein complex is complete ATP is 
exchanged for ADP and in doing so a number of other ATP dependant exonuclease, 
polymerases and ligases are recruited into the protein scaffold to complete the repair 
171 
CHAPTER 5 
5.1 CONCLUSIONS 
The partially transformed human thyroid epithelial cell line HTori-3 can be 
transformed in vitro following ionising radiation to produce detectable tumours In 
vivo 
• Tumours produced were confirmed e.g. derived from the human thyroid cell line 
HTori-3 Re-injection of these tumours confirmed the, tumourigenecity and 
progressive growth from the day of injection 
• Survival studies show that all cell lines investigated had individual radio-
sensitivities, some deviating considerable from the parental line. This was also 
observed in the screening of irradiated cells in nude mice. Each sampled 
screened having a variable time to the formation of a tumour. This may be 
indicative of the stochastic nature of radiation inducing indiscriminate damage 
and a unique sequence of mutability. 
• Doses of gamma radiation are able to induce a de-stabilisation of the genome 
resulting the Delayed Lethal Damage (DLD) phenotype. Induction of the DLD 
phenotype appears most significant at doses above 6Gy of radiation and is seen 
to persist for up to eight weeks in the parental cell line. However, data suggests 
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that doses less than 6Gy may also be involved. After this period phenotypic 
stability in the form of reproductive integrity is re-established. 
• High numbers of non-adherent cells, (floaters) were observed throughout the 
incubation period. A fraction of these were later established as an apoptotic 
population 
• Measurement of cell adherence using the MTT assay indicates that this variable 
may be important in the, reduced cloning efficiencies of cells observed in this 
study 
• Colony micronuclei formation has proven that nuclear damage has been 
sustained in a dose dependant manner and is a useful marker for delayed lethal 
damage. 
• Variable sequence length of Mu repeats may be indicative of a mutator 
phenotype and subsequent DLD expression. 
• P53 mutations, although difficult to confirm in this study, remain likely to 
enhance the expression of genome instability. 
• Although suitable in providing information about the delayed lethal damage 
phenotype, this cell line could not be recommended for in vitro transformation 
studies due to a level of radiation independent tumourigenesis 
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Appendix 
202 
Human Thyroid Tumours Coding Information 
Alpha Irradiated 
New Code Old Code ZH Old Code SG Dose 
(Gy) 
Source P53 Status 
Al 2 8 0.125 0.125 a2 
A2 4 2 0.25 0.25 a4 
A3 7 7 0.25 0.25 a7 Exon 5 & 7 
A4 2 10 0.5 0.5a2 Exon 7 
A5 8 3 0.5 0.5 a8 Exon 5 & 8 
A6 1 17 0.5 0.5 al Exon 7 
A7 6 0.5 0.5 a6 
A8 4 16 1.0 1.0 a4 Exon 7 
A9 9 18 1.5 1.5 a9 
Gamma Irradiated 
New Code Old Code 
ZH 
Old Code 
SG 
Dose (Gy) Source P53 Status 
G1 T 6 0.5 0.5 GT Exon 8 
G2 C 1, 11 1.0 1.0 GC Exon 7 
G3 1 23 2.0 
G4 6 13 2.0 1x2 G6 
G5 7 9 2.0 1x2 G7 
G6 9 12 2.0 1x2 G9 Exon 6 
G7 6 4 4.0 1x4 G6 
G8 19 3x1 3x1 Exon 6 
G9 3x2 3x2 Exon 6 & 7 
GIO X 22 3x3 3x2 Exon 7 & 8 
G11 21 3x2 3x3 
G12 14 6x1 6x1 
G13 15 6x3 5x3 Exon 5 & 6 
203 
MICRONUCLEI ANALYSIS 
GI T=0 weeks 
IT=0 weeks 10/12/99  
Colonies Counted per Slide Total Total Total 
Dose: Control [1] [2] [3] [4] [5] [6] [7] [8] [9] 10 11 12 13 14 [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
SildeA 4 4 6 4 2 6 4 4 6 6 8 4 4 6 8 76 2 1 
SildeB 6 4 4 6 4 4 4 4 4 4 4 2 4 4 2 60 0 0 
Silde C 4 4 4 8 4 4 4 6 4 6 4 2 2 2 4 62 0 0 
Silde D 2 2 2 4 6 4 4 4 2 6 6 2 6 4 4 58 1 3 
Totals 256 3 4 
1.17% 
I T=0 weeks 
Colonies Counted per Slide Total Total Total 
Dose: 8 Gy [1] [2] [3] [4] [5] [6] [7] [8] [9] 10 11 12 13 14 [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
Silde A 4 4 2 2 6 4 4 4 4 6 4 9 2 4 4 63 4 2 
Silde B 8 4 6 4 4 4 7 6 4 4 5 6 6 8 4 80 6 0 
Silde C 4 4 4 4 4 4 4 6 5 4 3 8 5 4 4 67 7 0 
Silde D 4 4 5 4 6 4 8 2 4 4 6 8 4 4 6 73 7 1 
Totals 283 24 3 
8.48% 
MICRONUCLEI ANALYSIS 
GI T=4 weeks 
T=4 weeks 
Colonies Counted per Slide Total Total Total 
Dose: Control [1] [2] [3] [4] [5] [6] [7] [8] [9] 10 11 12 13 14 [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
Silde A 6 8 15 8 10 12 6 14 16 6 4 6 4 10 6 131 4 3 
SildeB 6 6 6 4 14 8 9 4 7 6 4 4 8 6 6 98 6 2 
Silde C 4 10 8 7 7 6 6 8 10 6 8 6 8 8 6 108 7 5 
SildeD 8 14 6 5 10 16 4 4 8 4 4 8 6 4 10 111 7 1 
Totals 448 24 11 
5.36% 
T=4 weeks 
Colonies Counted per Slide Total Total Total 
Dose: 8 Gy [1] [2] [3] [4] [5] [6] [7] [8] [9] 10 11 12 13 14 [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
SildeA 6 8 8 15 18 8 7 14 14 8 14 12 4 9 10 155 7 10 
Silde B 10 18 25 12 8 8 10 4 8 5 8 9 10 12 8 155 6 6 
Silde C 12 9 6 8 8 11 9 8 12 14 8 12 4 12 12 145 7 7 
Silde D 9 14 4 12 8 14 14 10 10 10 7 12 9 9 7 149 7 5 
Totals 604 27 28 
4.47% 
204 
MICRONUCLEI ANALYSIS 
G3 T=0 Weeks 
T=0 weeks 10/12/99 
 
Colonies Counted per Slide Total Total Total 
Dose Control [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
Silde A 9 16 8 8 16 8 16 6 15 14 10 16 12 14 9 177 3 7 
Silde B 16 10 8 12 8 15 14 16 6 4 8 16 14 10 8 165 4 17 
Silde C 14 8 8 10 14 10 5 10 8 8 8 13 16 5 9 146 8 10 
Silde D 9 7 7 10 14 12 8 14 10 11 8 12 6 16 8 152 8 15 
Totals 640 23 49 
T=0 weeks 
Colonies Counted per Slide Total Total Total 
Dose 2 Gy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
Silde A 16 16 12 8 16 15 10 16 16 8 14 9 8 8 10 182 3 15 
Silde B 15 16 12 4 14 8 8 16 13 8 16 7 8 13 12 170 18 14 
Silde C 8 14 8 8 12 6 4 5 5 14 7 8 15 11 12 137 6 10 
Silde D 14 8 7 14 9 15 8 8 14 8 6 15 8 15 14 163 17 7 
Totals 652 44 46 
T=0 weeks 
 
10/12/99 
  
Colonies Counted per Slide Total Total Total 
Dose 4 Gy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
Silde A 13 10 15 15 16 4 7 9 7 8 8 9 4 8 7 140 11 12 
Silde B 6 15 16 12 8 8 6 8 14 13 7 14 10 6 15 158 4 18 
Silde C 0 
Slide D 15 12 8 16 8 11 11 14 12 10 16 8 5 8 13 167 16 9 
Totals 465 31 39 
T=0 weeks 
Colonies Counted per Slide Total Total Total 
Dose 8 Gy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
Silde A 4 4 4 4 6 4 16 4 7 6 8 4 6 4 6 87 8 8 
Silde B 16 6 10 4 7 4 8 5 8 4 8 10 6 5 4 105 5 5 
Silde C 4 8 4 8 8 7 8 6 4 8 7 8 8 10 8 106 15 2 
Silde D 5 12 8 6 4 5 7 4 6 8 6 4 8 6 6 95 10 10 
Totals 393 38 25 
205 
MICRONUCLEI ANALYSIS 
G3 T=4 weeks 
T=4 weeks 10/12/99 
 
Colonies Counted per Slide Total Total Total 
Dose Control [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
Silde A 12 4 10 16 16 8 12 14 16 16 16 6 8 8 9 171 9 1 
Silde B 16 6 14 14 6 4 10 12 16 12 6 13 14 8 8 159 15 4 
Silde C 4 16 8 10 16 10 7 4 16 16 14 16 13 6 14 170 7 8 
Silde D 12 4 g 4 4 8 12 g 8 16 8 16 4 12 6 130 0 0 
Totals 630 31 13 
T=4 weeks 
Colonies Counted per Slide Total Total Total 
Dose 2 Gy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
Silde A 16 14 4 14 10 12 16 14 15 16 14 8 4 12 6 175 13 4 
Silde B 5 8 12 8 16 6 16 16 8 16 6 7 6 6 12 148 7 8 
Silde C 0 
Slide D 0 
Totals 323 20 12 
T=4 weeks 10/12/99 
 
Colonies Counted per Slide Total Total Total 
Dose 4 Gy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
Silde A 16 12 7 12 4 4 9 6 7 4 4 10 8 14 16 133 12 10 
Silde B 13 6 8 10 16 12 12 15 16 13 10 16 8 4 6 165 10 8 
Silde C 16 6 12 10 8 10 8 8 16 8 7 11 7 11 9 147 15 6 
Silde D 12 15 4 16 9 4 8 6 10 16 8 14 10 15 8 155 6 7 
Totals 600 43 31 
T=4 weeks 
Colonies Counted per Slide Total Total Total 
Dose 8 Gy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Cells Micronuclei Pyknotic 
Scored Scored Scored 
Silde A 10 12 10 8 8 6 10 12 8 16 14 16 7 12 9 158 4 4 
Silde B 9 9 8 9 16 7 8 16 16 14 15 6 14 16 12 175 10 5 
Silde C 9 12 8 13 16 8 8 12 14 8 16 8 13 9 6 160 11 9 
Silde D 12 8 13 8 6 8 13 12 6 14 12 12 4 8 4 140 11 1 
Totals 633 36 19 
206 
SE 
%SE I MN 
%SE total MN 
. 	 . 
0.618581 0.198322 
0.173203 
0.067549 
SD 
SE 
%SE I MN 
%SE total MN 
1.480644. 057188 
0.410657 0.146606 
0.094451 
0.02928 
MICRONUCLEI COLONY FREQUENCIES 
G3 OG V T=0 
Colony size Frequency Cells sampled 1 
Number of Micronuclei 
2 	 3 	 >4 
4 1 4 0 
5 2 10 0 
63 18 
7 2 14 1 
3 15 120 6 
9 4 36 
II 8 80 6 
11 1 11 0  
12 4 48 2 
13 1 13 0 
14 8 112 
15 2 30 
16 9 144 
Colonies sampled 60 
Total cells sampled 640 
Micronuclei 21 	 0 	 0 	 0 
Total in icronuclei 3.28% 21 
Micronuclei per cell 3.28% 
SE 
	
0.572203 0.169863 
%SE 1 MN 
	
0.120263 
%SE total MN 
	
0.025234 
G 3 2G v T=0  
Colony site Frequency Cells sampled 1 
Number of M icronuclei 
2 	 3 	 >4 
4 2 8 0 
5 2 10 
6 Z 12 0 
7 3 21 1 
8 17 136 6 
9 2 18 0 
10 2 20 0 
11 1 11 1  
12 5 60 
13 2 26 
14 7 98 6 
15 7 105 4 
16 8 128 4 
Colonies sampled 60 
Total cells sampled 653 
Micronuclei 28 	 4 	 3 	 4 
Total m icronuclei 4.29% 39 
Micronuclei per cell 5.97% 
G 3 4G v T=0 
Colony size Frequency Cells sampled 
Number of Micronuclei 
1 	 2 	 3 	 >4 
4 2 8 
5 1 5  
6 3 18 
7 4 28 
8 10 80 
9 2 18 
10 3 30 
11 2 22 
12 3 36 
39 
4 3 42 
5 75 
6 4 64 
Colonies sampled 45 
Total cells sampled 465 
Micronuclei 23 	 2 	 6 	 0 
Total m icronuclei 4.95% 31 
Micronuclei per cell 6.67% 
G 3 8G v T=0 
Colony size Frequency Cells sampled 
Number of 1M icronuclei 
1 	 2 	 3 	 >4 
4 19 76 10 	 1 0 
5 20 0 0 
6 12 72 2 0 
7 35 0 0 
8 14 112 0 0 
9 0 0 0 
10 30 0 0 
11 0 0 
12 12 0 0 
13 0 0 0 
1 4 0 0 0 
15 0 0 0 
16 32 0 0 
Colonies sampled 60 
Total cells sampled 389 
Micronuclei 29 	 6 	 3 	 0 
Total m icronuclei 7.46% 38 
Micronuclei per cell 9.77% 
SD 3.00427 
0.833235 
1.760446 
0.24413 
%5E I MN 0.241638 
ASE total MN 0.091822 
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MICRONUCLEI ANALYSIS 
G4 
T=0 weeks 10/12/99 
Colonies Counted per Slide Total Total Total 
Dose: Control [1] [2] [3] [4] [5] [6] [7] [8] [9] 10 11 12 13 14 15 16 17 18 [19 [20] Cells Micronuclei Pyknotic 
Scored Scored Scored 
Silde A 7 4 6 4 7 4 6 7 4 8 8 9 4 4 5 7 8 8 4 4 118 14 7 
Slide B 7 11 4 8 12 8 4 4 8 6 4 8 4 8 6 5 8 6 9 6 136 7 4 
Silde C 5 5 5 5 4 4 5 5 4 4 12 4 6 4 4 7 8 5 4 10 110 6 6 
Slide D 8 6 4 5 9 12 8 4 4 5 7 7 4 5 4 4 4 4 4 8 116 7 5 
Silde E 5 4 9 6 6 6 7 6 4 5 4 6 12 8 8 5 4 8 4 8 125 9 5 
Totals 605 43 27 
7.11% 
T=4 weeks 10/12/99 
Dose: 	 8 Gy [1] [2] [3] [4] 
Colonies Counted per Slide 
[5] [6] [7] [8] [9] 	 10 	 11 	 12 13 14 15 16 17 18 [19 [20] 
Total 
Cells 
Scored 
Total 
Micronuclei 
Scored 
Total 
Pyknotic 
Scored 
Silde A 4 4 4 12 4 4 4 12 6 5 8 10 12 6 6 6 4 10 4 6 131 6 10 
Silde B 6 4 6 4 4 6 10 4 8 5 4 8 5 4 4 4 4 4 4 5 103 4 15 
Slide C 4 4 6 4 4 4 8 6 4 10 6 6 6 9 8 6 6 6 12 5 124 3 7 
Slide D 6 8 6 5 8 9 4 6 5 4 6 6 4 4 5 4 4 8 4 4 110 4 5 
Silde E 9 8 4 4 4 8 8 4 5 11 4 6 4 6 9 4 8 12 5 4 127 2 2 
Totals 595 19 39 
3.19% 
Miconuclei Analysis 
A5 
A4 Control T=4 weeks Colony Size Frequency Mn 
12 4 1 48 
11 1 0 11 
10 1 0 10 
9 4 4 36 
8 18 5 144 
7 9 6 63 
6 13 3 78 
5 15 5 75 
4 35 12 140 
Total cells 605 
Total Colonies Scored 100 
Total Micronuclei 35 
Total Pyknotic cells 14 
% Mn 5.79% 
A4 8 Gy T=4 weeks Colony Size Frequency Mn 
12 5 0 60 
11 1 0 11 
10 4 1 40 
9 4 0 36 
8 12 4 96 
7 0 0 0 
6 24 6 144 
5 9 0 45 
4 41 8 164 
Total Cell Scored 596 
Total Colonies Scored 100 
Total Micronuclei 19 
Total Pyknotic cells 31 
% Mn 3.19% 
210 
Miconuclei Analysis 
A8 
A8 Control T=8 weeks Colony Size Frequency 	 Mn 
12 	 0 	 0 	 0 
11 	 1 	 0 	 11 
10 	 3 	 2 	 30 
9 	 2 	 2 	 18 
8 	 20 	 5 	 160 
7 	 2 	 0 	 14 
6 	 11 	 9 	 66 
5 	 6 	 2 	 30 
4 	 55 	 19 	 220 
Total Cell Scored 	 549 
Total Colonies Scored 	 100 
Total Micronuclei 	 39 
Total Pyknotic cells 	 7 
7.10% 
A8 8 Gy T=8 weeks 	 Colony Size Frequency 	 Mn 
12 	 2 	 1 	 24 
11 	 3 	 0 	 33 
10 	 3 	 5 	 30 
9 	 7 	 4 	 63 
8 	 12 	 9 	 96 
7 	 9 	 9 	 63 
6 	 19 	 15 	 114 
5 	 15 	 7 	 75 
4 	 30 	 7 	 120 
Total Cell Scored 	 618 
Total Colonies Scored 	 100 
Total Micronuclei 	 56 
Total Pyknotic cells 	 12 
9.06% 
211 
MICRONUCLEI ANALYSIS 
XA-8 Tumour line 
  
T=0 weeks 10/12/99 
 
Colonies Counted per Slide Total Total Total 
Dose: Control [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16][17] [18] [19] [20] Cells Mn Pyknotic 
Scored Scored Scored 
Silde A 6 4 8 6 8 4 6 4 6 8 8 10 4 8 4 4 	 4 8 4 4 118 19 3 
Silde B 4 7 8 8 4 4 4 5 8 6 4 4 4 4 10 4 	 6 4 9 107 12 4 
Silde C 4 8 4 8 4 4 9 4 4 4 6 6 4 7 4 4 	 7 9 7 107 14 2 
Silde D 8 5 4 8 4 4 8 8 12 5 8 4 4 4 4 8 	 4 8 4 114 11 4 
Silde E 4 6 4 4 4 7 4 4 4 4 7 6 11 4 4 9 	 8 6 4 4 108 15 1 
Totals 554 71 14 
12.82% 
T=4 weeks 
 
10/12/99 
  
Dose: Control [1] [2] [3] [4] [5] [6] [7] [8] 
Colonies Counted per Slide 
[9] [10] [11] [12] [13] [14] [15] [16][17] [18] [19] [20] 
Total 
Cells 
Scored 
Total 
Mn 
Scored 
Total 
Pyknotic 
Scored 
Silde A 4 8 6 4 4 8 4 4 4 4 6 10 8 4 7 8 4 4 4 8 113 26 10 
Silde B 4 4 4 4 5 8 10 4 8 6 10 12 4 4 4 4 4 6 6 4 115 22 4 
Silde C 4 9 4 4 4 4 8 4 10 4 7 5 5 4 4 4 4 4 8 4 104 24 0 
Silde D 4 8 3 4 4 4 4 10 4 4 4 4 9 8 8 4 7 6 8 4 111 12 0 
Silde E 6 7 7 4 4 6 10 8 8 4 4 12 4 4 4 4 7 4 4 6 117 28 0 
Totals 560 112 14 
20.00% 
MICRONUCLEI ANALYSIS 
ST-8 Tumour line 
  
T=0 weeks 10/12/99 
 
Colonies Counted per Slide Total Total Total 
Dose: Control [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16][17] [18] [19] [20] Cells Mn Pyknotic 
Scored Scored Scored 
Silde A 12 8 4 8 8 6 9 4 4 8 5 8 8 7 8 8 	 5 11 8 11 150 9 3 
Silde B 7 7 4 8 8 9 8 12 6 8 6 8 6 9 8 4 	 4 4 4 4 134 17 2 
Silde C 8 8 8 4 8 8 4 8 8 5 4 4 4 8 6 4 	 4 8 4 8 123 5 1 
Silde D 4 8 8 7 10 10 5 7 8 4 4 4 5 4 4 8 	 5 4 8 7 124 7 5 
Silde E 4 8 4 6 10 4 4 8 9 4 4 7 8 110 8 6 	 5 8 4 5 226 9 6 
Totals 757 38 17 
5.02% 
  
T=4 weeks 10/12/99 
 
Colonies Counted per Slide Total Total Total 
Dose: Control [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16][17] [18] [19] [20] Cells Mn Pyknotic 
Scored Scored Scored 
Slide A 6 4 6 8 4 4 4 4 4 8 10 6 2 9 7 4 	 6 4 5 5 110 16 8 
Silde B 4 4 6 4 6 4 4 4 5 4 4 4 3 4 4 6 	 7 4 4 4 89 48 5 
Silde C 6 7 6 4 4 7 4 4 4 8 6 8 4 4 4 4 	 10 4 4 4 106 14 4 
Silde D 6 4 4 6 4 6 4 6 4 6 4 4 4 4 4 4 	 4 4 5 5 92 13 1 
Silde E 4 4 4 8 6 6 7 5 4 6 6 4 4 4 4 8 	 4 6 4 5 103 28 12 
Totals 500 119 30 
24% 
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MTT Assay Raw HT Data 
HT T=2 
	 26.11.98 
Plated Vol OD @ 570nm Mean 
40000 200 1.617 1.65 1.982 1.792 1.561 1.605 1.609 1.572 1.674 
20000 100 0.774 0.822 0.885 0.935 0.825 1.022 0.819 0.692 0.847 
15000 75 0.469 0.503 0.595 0.551 0.519 0.537 0.594 0.531 0.537 
10000 50 0.377 0.376 0.369 0.45 0.38 0.453 0.36 0.34 0.388 
5000 25 0.191 0.118 0.142 0.127 0.171 0.247 0.216 0.177 0.174 
2500 12.5 0.162 0.09 0.073 0.075 0.048 0.065 0.073 0.037 0.078 
1250 6.25 0.157 0.108 0.04 0.082 0.056 0.06 0.024 0.096 0.078 
HT T=2 
	 26.11.98 
Plated Vol OD @ 570nm Mean 
40000 200 1.187 1.117 1.003 1.188 1.071 1.246 1.278 1.181 1.159 
20000 100 0.587 0.555 0.487 0.598 0.557 0.567 0.612 0.625 0.574 
15000 75 0.344 0.338 0.35 0.359 0.358 0.388 0.38 0.409 0.366 
10000 50 0.288 0.275 0.298 0.324 0.327 0.314 0.348 0.355 0.316 
5000 25 0.092 0.159 0.162 0.178 0.158 0.13 0.104 0.099 0.135 
2500 12.5 0.163 0.069 0.087 0.074 0.052 0.056 0.077 0.083 
1250 6.25 0.063 0.072 0.045 0.049 0.033 0.057 0.025 0.029 0.047 
HT T=2 
	 26.11.98 
Plated Vol OD @ 570nm Mean 
40000 200 1.463 1.033 0.942 0.976 0.919 1.165 1.244 1.309 1.131 
20000 100 0.519 0.63 0.678 0.648 0.586 0.59 0.676 0.771 0.637 
15000 75 0.37 0.392 0.386 0.391 0.39 0.397 0.452 0.396 0.397 
10000 50 0.252 0.277 0.278 0.285 0.332 0.284 0.288 0.324 0.290 
5000 25 0.146 0.134 0.152 0.181 0.174 0.145 0.171 0.125 0.154 
2500 12.5 0.039 0.056 0.026 0.06 0.041 0.054 0.073 0.04 0.049 
1250 6.25 0.046 0.074 0.02 0.03 0.026 0.028 0.05 0.0193 0.037 
MTT Assay Raw HT Data 
HT-8 T=2 
	 26.11.98 
Plated Vol OD @ 570 nm Mean 
40000 200 1.366 1.189 1.07 1.037 1.08 1.177 1.034 1.351 1.163 
20000 100 0.298 0.238 0.245 0.207 0.218 0.2 0.21 0.248 0.233 
15000 75 0.203 0.169 0.166 0.129 0.133 0.149 0.142 0.152 0.155 
10000 50 0.11 0.083 0.063 0.061 0.067 0.066 0.08 0.09 0.078 
5000 25 0.03 0.026 0.037 0.026 0.032 0.045 0.038 0.018 0.032 
2500 12.5 0.006 0.011 0.005 0.006 0.004 0.015 0.004 0.004 0.007 
1250 6.25 0.006 0.027 0.013 0.016 0.04 0.029 0.033 0.007 0.021 
HT-8 T=2 
	 26.11.98 
Plated Vol OD @ 570 nm Mean 
40000 200 1.301 1.075 1.185 1.325 1.375 1.431 1.151 1.517 1.295 
20000 100 0.335 0.265 0.203 0.255 0.268 0.227 0.251 0.275 0.260 
15000 75 0.316 0.178 0.159 0.145 0.15 0.18 0.188 0.161 0.185 
10000 50 0.094 0.067 0.063 0.079 0.073 0.08 0.094 0.088 0.080 
5000 25 0.044 0.042 0.019 0.041 0.021 0.024 0.056 0.019 0.033 
2500 12.5 0.027 0.012 0.013 0.023 0.017 0.009 0.023 0.018 
1250 6.25 0.007 0.011 0.004 0.021 0.014 0.02 0.017 0.022 0.015 
HT-8 T=2 	 26.11.98 
Plated Vol OD @ 570 nm Mean 
40000 200 1.098 1.207 1.097 1.142 1.203 1.198 1.126 1.277 1.169 
20000 100 0.531 0.388 0.383 0.449 0.408 0.488 0.428 0.574 0.456 
15000 75 0.263 0.235 0.188 0.258 0.218 0.208 0.205 0.219 0.224 
10000 50 0.131 0.097 0.091 0.129 0.116 0.111 0.122 0.131 0.116 
5000 25 0.016 0.025 0.024 0.074 0.045 0.019 0.026 0.051 0.035 
2500 12.5 0.028 0.048 0.035 0.029 0.041 0.033 0.026 0.021 0.033 
1250 6.25 0.031 0.023 0.002 0.03 0.028 0.035 0.037 0.014 0.025 
MITAggliFtwXAlltagT 
X474 
VI ChT1 CD@Stlim Mal 
zo 400N 0972 Qe22 087 QM 	 0783 0.604 Q833 0633 0818 
100 23330 Q435 0.402 046 0448 	 MB Q431 Q433 Q443 0.441 
5) 1103 0194 Q16 0191 Q274 Q234 0.333 07i6 0211 0235 
3 510 Q033 013 0153 0133 0154 0122 0106 0123 Q129 
125 2E03 0043 0073 Q1333 0.033 QOM 0031 QOM Q111 Q018 
625 125) 0013 Q113 Q041 0017 032 0047 0061 4012 Q044 
Val thi CDaellan Akan 
230 40070 0E6 Q714 0718 1023 0664 Q741 Q74 0003 Q7 
Ica 2:010 Q412 0454 0434 Q93 0444 134E8 0406 Q615 0474 
93 1010 0211 Q219 Q237 Q233 Q314 Q36 0316 0237 0222 
3 5303 0123 0164 010. 018 11195 0061 QUI 013 04E 
125 2333 0057 0033 COM 0107 0.C98 0116 0084 01333 Q033 
63 1253 QOM 13037 0072 Q0E9 016 QOM QCE6 Q0E9 QOM 
Mr1W631R3IVXACetagP4 
X4TW 
Id On1 CD@Lithn Men 
211 4010 0233 1.117 1293 1.0)1 1.132 0932 1.015 Q83 1043 
112) 2101) 063 QM Q771 022 0615 0661 Q696 05 4678 
5) 11:011 0351 03 an 0403 0453 0.3/1 Q43 0431 Q416 
25 9333 0154 0183 Q18 0183 0211 Q1T 0.235 Q18 13166 
125 2310 011 0129 MI aces 083 0108 Q118 0106 0107 
E25 1260 QOM QC& 0(63 Q033 Q022 131E1 QOM OM Q033 
WI CM CD@5711144 Akan 
233 4310 12:6 1.103 0895 0863 an QM 0813 0873 MX 
133 2103 Q535 0615 0415 0434 0513 0464 Q474 Q3i6 043 
93 10311 022 Q233 0166 021 0.181 023 0235 0241 0216 
3 9333 027 0187 0211 C1192 0218 0225 013 Q221 027 
25 23:0 01 013 0131 0134 0129 014 0133 Q119 0126 
63  12E0 Q101 0033 VW 0024 0038 0078 QOM 0031 0CE9 
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MIT Assay Raw XC Data © T=2 
XC T=4 
Vol GM OD @ 570nm Mean 
2(X) 40000 0.941 0.805 0.785 0813 0.735 0.805 0.788 0.719 0.799 
103 20000 0.399 0.372 0.394 0.3E6 0.415 0.419 0.452 0.441 0.410 
50 10030 0.215 0.248 023 0.257 0.338 0.298 0.413 0.324 0.294 
25 5000 0.141 0.148 0.166 0.171 0.17 0.153 0.171 0.147 0.158 
12.5 2500 0.075 0.091 0.012 0.051 0.098 0.097 0.157 0.106 0.095 
6.25 1250 0.049 0.075 0.056 007 0.059 0.059 0.069 0.074 0.033 
XC8 T=4 
Vol GM OD ©570nm Mean 
210 40000 0.797 0.873 1.161 1.178 0.918 0.9 0.853 0.899 0.949 
100 20030 0.491 0.443 0.577 0.567 0.563 0.575 0.554 0.69 0.558 
53 10000 0.288 0.267 0.323 0.401 0.295 a 298 0.27 0.299 0.318 
25 5000 0.108 0.147 0.139 0155 0.144 0.183 0.133 0.136 0.143 
12.5 2503 0.095 0.119 0.089 0.016 0.109 0.112 0.123 0102 0.106 
6.25 125) 0.078 0.045 0.086 0.154 0.078 0.054 0.072 0,088 0.093 
MIT Assay Raw XC Data @ T=4 
XC T=4 
Vol Gm! OD @ 570nm
-  
Moan 
200 40000 1.374 1.356 1.636 1.219 1.4 1.407 1.171 1.1320.799 
100 20000 0.672 0653 0.677 067 0.749 0.687 0.664 0.599 0410 
50 10000 0363 0403 0.372 0.359 0376 0.378 0.357 0.406 0294 
25 500) a (6-7 0078 0.072 0.053 0079 005 0.071 0.109 0 158 
12.5 2500 0.053 0055 0.057 0.051 0056 0.054 005 0.057 0.096 
625 1250 0061 0.065 0.044 0049 0064 0.046 0.056 0.048 0(63 
XC8 T.4 
Vol GM OD @ 570nm Mean 
200 40000 0.147 0126 0148 0.158 0142 0135 0.11 0.13 0949 
100 20000 0.085 0.09 009 0.063 0085 0.086 0073 0.077 0.558 
50 10100 0.161 0057 0.032 0.061 0063 0.065 0.055 0.06 0.318 
25 5003 0.037 0037 0.038 0.034 0036 0032 0.034 0.041 0 143 
12.5 2500 0.033 0.037 0034 am 0.047 0037 0.040 0.04 0106 
6.25 1250 0.032 0.032 0032 0.033 0.035 0034 0039 0.038 0.083 
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SURVIVAL ANALYSIS 
 
16.07.97 HTori-3 Survival (4; T43 
Control & 
Code 
Dose 
Cry 
Number 
of Cells 
Seeded 
per Flask 
[1] [2] 
Numbers of Colonies Scoredper Plate 
[3] 	 [4] 	 [5] 	 [6] 	 [7] [S] [9] [10] 
Number of 
Colonies 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
EffiriiniryPlo 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dee. 
cd / cli 0 125 63 56 86 56 65 75 62 68 77 74 68.20 9.70 10 68.20 & 9.70 
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., 1.000 ± 0.0636 
al 	 / al 2 167 71 63 73 61 68 57 64 66 62 65.00 5.05 9 91.12 & 5.05 0.713 ± 0.0370 
a2 / a2 4 250 72 64 70 72 64 73 66 69 61 60 67.10 4.75 10 136.40 ± 4.75 0.492 ± 0.0247 
a3 / a3 6 500 64 71 66 64 70 64 73 81 69 66 68.80 5.35 10 272.80 ± 5.35 0.252 ± 0.0129 
a4 I a4 8 2500 134 138 165 156 133 120 131 131 132 134 137.40 13.18 10 1364.00 ± 13.18 0.101 ± 0.0055 
cli 	 / ctl. 0 125 60 45 51 56 52 45 50 46 48 50.33 5.12 9 50.33 ± 5.12 1.000 & 0.0480 
al 	 / al 2 167 45 51 50 49 55 48 51 51 51 57 50.80 3.36 10 67.25 ± 3.36 0.755 ± 0.0301 
a2 / a2 4 250 44 40 35 38 41 34 39 54 52 40 41.70 6.62 10 100.67 ± 6.62 0.414 & 0.0251 
a3 / a3 6 500 54 47 30 35 37 42 33 40 45 36 39.90 7.25 10 201.33 ± 7.25 0.198 ± 0.0132 
a4 / a4 8 2500 28 30 28 31 38 41 33 30 40 33.22 5.12 9 1006.67 ± 5.12 0.033 ± 0.0020 
c8 I MI 0 125 69 71 72 68 76 71.20 3.11 5 71.20 ± 3.11 1.000 ± 0.0277 
al I al 2 167 78 79 80 89 72 79.60 6.11 5 95.12 ± 6.11 0.837 ± 0.0331 
a2 1 a2 4 250 84 80 82 79 91 83.20 4.76 5 142.40 ± 4.76 0.584 ± 0.0188 
a3 I a3 6 500 99 86 116 96 102 99.80 10.87 5 284.80 ± 10.87 0.350 ± 0.0184 
a4 I a4 8 2500 185 200 221 181 184 194.20 16.69 5 1424.00 ± 16.69 0.136 ± 0.0059 
SURVIVAL ANALYSIS 
BTori-3 Survival @ T=2 weeks 01.08.97 
 
Control & 
Code 
Dose 
GY 
Number 
of Cells 
Seeded 
per Flask 
[1] [2] 
Numbers of Colonies 1 
[3] 	 [4] 	 [5] 
Number of 
Colonies 
No. 
of 
Plates 
'Table Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency P/o 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dev. 
ctl 	 1 cti 0 125 63 60 62 65 62 6240 1.82 5 62.40 ± 1.82 49.92 ± 0.65 1.000 ± 0.0184 
al 	 / al 2 125 69 60 61 66 60 63.20 4.09 5 62.40 ± 4.09 50.56 t 1.46 1.013 ± 0.0321 
a2 / a2 4 125 59 73 51 57 52 58.40 8.82 5 62.40 ± 8.82 46.72 ± 3.16 0.936 ± 0.0644 
a3 1 a3 6 125 53 61 45 62 56 55.40 6.88 5 62.40 ± 6.88 44.32 ± 2.46 0.888 ± 0.0506 
a4 / a4 8 125 63 63 60 63 67 63.20 2.49 5 62.40 ± 2.49 50.56 ± 0.89 1.013 ± 0.0222 
ctl 	 1 cti. 0 125 66 67 57 69 66 65.00 4.64 5 65.00 ± 4.64 52.00 ± 1.66 1.000 ± 0.0451 
al 	 1 al 2 125 62 64 68 73 59 65.20 5.45 5 65.00 ± 5.45 52.16 ± 1.95 1.003 ± 0.0493 
a2 / a2 4 125 62 55 61 59 56 58.60 3.05 5 65.00 ± 3.05 46.88 ± 1.09 0.902 ± 0.0356 
a3 / a3 6 125 64 56 55 54 65 58.80 5.26 5 65.00 ± 5.26 47.04 ± 1.88 0.905 ± 0.0463 
a4 / a4 8 125 68 70 69 60 65 66.40 4.04 5 65.00 ± 4.04 53.12 ± 1.44 1.022 ± 0.0428 
al I ctl 0 125 80 84 72 82 86 80.80 5.40 5 80.80 ± 5.40 64.64 ± 1.93 1.000 ± 0.0423 
al 	 / al 2 125 68 77 73 72 73 72.60 3.21 5 80.80 ± 3.21 58.08 ± 1.15 0.899 ± 0.0322 
a2 1 a2 4 125 74 85 90 83.00 8.19 3 80.80 ± 8.19 66.40 ± 3.78 1.027 ± 0.0661 
a3 / a3 6 125 80 99 86 83 85 86.60 7.30 5 80.80 ± 7.30 69.28 ± 2.61 1.072 ± 0.0516 
a4 1 a4 8 125 88 94 89 92 87 90.00 2.92 5 80.80 1 2.92 72.00 ± 1.04 1.114 ± 0.0370 
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SURVIVAL ANALYSIS 
Htori-3 Survival ®11=8 weeks 16.09.97 
Number & 
Control 
Dose 
Cy 
Number 
of Cells 
Seeded 
per Flask 
[1] [2] 
Numbers of Colonies ' 
[3] 	 [4] 	 [5] 
Number of 
Colonies 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(1 Standard 
Deviation) 
Plating 
Efficiency lYa 
(+ Standard 
Error) 
Surviving 
Fraction 
(+ Standard 
Error) 
Mean Std. 
Dev. 
ctt 	 I ad 0 150 63 64 59 62 65 62.60 2.30 5 62.60 + 2.30 41.73 th 0.69 1.000 + 0.0233 
al 	 / al 2 150 50 65 66 51 52 56.80 7.98 5 62.60 + 7.98 37.87 + 2.38 0.907 + 0.0589 
a2 I a2 4 150 52 51 61 59 59 56.40 4.56 5 62.60 + 4.56 37.60 + 1.36 0.901 + 0.0358 
a3 I a3 6 150 58 54 49 51 56 53.60 3.65 5 62.60 + 3.65 35.73 th. 1.09 0.856 + 0.0296 
a4 / a4 8 150 54 57 61 61 51 56.80 4.38 5 62.60 th 4.38 37.87 + 1.31 0.907 + 0.0347 
al I ctl 0 150 98 84 100 89 101 94.40 7.50 5 94.40 + 52.88 62.93 + 2.24 1.000 + 0.0503 
al 	 I al 2 150 88 89 93 91 85 89.20 3.03 5 94.40 + 48.01 59.47 + 0.90 0.945 + 0.0365 
a2 I a2 4 150 83 84 83 84 78 82.40 2.51 5 94.40 + 44.18 54.93 + 0.75 0.873 th 0.0332 
a3 I a3 6 150 81 82 88 89 88 85.60 3.78 5 94.40 + 47.59 57.07 th 1.13 0.907 +. 0.0369 
a4 I a4 8 150 86 98 84 97 103 93.60 8.20 5 94.40 + 53.10 62.40 + 2.45 0.992 + 0.0525 
di / ca 0 150 65 63 68 69 71 67.20 3.19 5 67.20 th 37.57 44.80 + 1.43 1.000 + 1.43 
al 	 I at 2 150 55 65 62 69 55 61.20 6.18 5 67.20 + 30.43 40.80 + 2.76 0.911 + 2.76 
a2 1 a2 4 150 60 59 58 55 55 57.40 2.30 5 67.20 + 30.37 38.27 + 1.03 0.854 + 1.03 
a3 f a3 6 150 62 69 71 75 63 68.00 5.48 5 67.20 + 34.85 45.33 + 2.45 1.012 + 2.45 
a4 I a4 8 150 71 55 52 75 68 64.20 10.13 5 67.20 + 33.89 42.80 + 4.53 0.955 + 4.53 
SURVIVAL ANALYSIS 
 
20.06.97 HT Tumour A2 
Number & 
Control 
Dose 
Cry 
Number 
of Cells 
Seeded 
per plate 
Numbers of Colonies 
[1] 	 [2] 	 [3] [4] 	 [5] 
Number of Colonies No. 
of 
Plates 
Viable Fraction 
(Colonies /cep 
(± Standard 
Deviation) 
Plating 
Efficiency PA. 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) Mean 
Std. 
Dev. 
T=3 / ctl 0 125 65 71 58 59 61 62.80 5.31 5 62.80 ± 32.77 50.24 Jr 1.90 1.000 ± 0.0535 
T4 I al 2 175 66 62 68 62 81 67.80 7.82 5 87.92 Jr 39.64 38.74 1 2.00 0.771 1 0.0493 
T4 / a2 4 250 60 63 65 64 67 63.80 2.59 5 125.60 Jr 2.16 25.52 ± 0.46 0.508 ± 0.0213 
T0 I a3 6 500 62 54 45 50 51 52.40 6.27 5 251.20 ± 6.27 10.48 ± 0.56 0.209 Jr 0.0137 
T4 / a4 8 1000 28 30 32 39 30 31.80 4.27 5 502.40 ± 4.27 3.18 ± 0.19 0.063 ± 0.0045 
T=3 / a5 16 10000 4 1 1 0 0 1.20 1.64 5 5024.0 1 1.64 0.01 ± 0.01 0.000 ± 0.0001 
T=4 	 I ctl. 0 125 55 65 67 45 50 56.40 9.48 5 56.4 1 9.48 45.12 Jr 339 1.000 0.0841 
T=4 / al 2 125 50 53 55 61 54 54.60 4.04 5 56.4 ± 4.04 43.68 Jr 1.44 0.968 Jr 0.0486 
T=4 / a2 4 125 44 46 52 54 45 48.20 4.49 5 56.4 ± 4.49 38.56 Jr 1.61 0.855 1 0.0481 
T=4 / a3 6 125 34 35 31 39 40 35.80 3.70 5 56.4 Jr 3.70 28.64 Jr 1.32 0.635 ± 0.0379 
T=4 / a4 8 125 22 29 32 30 19 26.40 5.59 5 56.4 1 5.59 21.12 Jr 2.00 0.468 Jr 0.0478 
T=4 / a5 16 125 10 5 5 10 7 7.40 2.51 5 56.4 Jr 2.51 5.92 Jr 0.90 0.131 * 0.0205 
SURVIVAL ANALYSIS 
HT Tumour A3 2a 06.97 
 
Number & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
Numbers of Colonies Scored 
per plate 
[1] 	 [2] 	 [3] 	 [4] [5] 
Number of Colonies No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency Pio 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std 
Dev. 
T=0 I ctl 0 100 60 64 67 54 62 61.40 4.88 5 61.40 --ti 4.88 61.40 ± 2.18 1.000 ± 0.0503 
T) / al 2 133 61 64 66 60 63 62.80 2.39 5 81.66 ± 2.39 47.22 ± 0.80 0.769 t 0.0303 
TO f a2 4 200 74 74 78 67 79 74.40 4.72 5 122.80 --ti 4.72 37.20 ± 1.06 0.606 ± 0.0276 
`I'll f a3 6 400 81 92 81 82 82 83.60 4.72 5 245.60 &-- 4.72 20.90 ± 0.53 0.340 ± 0.0148 
T) I a4 8 1335 89 82 92 96 103 92.40 7.83 5 819.69 e- 7.83 6.92 ± 0.26 0.113 ± 0.0059 
T I cd 0 250 19 19 18 15 17.75 1.89 4 17.75 ± 1.89 7.10 ± 0.38 1.000 ± 0.0754 
Tl, I al 2 250 
T=4 / a2 4 250 
T=4 I a3 6 250 28 25 25 24 24 25.20 1.64 5 17.75 ± 1.64 10.08 ± 0.29 1.420 ± 0.0653 
T=4 1 a4 8 250 48 32 35 37 32 36.80 6.61 5 17.75 f 6.61 14.72 ± 1.18 2.073 ± 0.1821 
SURVIVAL ANALYSIS 
HT Tumosu A4 31.6.97 
Number & 
Control 
Dose 
Cy 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies 
[2] 	 [3] 	 [4] [5] 
Number of Colonies No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency P/o 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) Mean 
Std, 
Dec. 
T=0 1 cii 0 125 52 53 49 50 54 51.60 2.07 5 51.6 ± 2.07 41.28 ± 0.93 1.000 ± 0.03 
T4 / al 2 167 42 40 48 43 44 43.40 2.97 5 68.9 ± 2.97 25.99 ± 133 0.630 ± 0.04 
T3 I a2 4 250 23 29 30 30 22 26.80 3.96 5 103.2 ± 3.96 10.72 ± 1.77 0.260 ± 0.04 
T4 / a3 6 500 15 10 12 10 10 11.40 2.19 5 206.4 ± 2.19 2.28 1 0.98 0.055 1 0.02 
T±0 / a4 8 1250 6 7 7 7 8 7.00 0.71 5 516.0 ± 0.71 0.56 1 0.32 0.014 1 0.01 
T=0 / a5 12 12500 2 2 2.00 0.00 2 5160.0 ± 0.00 0.02 ± 0.00 0.000 ± 0.00 
T=0 / a6 16 125000 1 1 1 1.00 0.00 3 51600.0 ± 0.00 0.00 ± 0.00 0.000 ± 0.00 
T=4 / etl 0 125 57 76 70 60 70 66.60 7.86 5 66.60 ± 7.86 53.28 1 2.81 1.000 - 0.06 
T=4 / a2 2 125 83 71 74 99 83 82.00 10.91 5 66.60 ± 10.91 65.60 ± 3.90 1.231 ± 0.08 
T=4 I a3 4 125 72 67 76 57 56 65.60 8.91 5 66.60 ± 8.91 52.48 ± 3.19 0.985 -L 0.06 
T=4 / a4 6 125 
T=4 / a5 8 125 14 19 19 19 17 17.60 2.19 5 66.60 4: 2.19 14.08 ± 0.78 0.264 ± 0.02 
T=4 1 a6 12 125 49 40 50 28 47 42.80 9.15 5 66.60 ± 9.15 34.24 ± 3.27 0.643 ± 0.06 
SURVIVAL ANALYSIS 
HT Tumour A5 28.05.97 
Number & 
Control 
Dose 
Cry 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies Scored per plate 
[2] 	 [3] 	 [4] 	 [5] 	 [6] 	 [7] [8] [9] [10] 
NurnE Colonies No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(= Standard 
Deviation) 
Plating 
Efficiency Pla 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) Mean 
Std. 
Dev. 
T=1 I nil 0 125 39 56 52 50 43 49 57 51 56 48 50.10 5.78 10 50.10 ± 19.31 40.08 ± 1.46 1.000 ± 0.0516 
T=:/ I al 2 192 50 41 48 39 41 38 45 42 55 50 44.90 5.63 10 76.95 ± 17.23 23.39 ± 0.93 0.583 ± 0.0314 
T=C1 I a2 4 313 24 29 27 33 31 29 36 35 39 33 31.60 4.50 10 125.45 ± 3.77 10.10 ± 0.45 0.252 t 0.0146 
T4 / a3 8 1250 12 13 9 16 12 11 12 18 18 14 13.50 2.99 10 501.00 t 3.17 1.08 ± 0.08 0.027 ± 0.0021 
T4 I a4 12 2500 1 1 1 1 1 1 1 2 4 1.44 1.01 9 1002.00 ± 1.01 0.06 ± 0.01 0.001 ± 0.0003 
T=4 / ctl 0 125 53 50 51.50 2.12 2 51,50 ± 2.12 41.20 = 1.20 1.000 ± 0.0412 
T=4 I al 2 250 82 82.00 isDNI01 1 103.00 ± i/DN/0! 32.80 = IODIVIOI 0.796 ± #DIV101 
T=4 I 32 4 625 89 86 93 103 86 91.40 7.09 5 257.50 ± 7.09 14.62 ± 0.51 0.355 ± 0.0161 
T=4 / a3 8 1250 165 170 167.50 3.54 2 515.00 ± 3.54 13.40 1 0.20 0.325 ± 0.0106 
T=4 / a4 12 2500 560 580 570.00 14.14 2 1030.00 ± 14.14 22.80 ± 0.40 0,553 ± 0.0188 
SURVIVAL ANALYSIS 
E1T Tumour A6 200697 
Number & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
Numbers of Colonies 
[1] 	 [2] 	 [3] 	 [4] [5] 
Numbe Colonies No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(th Standard 
Deviation) 
Plating 
Efficiency P/o 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) Mean 
Std. 
Dev. 
T=0 f ctl 0 125 25 18 23 25 24 23.00 2.92 5 23.00 ± 11.32 18.40 ± 1.04 1.000 ± 0.0802 
T=0 / al 2 133 19 18 15 14 16 16.40 2.07 5 24.47 ± 7.41 12.33 ± 0.70 0.670 ± 0.0537 
T4 1 a2 4 200 9 10 8 6 8 8.20 1.48 5 36.80 ± 1.71 4.10 ± 0.33 0.223 ± 0.0220 
T) I a3 6 400 2 1 1 3 7 2.80 2.49 5 73.60 ± 2.49 0.70 ± 0.28 0.038 ± 0.0153 
T4 / a4 8 2000 1 4 1 3 0 1.80 1.64 5 368.00 ± 1.64 0.09 ± 0.04 0.005 ± 0.0020 
T=4 1 ctl 0 250 69 80 92 80 73 78.80 8.76 5 78.80 ± 8.76 31.52 ± 1.57 1.000 ± 0.0703 
T=4 / al 2 250 #D1V101 tI/DN/0.! 0 78.80 #1DIV/0! #DIV/01 ±DIVIO! #D111/0! 11DIV/01 
T=4 I a2 4 250 #DIV101 41D111/01 0 78.80 #DIVIO I #DIV/01 #DIV/01 401V/01 #DIV/01 
T=4 I a3 6 250 #DIV/01 #DIV101 0 78.80 i/DIV701 #DIV/0 I IfDIVIOI #DIVIO! #D11/701 
T=4 / a4 8 250 62 70 72 62 70 67.20 4.82 5 78.80± 4.82 26.88 ± 0.86 0.853 * 0.0555 
SURVIVAL ANALYSIS 
 
21.6.98 HT Tumour A7 
 
Number & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies 
[2] 	 [3] 	 [4] [5] 
Ntanber (Colonies No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency & 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) Mean 
Std. 
Dev. 
T) I cd 0 125 71 69 59 54 60 62.60 7.16 5 62.60 ± 31.91 50.08 ± 2.56 1.000 ± 0.0724 
T4 / al 2 192 #D1V(01 #DD/701 0 96.15 ± CIV101 4DET/01 ± #DIV101 IDD/701 ± 011/101 
T4 1 a2 4 313 ifDIV/01 CIVIC! 0 156.75 1 ADIWO! OW/0! ± #DIV/0! #D1W01 ± #DIV/01 
T4 / a3 8 2500 147 145 151 155 148 149.20 3.90 5 1252.00 1 3.90 5.97 ± 0.07 0.119 ± 0.0063 
T=4 1 cii 0 125 89 96 92 81 96 90.80 6.22 5 90.80 ± 6.22 72.64 ± 2.23 1.000 ± 0.0433 
T=4 1 al 2 125 MDIV101 #D117101 0 90.80 ± ifDIWO! ON/0! ± #DIV10! *DM! I 0111/0! 
T=4 I a2 4 125 #DIV101 #011/701 0 90.80 1 CDT/01 #DIV/01 ± #DIVIO! 0111101 ± #DIVICI! 
T9 1 a3 8 125 53 49 38 42 60 48.40 8.73 5 90.80 ± 8.73 38.72 ± 3.13 0.533 ± 0.0460 
SURVIVAL ANALYSIS 
HT Tumour A8 20.06.97 
Number & 
Control 
Dose 
GY 
Number 
of Cells 
Seeded 
per plate 
Numbers of Colonies 
[1] 	 [2] 	 [3] 	 [4] 	 [5] 
Number of Colonies No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(Jr Standard 
Deviation) 
Plating 
Efficiency /% 
(1 Standard 
L-ror) 
Surviving 
Fraction 
(± Standard 
Error) Mean 
Std. 
Day_ 
T=l) 	 / ctl 0 125 27 25 24 31 35 28.40 4.56 5 28.40 	 i 15.77 22.72 1 1.63 1.000 1 0.1016 
T=11 / al 2 167 34 45 45 35 34 38.60 5.86 5 37.94 	 4 17.93 23.11 1 1.57 1.017 1 0.1005 
T=ll / a2 4 250 18 14 16 18 22 17.60 2.97 5 56.80 	 4 1.91 7.04 1 0.53 0.310 1 0.0323 
Tll 	 / a3 6 500 21 21 25 25 22 22.80 2.05 5 113.60 	 1 2.05 4.56 1 0.18 0.201 1 0.0165 
T0 / a4 8 1250 20 22 21 22 18 20.60 1.67 5 284.00 1 1.67 1.65 1 0.06 0.073 1 0.0058 
T=4 / ctl 0 250 41 37 45 35 35 38.60 4.34 5 38.60 	 1 4.34 15.44 1 0.78 1.000 1 0.0710 
T=4 I a2 4 250 33 30 35 29 34 32.20 2.59 5 38.60 	 4 2.59 12.88 1 0.46 0.834 1 0.0670 
T=4 I a3 6 250 38 44 36 35 36 37.80 3.63 5 38.60 	 i 3.63 15.12 1 0.65 0.979 1 0.0820 
T=4 I a4 8 250 30 29 31 34 33 31.40 2.07 5 38.60 	 1 2.07 12.56 Jr 0.37 0.813 1 0.0632 
SURVIVAL ANALYSIS 
HT Tumour A9 20.06.97 
Number & 
Control 
Dose 
Cry 
Number 
of Cells 
Seeded 
per plate 
Numbers of Colonies 
[1] 	 [2] 	 [3] 	 [4] 	 [5] 
Number of Colonies No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
Standard 
Deviation) 
Plating 
Efficiency Pio 
(± Standard 
Error) 
Surviving 
Fraction 
(i Standard 
Error) Mean 
Std. 
Dev. 
-. 
T=0 ( ctl 0 125 25 28 25 24 21 24.60 2.51 5 24.60 	 i 11.14 19.68 t 0.90 1.000 at  0.0645 
T=0 / al 2 167 22 22 15 14 16 17.80 3.90 5 32.87 	 1 7.24 10.66 t 1.04 0.542 at 0.0585 
T=0 I a2 4 250 20 15 12 17 14 15.60 3.05 5 49.20 	 i 3.37 6.24 at 0.55 0.317 at 0.0313 
T=0 I a3 6 500 8 7 7 11 14 9.40 3.05 5 98.40 	 1 3.05 1.88 at 0.27 0.096 = 0.0145 
T=0 / a4 8 1250 8 17 11 7 5 9.60 4.67 5 246.00 1 4.67 0.77 at 0.17 0.039 4 0.0087 
T=0 I ctl 0 250 21 24 23 26 26 24.00 2.12 5 24.00 	 1 2.12 9.60 at  0.38 1.000 at 0.0559 
T=0 1 al 2 625 25 25 26 25 22 24.60 1.52 5 60.00 	 1 1.52 3.94 t 0.11 0.410 at 0.0219 
T=0 1 a2 4 1250 18 15 7 20 15.00 5.72 4 120.00 	 1 5.72 1.20 at 0.23 0.125 at 0.0245 
T=0 I a3 6 2500 6 6 7 13 8.00 3.37 4 240.00 1 3.37 0.32 t 0.07 0.033 = 0.0072 
T=0 I a4 8 5000 6 8 4 12 2 6.40 3.85 5 480.00 i 3.85 0.13 at 0.03 0.013 at 0.0036 
T=0 1 ctl 0 250 25 26 28 26 31 27.20 2.39 5 27.20 	 1 2.39 10.88 at 0.43 1.000 = 	 0.06 
T=0 / al 8 250 13 12 12 17 18 14.40 2.88 5 27.20 	 1 2.88 5.76 at 0.52 0.529 at 	 0.05 
SURVIVAL ANALYSIS 
 
13.07.97 HT Tumour G1 
Nunaber & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
[1] [2] 
Numbers of Colonies Scored per plate 
[3] 	 [4] 	 [5] 	 [6] 	 [7] [8] [9] [10] 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(*Standard 
IDevialion) 
Plating 
Efficiency My 
(*Standard 
Error) 
Surviving 
Fraction 
(*Standard 
Error) 
Mean Std. 
Dev. 
24 / di 0 125 52 37 46 43 46 47 50 41 58 51 47.10 601 10 47.10 6.01 37.68 ± 1.90 1.000 * 0.0713 
T4 / al 2 167 44 36 41 38 40 44 45 37 40 37 40.20 3 26 10 62.93 ± 3.26 24.07 ± 1.03 0.639 * 0.0423 
T4 / a2 4 250 25 34 25 36 28 30 31 28 26 26 28.90 181 10 94.20 4-_ 3.81 11.56 ± 1.21 0.307 ± 0.0355 
T4 / a3 6 500 27 19 15 17 21 17 16 20 15 22 18.90 175 10 188.40 1 3.75 178 ± 1.19 0.100 ± 0.0319 
24 / a4 8 2500 17 20 25 18 21 24 29 21 21.88 3.94 8 942.00 ± 3.94 0,88 ± 1.39 0.023 ± 0.0370 
T=4 / ctl 0 125 55 42 52 58 56 52.60 6.31 5 5260 - 6.31 42.08 ± 2.82 1.000 ± 0.0948 
T=4 / al 2 125 61 61 73 53 65 62.60 7.27 5 52.60 ± 7.27 50.08 ± 3.25 1.190 ± 0.1110 
T=4 1 a2 4 125 53 58 49 58 62 56.00 5.05 5 5260 ± 5.05 44.80 ± 2.26 1.065 ± 00893 
T=4 / a3 6 125 33 29 30 35 40 33.40 4.39 5 5260 ± 4.39 26.72 ± 1.96 0.635 ± 00632 
T=4 / a4 8 125 46 49 46 43 60 48.80 6.61 5 5260 ± 6.61 39.04 ± 2.96 0.928 1 00938 
T=0 / cd 0 125 49 44 56 49.67 603 3 49.67 ± 6.03 39.73 ± 3.48 1.000 ± 0.1239 
2,0 / al 2 125 47 47 44 45 50 46.60 2.30 5 49.67 1 2.30 37.28 ± 1.03 0.938 ± 0.0862 
2,-4 / a3 0 150 70 75 78 83 99 81.00 11.11 5 81.00 ± 11.11 54.00 ± 4.97 1.000 ± 0.1302 
T=4 / a4 8 150 38 35 46 38 33 38.00 4.95 5 81.00 ± 4.95 25.33 ± 2.21 0.469 ± 3.0588 
SURVIVAL ANALYSIS 
 
1206.97 HT Tumour G2 
Number & 
Control 
Dose 
Crir 
Number 
of Cells 
Seeded 
Per Plate 
[1] 
Numbers of Colonies Scored per plate 
[2] 	 [3] 	 [4] 	 [5] 	 [6] 	 [7] [8] [9] [10] 
No. 
of 
Plates 
Viable Fraction 
(Colonies Ica) 
(+Standard 
Deviation) 
Plating 
EfficiencyPh 
(*Standard 
Error) 
Swerving 
Fraction 
(+ Standard 
Error) 
Mean SM. 
Dee. 
T;) / otl o 125 55 63 64 53 61 65 54 63 58 67 60. 30 4.97 10 60.30 a 4.97 48.24 1.57 1.000 + 0.0461 
T.A3 I al 2 167 57 45 53 54 57 63 63 55 5588 5.79 e 80.56 a 5.79 33.46 1 2.05 0.694 a 0.0481 
T4 / a2 4 250 77 72 80 100 8225 12.28 4 120.60 a 12.28 32.90 + 6.14 0.682 1 0.1293 
T / .3 6 500 39 53 45 38 33 40 37 38 37 40. oo 5.81 9 241.20 a 5.81 8.00 1.94 0.165 1 0.0405 
T:1 / n4 8 2500 15 22 25 26 25 42 38 27 27 27 27.43 7.62 10 1206.00 + 7.62 1.10 + 241 0.023 a 0.0499 
T=4 / r8 0 125 59 71 53 61 51 6000 7.21 5 60.00 ± 7.21 48.00 + 3.22 1.000 1 0.0950 
T=4 / al 8 2500 20 21 21 27 25 2280 3.03 5 1200.00 + 3.03 0.91 ± 1.36 0.019 ± 0.0263 
T.: / cd 0 125 51 53 64 46 53 53.40 6.58 5 53.40 ± 6.58 42.72 + 294 1.000 ± 0.0974 
T+0 / al 8 2500 43 50 40 49 54 48E0 3.96 5 1068.00 ± 3.96 1.95 ± 1.77 0.040 + 0.0416 
T64 / a3 0 150 98 96 97 112 107 102.00 7.11 5 102.00 + 7.11 68.00 + 3.18 1.000 ± 0.0661 
T=4 / a4 8 150 49 50 37 45 48 45.80 5.26 5 102.00 + 5.26 30.53 + 235 0.449 ± 0.0405 
SURVIVAL ANALYSIS 
HT Tarnow G3 04.06.97 
Merles & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per [Axe 
[1] 
Numbers of Colories Scored per plate 
[2] 	 [3] 	 [4] 	 [5] 	 [6] 	 [7] 	 [8] [9] (10] 
No. 
of 
Plates 
Yoble Fraction 
(Colonies/cell) 
(4 Standard 
1Deaialion) 
Plating 
Efficiency A/o 
(4 Standard 
Error) 
Swaieing 
Fraction 
(4 Stamdard 
Ear or) 
Mean Std. 
Dev. 
3.3 1 di 0 125 40 33 42 33 30 32 28 39 34.63 5.07 8 34.63 ± 13.28 27.70 ± 1.79 1.000 * 0.0915 
3..0 / al 2 167 37 35 41 42 46 42 40 45 31 48 40.70 5.21 10 46.26 4 15.89 24.37 4 1.65 0.880 4 0.0823 
3=0 / a2 4 250 31 36 38 30 41 33 21 36 32 34 33.20 5.43 10 69.25 4 3.86 13.28 ± 1.72 0.479 * 0.0693 
T=0 1 a3 6 625 34 21 23 30 30 23 29 25 20 28 25.80 3.85 10 17313 ± 4.00 4.13 i 1.22 0.149 4 0.0450 
TO / a4 8 1250 28 26 24 30 29 24 29 33 25 22 27.00 3.37 10 346.25 * 3.37 2.16 4 1.06 0.078 4 0.0388 
3-4 / ad 0 125 69 70 80 81 67 75 78 73 66 73.22 5.61 9 73.22 4 5.61 58.58 4 1.87 1.000 4 0.0451 
T=4 / al 2 125 81 81 70 77 80 71 63 76 71 75 74.50 5.78 10 73.22 4 578 59.60 4 1.83 1.017 4 0.0450 
T=4 / a2 4 156 88 90 95 88 94 101 81 89 90.75 5.95 8 9138 * 5 95 58.17 4 2.10 0.993 4 0.0479 
T=4 / e4 8 400 156 138 170 157 154 179 146 165 155 157.78 12.29 9 234.31 4 12.29 39.44 I 4.10 0.673 4 0.0731 
T4 1 ctl 0 133 06 89 84 72 82.75 7.46 4 82.75 4 7.46 62.22 ± 3.73 1.000 4 0.0847 
T4 1 al 8 1333 130 148 141 161 145.00 12.99 4 829.37 4 12.99 10.88 4 6.49 0.175 * 0.1049 
SURVIVAL ANALYSIS 
 
11.07.97 HT Tumour G4 
 
Number & 
Control 
Dose 
Gy 
Number 
of Cele 
Seeded 
par plate 
[1] [2] 
Numbers of Colonies Scored per plate 
[3] 	 [4] 	 [5] 	 [6] 	 [7] [8] [9] [10] 
No. 
of 
Plates 
Viable Fraction 
(Colonies Su) 
(4 Standard 
I Deviaten) 
Plating 
EfficiencylVa 
(t Standard 
Furor) 
Surviving 
Fraction 
Standard 
Error) 
Mcan Std. 
Day. 
T=3 / cd 0 125 87 86 76 64 68 80 73 74 63 7456 872 9 74.56 4 872 5964 4 2.91 1 000 in 0.0689 
T.9 / al 2 156 51 66 60 57 58 64 72 53 57 51 58.99 6.81 10 93.05 4 6.81 37.76 4 2.15 0.633 t 0.0475 
'1•1 / a2 4 156 36 38 33 35 41 34 27 31 34 34.33 4.00 9 93.05 4 4.00 22.01 ± 1.33 0.369 th 0.0287 
T=0 / a 6 625 39 43 30 34 30 32 30 36 36 35.33 4 33 9 372 78 4 4 33 595 t 144 0.095 th 0.0246 
T=0 / a4 8 1250 21 19 16 11 12 13 18 15.71 3.82 7 745.56 4 3.82 1.26 4 1.44 0.021 t 0.0242 
T=4 I cd 0 125 93 90 82 81 95 88.20 6.38 5 88.20 t 6.38 70.56 4 2.65 1.000 4 0.0633 
T=4 I al 2 125 90 94 86 98 91 91.80 4.49 5 88.20 ii 4.49 73.44 4 2.01 1.041 ± 0.0582 
1=4 I 32 4 125 55 56 58 60 49 5960 4.16 5 88.20 th 4,16 44.48 4 186 0.630 ± 0.0405 
T=4 / a3 6 125 73 72 71 66 68 70.00 2.92 5 88.20 4 2.92 56.00 t 1.30 0.794 t 0.0429 
T=4 i .4 8 125 03 54 63 56 52 57.60 5.13 5 88.20 4 513 46.08 4 2.29 0 653 t 0.0455 
SURVIVAL ANALYSIS 
 
30.07.97 &T Thmour G5 
 
Number & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies Scored per plate 
[2] 	 [3] 	 [4] 	 [5] 
	 [61 	 [7] 	 [8] [9] [10] 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(*Standard 
Deviation) 
Plating 
Efficiency l% 
(*Standard 
Error) 
SuriUing 
Fraction 
(*Standard 
Error) 
Mean Std. 
Dev. 
T1 ! cd 0 125 37 38 30 36 51 50 41 45 48 45 42.10 6.84 10 42.10 ± 6.84 33.68 1 216 1.000 ± 0.0908 
T.1 ! al 2 156 39 27 23 25 26 26 34 28 25 35 28.80 5.29 10 52.54 * 5.29 18.46 ± 1.67 0.548 ± 0.0609 
T:t 1 a2 4 208 19 18 21 10 18 20 12 19 23 16 17.60 3.98 10 70.05 ± 3.98 8.46 ± 1.26 0.251 * 0.0407 
T) ! a3 6 625 18 24 18 17 17 14 11 24 18 24 18.50 4.38 10 210.50 * 4.38 2.96 ± 1.38 0.088 ± 0.0415 
T0 1 a4 a 1250 10 11 11 11 8 12 14 16 13 B 11.40 2.50 10 421.00 ± 2.50 0.91 * 0.79 0.027 ± 0.0236 
T=4 / ctl 0 125 72 72 74 82 82 7640 5.18 5 76.40 ± 5.18 61.12 1 2.32 1.000 ± 0.0536 
T=4 / al 2 125 *D1V701 #DIV/01 0 76.40 ± *DIV/01 *DIV/01 ± #D111101 *D1V/01 ± *D1V101 
T=4 / e2 4 125 #12/111/01 *DIV/0! 0 76.40 * *DIV/0! *D1V/01 * fDIVI01 *0117/0! ± *DIV/01 
T--4. 1 a3 6 125 44 44.00 *DIV/01 1 76.40 * *DIV/0! 35.20 1 *DIV/01 0.576 ± *D1V/01 
T=4 ! a4 8 125 18 16 18 31 23 21.20 6.06 5 76.40 ± 6.06 16.96 ± 2.71 0.277 ± 0.0456 
SURVIVAL ANALYSIS 
 
2805.97 HT Tumour G6 
Number & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
Nimbus of Colonies Scored per plate 
[1] 	 [2] 	 [3] 	 [4] 	 [5] 	 [6] 	 [7] 	 [8] 	 [9] [10] 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(* Standard 
Deviation) 
Plating 
Efficiency /15 
(t Standard 
Furor) 
Surviving 
Fraction 
(th Standard 
P.m.) 
Mean Std. 
Dev. 
T:1 I cd 0 83 2 	 4 2 0 1 2 7 4 	 4 4 100 /00 10 100 * 2.00 3.61 t 0.63 1.000 - 0.2475 
T*0 I al 2 138 3 	 4 4 4 4 2 6 9 	 8 4.89 2.32 9 4.99 i 232 3.54 * 0.77 0.980 * 0.2739 
T=3 / a2 4 208 4 	 8 9 2 7 8 4 4 	 7 8 6.10 2.38 10 7.52 * 2.38 2.93 t 0.75 0.811 * 0.2519 
T=0 / a3 8 416 1 	 1 1 3 1 1 1.33 0.82 6 15.04 * 0.82 0.32 * 0.33 0.089 * 0.0935 
Til t a4 12 1667 1 	 1 1 1.00 0.00 3 60.25 t 0.00 0.06 6 0.00 0.017 t 0.0029 
T=4 / di 0 125 62 	 57 60 52 51 56.40 483 5 5640 * 4 83 45.12 * 216 1.000 * 0.0677 
T=4 / al 2 138 77 	 65 62 65 67 80 71 73 	 75 76 71.10 6.06 10 62.27 * 6.06 51.52± 1.92 1.142 i 0.0692 
T=4 / a2 4 166 81 	 80 71 62 60 55 665 68 	 62 71 127.50 189.05 10 74.90 ± 189.05 75.81 ± 59.78 1.702 t 1.3274 
T=4 t a3 8 250 86 	 91 96 96 95 78 76 83 	 98 88.78 8.32 9 112.80 ± 832 35.51 * 277 0.787 ± 0.0721 
T=4 I a4 12 500 7 	 5 7 4 4 8 7 600 1.63 7 225.60 ± 1.63 1.20± 0.62 0.027 ± 0.0137 
T=0 I of 0 125 14 	 10 10 9 14 11.40 2.41 5 11.40 ± 2.41 9.12 t 108 1.000 * 01670 
T=0 I al 2 2500 20 	 18 20 22 20 20.00 1.41 5 228.00 ± 1.41 0.80 6 0.63 0.088 ± 0.0701 
SURVIVAL ANALYSIS 
HT Tumour G7 30.07.97 
Number & 
Control 
Dose 
Cry 
Number 
of Cells 
Seeded 
per Pi* 
[1] 
Numbers of Colonies Scored per plate 
[2] 	 [3] 	 [4] 	 [5] 	 [6] 	 [7] 	 [8] [9] [10] 	 (10) 
No. 
of 
?Wes 
Viable Fraction 
(Colo*. /cell) 
(*Standard 
1 Deviation) 
Plating 
Floc:env; tr% 
(± Standard 
Error) 
S 	 Qsg 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dee. 
T=3 / cti 0 125 56 53 70 61 75 53 50 63 56 62 60.70 7.21 10 60.70 1 7.21 48.56 ± 2.28 1.000 ± 0.066 
T±) / al 2 192 63 69 52 55 50 61 60 51 65 51 57.70 638 10 93.24 ± 6.78 30.05 ± 2.15 0.619 ± 0.053 
T±) / a2 4 313 40 43 35 39 39 40 40 44 58 72 45.00 11.30 10 151.99 ± 11.30 14.38 ± 3.57 0.296 ± 0.075 
T±71 I a3 6 1250 22 20 28 24 26 31 24 30 30 37 27.20 5.03 10 607.00 ± 5.03 2.18 ± 1.59 0.045 ± 0033 
T=0 / a4 8 2500 16 15 16 12 11 15 12 13 14 15 13.90 1.79 10 1214.00 ± 1.79 0.56 ± 0.57 0.011 ± 0.012 
T=4 f ea 0 125 40 23 24 22 36 29.00 8.37 5 29.00 ± 8.37 23.20 ± 3.74 1.000 0.228 
T=4 1 al 2 125 31 28 29 29 30 29.40 1.14 5 29.00 ± 1.14 23.52 ± 0.51 1.014 0352 
T=4 I a2 4 167 23 27 21 23 32 25.20 4.38 5 38.74 ± 4.38 15.09 ± 1.96 0.650 ± 0.090 
T=4 I a3 6 250 19 24 18 22 21 20.80 2.39 5 58.00 ± 2.39 8.32 ± 1.07 0.359 0.049 
T=4 I a4 8 666 15 18 17 19 19 17.60 1.67 5 154.51 ± 1.67 2.64 ± 0.75 0.114 ± 0.033 
SURVIVAL ANALYSIS 
 
17.06.97 ET Tumour G8 
 
Number & 
Control 
Dox 
Csy 
Number 
of Cells 
Seeded 
ptielate 
[1] [2] 
Numbers of Colonies Scored per plate 
[3] 	 [4] 	 [5] 	 [6] 	 [7] [8] [9] [181 
No. 
of 
Plates 
Viable Fraction 
(Colonies !ea) 
(4 Standard 
]Deviation) 
Plating 
Efficiency /% 
(4 Standard 
Error) 
Surviving 
Fraction 
(4 Standard 
Error) 
Mem Std. 
Dev. 
5.0 / al 0 125 23 55 73 74 72 71 67 75 66 71 70.70 7.23 10 70.70 4 7.23 56.56 4 2.29 1.000 4 0.0571 
TtO / a1 2 192 89 73 68 63 72 79 89 77 76 69 7550 8.51 10 108.60 4 8.51 39.32 4 2.69 0.695 4 0.0553 
T4 I a2 4 313 73 62 55 54 53 58 57 54 66 69 60.10 7.06 10 177.03 4 7.06 19.20 4 2.23 0.339 4 0.0416 
T4 ! a3 6 1250 55 40 47 42 62 56 66 56 63 65 55.20 9.39 10 707.00 4 9.39 4.42 4 2.97 0.078 6 0.0526 
Ti I a4 8 2500 18 22 24 19 20 24 26 23 25 20 22 10 2.73 10 1414.00 4 2.73 0.88 4 0.86 0.016 4 0.0153 
T=4 / ad 0 125 81 87 70 75 63 83 81 75 74 81 77.00 7.04 10 77.00 4 7.04 61.60 4 2.23 1.000 4 0.0511 
T=4 / al 2 125 68 63 64 56 69 60 62 72 80 66 66.00 6.75 10 77.00 4 6.75 52.80 4 2.13 0.857 4 0.0490 
Tt4 / a2 4 167 68 70 76 34 89 79 69 7643 8.06 7 102.87 4 8.06 45.77 4 3.05 0.743 4 0.0578 
T=4 / a3 6 250 99 94 100 94 116 104 105 106 105 07 101.00 8.10 10 154.00 4 2.10 40.40 4 2.56 0.656 4 0.0493 
5=4 I a4 6 666 161 178 143 167 174 175 170 167 176 180 169.10 10.86 10 410.26 4 10.66 25.39 4 343 0,412 ± 0.0582 
SURVIVAL ANALYSIS 
 
07.08.97 HT Tumour G9 
 
Number & Dose 
Number 
of Cells Numbers of Colonies 
No. 
of 
Viable Fraction 
(Colonies (cell) 
Plating 
Efficiency PA 
Surviving 
Fraction 
Control Gy Seeded [1] [2] [3] [4] [5] Mean Std. Plates (t Standard (± Standard (± Standard 
per plate Dev. Deviation) Error) Error) 
T:1 	 / ctl 0 125 56 52 56 44 47 51.00 5.39 5 51.00 	 ± 5.39 40.80 t 2.41 1.000 ± 0.0835 
T=0 	 / a3 6 625 90 99 97 92 100 95.60 4.39 5 255.00 	 t 4.39 15.30 t 1.96 0.375 t 0.0530 
T4 	 I a4 8 1250 13 16 9 10 8 11.20 3.27 5 510.00 	 t 3.27 0.90 ± 1.46 0.022 t 0.0359 
T=4 	 I ctl 0 125 70 59 62 54 61 61.20 5.81 5 61.20 	 t 5.81 48.96 ± 2.60 1.000 t 0.0750 
T=4 	 / a4 8 125 9 3 8 6 7 6.60 2.30 5 61.20 	 ± 2.30 5.28 t 1.03 0.108 t 0.0218 
SURVIVAL ANALYSIS 
TIT 'Emma G10 07.08.97 
 
Number & 
Control 
Dom 
Cy 
Number 
of Cells 
Seeded 
Pm 044 
[1] 
Numbers of Colonies 
[2] 	 [3] 	 [4] [5] 
No. 
of 
Plates 
Viable Fraction 
(Colonies feel) 
(*Standard 
Deviation) 
Plating 
Efficiency /A 
(*Stndard 
Fav) 
Surviving 
Fraction 
(*Standard 
Error) 
Mem Std 
Dev. 
T-41 
T4 
Tgl 
T*4 
T*4 
T*4 
7 
f 
I 
I 
I 
I 
cil o 
e3 
a4 
al 
a3 
a4 
6 
1 
o 
6 
8 
125 
625 
1250 
125 
125 
125 
77 
61 
45 
66 
58 
31 
65 
70 
45 
65 
61 
49 
77 
55 
41 
59 
55 
46 
69 
70 
51 
65 
65 
43 
59 
55 
51 
62 
72.00 
6100 
47.40 
63.75 
58.00 
46.20 
6.00 
675 
555 
120 
5.39 
11.17 
4 
5 
5 
4 
5 
5 
72.00 
560.00 
720.00 
6175 
63.75 
6175 
* 
± 
* 
± 
1 
+ 
6.00 
675 
5.55 
3.20 
5.39 
11.17 
57.60 
mos 
3.79 
51.00 
46.40 
36.96 
* 
± 
* 
± 
* 
it 
3.00 
102 
2.48 
1.60 
2.41 
4.99 
1.000 
0.175 
0.066 
1.000 
0.910 
0.725 
* 
* 
* 
* 
+ 
* 
0.0737 
0.0532 
0.0432 
0.0444 
0.0552 
0.1005 
SURVIVAL ANALYSIS 
ELT Tumour G11 28.08.97 
.Nomber & Dose 
Number 
of Cells Numbers of Colonies 
No. 
of 
Viable Fraction 
(Colonies /cell) 
Plating 
Efficiency PA 
Surviving 
Fraction 
Control GY Seeded [1] [2] [3] [4] [5] Mean Std. Plates (t Standard (+ Standard (+ Standard 
per plate Dev. Deviation) Error) En-or) 
T.) I cli 0 125 35 28 28 27 31 29.80 3.27 5 29.80 ± 3.27 23.84 ± 1.46 1.000 ± 0.0868 
T.) f ad 0 2500 20 17 17 19 17 18.00 1.41 5 596.00 ± 1.41 0.72 1 0.63 0.030 k 0.0266 
T.4 1 cli 0 125 47 41 40 48 41 43.40 3.78 5 43.40 ± 3.78 34.72 ± 1.69 1.000 ± 0.0861 
T=4 I a4 8 125 35 35 31 37 35 34.60 2.19 5 43.40 ± 2.19 27.68 ± 0.98 0.797 ± 0.0632 
SURVIVAL ANALYSIS 
 
27.08.47 HT Tumour G12 
Number & 
Control 
Dose 
Gy 
Number 
of Ce.ls 
Seeded 
per plate 
[1] 
Numbers of Colonies 
[2] 	 [3] 	 [4] [5] 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency Pio 
(f Standard 
Error) 
Surviving 
Fraction 
Standard 
Error) 
Me= Std. 
Dev. 
T=0 	 I' 
TO 	 f 
T=4 	 f 
T=4 	 I 
di 
a4 8 
at 0 
n4 
0 
8 
125 
2500 
125 
125 
19 
34 
35 
22 
16 
29 
38 
23 
19 
36 
38 
21 
25 
46 
35 
23 
13 
23 
40 
18 
19.40 
33.60 
37.20 
21.40 
3.36 
8.56 
2.17 
2.07 
5 
5 
5 
5 
19.40 
388.00 
37.20 
37.20 
* 
+ 
3 
3 
3.36 
8.56 
2.17 
2.07 
15.52 
1.34 
17.12 
+ 
± 
t 
29.76 3 
1.50 
3.83 
0.97 
0.93 
1.009 
0.087 
1.500 
0.575 
± 
+ 
3 
0.1310 
0.2468 
0.0461 
0.0364 
SURVIVAL ANALYSIS 
 
11.06.97 PET Tumour 013 
Number & 
Control 
Dose 
GY 
Number 
of Cols 
Seeded 
per plate 
[1] 
Numbers of Colonies Scored per plate 
[2] 	 [3] 	 [4] 	 [5] 	 [6] 	 [7] 	 [8] [9] [10] 
No. 
of 
Plates 
(Co/onies 
Viable Fraction 
kelp 
4 Standard 
Deviation) 
Plating 
EfEci racy flit 
4 Standard 
Erro) 
Stasi/ea 
Fraction 
(1 Standard 
Error) 
lAvan Std 
Dm. 
500 / cti 0 125 55 40 48 49 30 24 24 21 22 34.79 13.33 9 34.76 0 13.33 27.82 1 3.55 1.000 I 0.18077 
T4 / al 2 156 38 61 50 63 60 37 45 53 52 49 50.80 9.04 10 43.40 4 9.0.4 3256 9 1.83 1.170 9 0.1634 
1*.1 / 32 4 208 36 40 42 46 45 35 40 40 42 49 41.50 4.33 ID 57.87 1 4.33 19.95 6 0.65 0.717 1 0.0946 
T.7 / a3 6 312 52 33 33 31 37 32 35 30 31 26 34.00 698 10 86.81 9 6.98 1090 ± 0.71 0392 1 00561 
13 / .4 8 625 32 30 29 30 34 31 26 22 32 35 30.10 3.81 10 17289 6 3.81 4.82 --E 0.19 0.173 1 00232 
1=4 / cd 0 125 104 111 117 115 115 105 119 106 110 111.33 5.50 9 111.33 1 5 50 89 07 1 147 1.000 9 0.0233 
154 / al 2 125 116 107 103 109 99 94 99 102 110 100 10300 654 10 11133 1 6.54 83.12 9 1.65 0.933 9 0.0241 
T=4 / a3 6 125 113 123 118 143 156 118 124 118 116 125.44 14.41 9 111 33 1 14 Al 100.36 1 304 1.127 1 0.0470 
T=4 i N4 8 125 226 225 225 244 230 227 232 260 256 264 23090 15.69 10 111.33 4 15.69 191.12 1- 3.97 2146 9 oosoo 
SURVIVAL ANALYSIS 
 
12.06.97 SET Strontium. g  
Number & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies Scored per plate 
[2] 	 [3] 	 [4] 	 [5] 	 [6] 	 [7] 	 [8] 	 [9] 	 [10] 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency Ph 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dee 
T=0 1 cti 0 160 85 68 83 75 62 76 71 73 74.13 7.53 8 74.13 1 7.53 46.33 ± 2.66 1.000 ± 	 0.0813 
T=0 1 al 0.25 160 79 69 88 76 78,00 7.87 4 74.13 1 7.87 48.75 ± 3.94 1.052 ± 	 0.1043 
T=0 1 a2 0.5 160 73 86 82 91 83.00 7.62 4 74.13 ± 7.62 51.88 ± 3.81 1.120 1 	 0.1044 
T=0 1 a3 0.75 160 91 87 86 80 86.00 4.55 4 74.13 ± 4.55 53.75 ± 2.27 1.160 ± 	 0.0828 
T=01 a4 1 177 80 81 85 82 82.00 2.16 4 82.00 ± 2.16 46.33 1 1.08 1.000 ± 	 0.0620 
T=01 a5 2 200 72 83 72 74 75.25 5.25 4 92.66 ± 5.25 37.63 ± 2.63 0.812 ± 	 0.0734 
T=0/ a6 3 267 55 35 65 44 49.75 13.05 4 123.70 1 13.05 18.63 -1- 6.52 0.402 ± 	 0.1427 
T=0 I a7 4 400 73 69 77 77 74.00 3.83 4 185.31 ± 3.83 18.50 ± 1.91 0.399 ± 	 0.0473 
T=0 I a8 5 800 137 153 143 125 139.50 11.70 4 370,63 ± 11.70 17.44 ± 5.85 0.376 ± 	 0.1282 
T=0 I a9 6 1600 104 112 98 123 109.25 10.81 4 298.13 ± 10.81 6.83 ± 5.41 0.366 ± 	 0.2902 
T=0 1 a10 7 3200 163 171 172 170 169.00 4.08 4 596.25 ± 4.08 5.28 ± 2.04 0.283 ± 	 0.1096 
T=0 1 all 8 6400 318 329 336 355 334.50 15.55 4 1192.51 ± 15.55 5.23 ± 7.77 0.281 ± 	 0.4172 
SURVIVAL ANALYSIS 
 
12.06.97 HT Strontium t T=4 
Number St 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
Numbers of Colonies 
[1] 	 [2] 	 [3] 	 [4] [5] 
Number of 
Colonies 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency 1% 
(+ Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dev. 
T=4 f ctl 0 125 23 22 24 22 25 23.20 1.30 5 23.20 at 1.30 18.56 at 0.58 1.000 at 0.0444 
T=4 I al 2 125 30 28 22 24 26 26.00 3.16 5 23.20 at 3.16 20.80 ± 1.41 1.121 at 0.0839 
T=4 I a2 4 125 22 19 20 20 21 20.40 1.14 5 23.20 at 1.14 16.32 at 0.51 0.879 at 0.0390 
T=4 / a3 8 125 18 14 12 16 10 14.00 3.16 5 23.20 ± 3.16 11.20 at 1.41 0.603 t 0.0785 
T=4 / rt.]. 0 125 25 28 30 22 25 26.00 3.08 5 26.00 at 3.08 20.80 at 1.38 1.000 0.0733 
T=4 / al 2 125 30 22 21 24 27 24.80 3.70 5 26.00 --b 3.70 19.84 at 1.66 0.954 at 0.0850 
T=41 a2 4 125 22 28 25 24 27 25.20 2.39 5 26.00 at 2.39 20.16 at 1.07 0.969 at 0.0597 
T=4 / a3 8 125 19 12 18 22 11 16.40 4.72 5 26.00 at 4.72 13.12 at 2.11 0.631 at 0.1034 
T=4 I ctl 0 500 91 91 101 99 88 94.00 5.66 5 94.00 at 5.66 18.80 at 2.53 1.000 0.1382 
T=4 I al 2 500 118 108 108 115 93 108.40 9.66 5 94.00 at 9.66 21.68 at 4.32 1.153 at 0.2326 
T=4 I a2 4 500 90 109 92 101 83 95.00 10.12 5 94.00 at 10.12 19.00 at 4.53 1.011 at 0.2408 
T=4 / a3 8 500 134 112 122 132 134 126.80 9.65 5 94.00 at 9.65 25.36 at 4.32 1.349 at 0.2296 
SURVIVAL ANALYSIS 
 
12.06.97 HT Point Source 
Number & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
[1] [2] [3] [4] 
Number of 
Colonies 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency /Vo 
(± Standard 
Error) 
Surviving 
Fraction 
(I Standard 
Error) 
Mean Std 
Dev. 
T=0 / ctl 0 266 80 82 86 88 84.00 3.65 4 84.00 	 ± 3.65 31.58 at 	 1.83 1.000 at 0.0818 
T=0 / al 1 311 35 37 41 35 37.00 2.83 4 98.21 	 at 2.83 11.90 ± 	 1.41 0.377 at 0.0498 
T=0 / a2 3 280 47 50 44 47 47.00 2.45 4 88.42 	 at 2.45 16.79 at 1.22 0.532 at 0.0495 
T3 I a3 5 272 61 66 68 65 65.00 2.94 4 85.89 	 at 2.94 23.90 at 1.47 0.757 at 0.0639 
T=4 / ctl 0 267 69 70 75 66 70.00 3.74 4 70.00 	 at 3.74 26.22 at 1.87 1.000 at 0.1009 
T=4 / al 1 272 74 79 75 68 74.00 4.55 4 71.31 	 at 4.55 27.21 at 2.27 1.038 at 0.1140 
T=4 / a2 3 335 84 79 81 76 80.00 3.37 4 87.83 	 at 3.37 23.88 at 1.68 0.911 at 0.0914 
T=4 / a3 6 403 109 104 101 98 103.00 4.69 4 105.66 	 at 4.69 25.56 at 2.35 0.975 t 0.1133 
SURVIVAL ANALYSIS 
 
12.06.97 Tumour A7 Feeder 
 
Number & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
Per plate 
[1] [2] 
Numbers of Colonies Scored per plate 
[3] 	 [4] 	 [5] 	 [6] 	 [7] 	 [8] 	 [9] 	 [10] 
Number of 
Colonies 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency Ph 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std 
Dee. 
T=4 t 	 cif 0 125 55 57 55 47 57 54.20 4.15 5 54.20 ± 	 4.15 43.36 ± 	 1.85 1.000 ± 0.0605 
T-4 / HTF 8 125 47 33 37 43 43 40.60 5.55 5 54.20 ± 	 5.55 32.48 ± 	 2.48 0.749 ± 0.0655 
T=4 I 	 ctl 0 125 48 58 52 59 45 52.40 6.11 5 52.40 ± 	 6.11 41.92 ± 	 2.73 1.000 ± 0.0921 
T=4 I A7F 8 125 34 39 40 38 40 38.20 2.49 5 52.40 ± 	 2.49 30.56 ± 	 1.11 0.729 ± 0.0544 
T=4 I 	 ctl 0 125 54 43 49 35 51 46.40 7.54 5 46.40 ± 	 7.54 37.12 ± 	 3.37 1.000 ± 0.1284 
T=4 I 	 NF 8 125 32 31 50 37 40 38.00 7.65 5 46.40 = 	 7.65 30.40 ± 	 3.42 0.819 ± 0.1184 
SURVIVAL ANALYSIS 
Strontium T=0 and T=4 27.03.98 
Number & 
Control 
Dose 
Cry 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies 
[2] 	 [3] 	 [4] [5] 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency Pio 
(d Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Meals Std. 
Dev. 
T0 / cd 0 250 16 12 12 12 10 12.40 2.19 5 12.40 ± 2.19 4.96 ± 0.98 1.000 ± 	 0.2794 
/ al 2 625 13 11 15 18 8 13.00 3.81 5 31.00 ± 3.81 2.08 ± 1.70 0.419 ± 	 0.3532 
T4 I a2 4 1250 8 12 7 9 5 8.20 2.59 5 62.00 ± 2.59 0.66 ± 1.16 0.132 ± 	 0.2348 
T4 I a3 8 5000 1 2 2 0 0 1.00 1.00 5 248.00 ± 1.00 0.02 ± 0.45 0.004 ± 	 0.0902 
T=ll 1 a4 16 20000 0 0 0 0 0 0.00 0.00 5 992.00 ± 0.00 0.00 ± 0.00 0.000 ± 	 #D111701 
T=4 / ctl 0 500 91 91 101 99 88 94.00 5.66 5 24.80 ± 5.66 18.80 ± 2.53 3.790 ± 	 0.9060 
T=4 i al 2 500 118 108 108 115 93 108.40 9.66 5 24.80 ± 9.66 21.68 ± 4.32 4.371 ± 	 1.2264 
T=4 I a2 4 500 90 109 92 101 83 95.00 10.12 5 24.80 ± 10.12 19.00 ± 4.53 3.831 ± 	 1.1857 
T=4 I a3 8 500 	 • 134 112 122 132 134 126.80 9.65 5 24.80 ± 9.65 25.36 ± 4.32 5.113 ± 	 1.3333 
SURVIVAL ANALYSIS 
Stontium Survival T=4 12.06.97 
Number & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies 
[2] 	 [3] 	 [4] [5] 
No. 
of 
Plates 
Viable Fraction 
(Colonies Iced) 
(± Standard 
Deviation) 
Plating 
Effir4eney J.Y0 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dev. 
T=41 cd 0 500 91 91 101 99 88 94.00 5.66 5.00 94.00 at 5.66 18.80 * 2.53 1.00 1 0.19 
T=4 1 	 al 2 500 118 108 108 115 93 108.40 9.66 5.00 94.00 at 9.66 21.68 1 4.32 1.15 1 0.28 
T14 / a2 4 500 90 109 92 101 83 95.00 10.12 5.00 94.00 t 10.12 19.00 at 4.53 1.01 ± 0.28 
T=4 I 	 a3 8 500 134 112 122 132 134 126.80 9.65 5.00 94.00 at 9.65 25.36 at 4.32 1.35 ± 0.29 
7 	 I 	 cti 0 125 25 28 30 22 25 26.00 3.08 5.00 23.50 d- 3.08 20.80 ± 1.38 1.11 ± 0.17 
T=4 / 	 a5 2 125 30 22 21 24 27 24.80 3.70 5.00 23.50 ± 3.70 19.84 * 1.66 1.06 ± 0.17 
T=4 I 	 a6 4 125 22 28 25 24 27 25.20 2.39 5.00 23.50 at 2.39 20.16 at 1.07 1.07 at 0.16 
TI / 	 a7 8 125 19 12 18 22 11 16.40 4.72 5.00 23.50 t 4.72 13.12 at all 0.70 at 0.15 
T=4 I 	 ctl 0 125 23 22 24 22 25 23.20 1.30 5.00 23.50 at 1.30 18.56 at 0.58 0.99 at 0.14 
T=4 1 a10 2 125 30 28 22 24 26 26,00 3.16 5.00 23.50 at  3.16 20.80 at  1.41 1.11 at  0.17 
T=4 I all 4 125 22 19 20 20 21 20.40 1.14 5.00 23.50 at 1.14 16.32 at 0.51 0.87 at 0.12 
T=4 / a12 8 125 18 14 12 16 10 14.00 3.16 5.00 23.50 at 3.16 11.20 at 1.41 0.60 at 0.11 
SURVIVAL ANALYSIS 
 
12.06.97 HT X-Ray Acute Repeat 1 
Number Se 
Control 
Dose 
GY 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies 
[2] 	 [3] 	 [4] [5] 
Nimibes- of 
Colonies 
No. 
of 
Plates 
Viable Fraction 
(Colonies !cell) 
(*Standrd 
Deviation) 
Plating 
Efficiency PA 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dev. 
T.1 I al 0 200 130 139 120 124 114 125.40 9.58 5 125.40 ± 9.58 62.70 ± 4.28 1.000 ± 0.0966 
T-0 f al 0.25 222 139 150 130 108 132 131.80 15.43 5 139.19 t 15.43 59.37 ± 6.90 0.947 ± 0.1277 
T=0 I a2 0.5 225 125 141 145 146 127 136.80 10.06 5 141.08 ± 10.06 60.80 ± 4.50 0.970 ± 0.0977 
T=0 f a3 0.75 235 120 129 108 129 126 122.40 8.85 5 147.35 ± 8.85 52.09 ± 3.96 0.831 ± 0.0849 
T=0 I a4 1 250 129 128 140 134 149 /36.00 8.69 5 156.75 * 8.69 54.40 ± 3.89 0.868 ± 0.0858 
T3 I a5 2 444 167 176 146 174 172 167.00 12.21 5 278.39 t 12.21 37.61 ± 5.46 0.600 ± 0.0962 
T.) I a7 8 666 177 158 158 158 167 163.60 8.44 5 417.58 + 8.44 24.56 ± 3.78 0.392 ± 0.0659 
SURVIVAL ANALYSIS 
HT X-Ray Acute Repeat 2 12.0E97 
Number & 
Control 
Dose 
Cry 
Number 
of Cells 
Seeded 
per plate 
Numbers of Colonies 
[1] 	 [2] 	 [3] 	 [4] 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(I Standard 
Deviation) 
Plating 
Efficiency P/0 
(1 Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dev. 
T=0 / ml. 0 150 98 91 80 132 100.25 22.43 4 100.25 ± 	 22.43 66.83 ± 	 11.21 1.000 ± 	 0.2373 
T=0 / al 0.25 168 83 95 88 110 94.00 11.75 4 112.08 ± 	 11.75 56.05 ± 	 5.87 0.839 ± 	 0.1659 
T=0 / a2 0.5 178 106 97 107 102 103.00 4.55 4 118.90 Jr 	 4.55 57.90 ± 	 2.27 0.866 -± 	 0.1493 
T=0 / a3 0.75 188 102 101 120 120 110.75 10.69 4 125.31 Jr 	 10.69 59.07 ± 	 5.34 0.884 ± 	 0.1685 
T=0 / a4 1 213 104 99 117 106 106.50 7.59 4 142.49 Jr 	 7.59 49.95 Jr 	 3.80 0.747 Jr 	 0.1377 
T=0 / a5 2 355 126 140 110 106 120.50 15.61 4 237.12 Jr 	 15.61 33.96 Jr 	 7.80 0.508 ± 	 0.1446 
T=0 / a6 3 426 140 130 110 125 126.25 12.50 4 284.64 ± 	 12.50 29.64 ± 	 6.25 0.444 ± 	 0.1195 
T=0 1 a7 4 530 159 179 146 146 157.50 15.59 4 354.35 ± 	 15.59 29.71 ± 	 7.79 0.444 Jr 	 0.1384 
T=0 / a8 5 800 124 121 117 116 119.50 3.70 4 534.93 ± 	 3.70 14.93 Jr 	 1.85 0.223 Jr 	 0.0466 
T=0 / a9 6 1599 140 117 117 126 125.00 10.86 4 474.05 ± 	 10.86 7.82 Jr 	 5.43 0.264 Jr 	 0.1832 
T=0 / a10 7 3202 139 134 138 139 137.50 2.38 4 949.08 Jr 	 2.38 4.29 1 	 1.19 0.145 Jr 	 0.0402 
T=0 1 all 8 3999 120 122 121 120 120.75 0.96 4 1185.52 Jr 	 0.96 3.02 Jr 	 0.48 0.102 Jr 	 0.0161 
SURVIVAL ANALYSIS 
 
12.06.97 HT X-Ray Acute Repeat 3 
Number & 
Control 
Dose 
3y 
Number 
of Cells 
Seeded 
pm plate 
[1] [2] 
Numbers of Colonies Scoredperplate 
[3] 	 [4] 	 [5] 	 [6] 	 [7] [8] 	 [9] 	 110] 
No. 
of 
Plates 
Viable Fracion 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
EGoiency PA 
(4 Standard 
Env) 
Surviving 
Fraction 
(4 Standard 
Ennr) 
Mean Std. 
Dv. 
T4 / di 0 200 129 171 95 116 127 113 139 130 120.00 13.958 02400 	 t 13.95 40.00 ± 4.93 1.00 ± 0.12 
T4 / al 0.25 210 138 113 118 116 121.75 11.094 125.78 	 ± 11.09 58.08 * 5.54 0.97 ± 0.12 
T4 / a2 0.5 222 124 120 133 129 126.50 5.69 4 133.09 	 ± 5.69 57.03 ± 2.84 0.95 * 0.09 
T 1 a3 0.75 235 160 162 157 164 160.75 2.99 4 141.01 	 ± 2.99 68.40 ± 1.49 1.14 * 0.00 
T*) / a4 1 267 174 169 145 167 163.75 12.84 4 160.05 	 4 12.84 61.39 ± 6.42 1.02 ± 0.14 
T*:1 / a5 2 444 167 170 158 169 166.00 5.48 4 266.39 	 ± 5.48 37.39 ± 2.74 0.62 ± 0.07 
T*3 / .6 3 530 159 169 178 009 165.00 10.684 317.66 	 ± lass 31.15 ± 534 0.52 ± 0.10 
IVI / e7 4 655 136 152 148 158 148_50 9.29 4 399.19 	 ± 9.29 22.32 ± 465 037 ± 0.08 
IV) / a8 5 1002 145 148 144 168 151.25 11.30 4 600.99 	 ± 11.30 15.10 ± 5.65 0.25 ± 0 10 
Tv0 / a9 6 1999 178 167 167 057 167.25 8.58 4 622.70 	 ± 8.58 8.37 - 4.29 0.27 ob 0.14 
T4 / a70 7 3997 173 184 162 173 173.00 8.98 4 1244.80 	 ± 8.98 4.33 ± 4.49 0.14 ± 0.14 
T4 / all 8 4997 104 98 91 87 95.00 7.53 4 1556.46 	 ± 7.55 1.90 - 3.76 0.06 ± 0.12 
SURVIVAL ANALYSIS 
HT X-Ray Acute Repeat 4 12.06.97 
Number & 
Control 
Dose 
GY 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies 
[2] 	 [3] 	 [4] [5] 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency PA 
(t Standard 
Error) 
Surviving 
Fraction 
(t Standard 
Error) 
Mean Std. 
Dcv. 
T4 / ctl 0 267 170 146 148 165 148 155.40 11.22 5 155.40 	 t 11.22 58.20 t 5.02 1.00 t 0.12 
T4 / al 0.25 270 148 145 134 134 137 139.60 6.50 5 157.15 	 t 6.50 51.70 at 2.91 0.89 t 0.09 
T4 / a2 0.5 300 141 141 156 165 168 154.20 12.83 5 174.61 	 t 12.83 51.40 t 5.74 0.88 at 0.12 
Tli / a3 0.75 314 161 165 164 144 159 158.60 8.50 5 182.76 	 t 8.50 50.51 t 3.80 0.87 t 0.10 
T4 / a4 1 406 176 193 201 171 209 190.00 16.19 5 236.30 	 t 16.19 46.80 t 7.24 0.80 t 0.14 
T4 / a5 2 1026 273 273 274 263 280 272.60 6.11 5 597.16 	 t 6.11 26.57 t 2.73 0.46 t 0.06 
T4 / a6 4 889 153 151 149 156 146 151.00 3.81 5 517.42 	 t 3.81 16.99 t 1.70 0.29 t 0.04 
T4 / a7 8 1044 19 20 21 22 24 21.20 1.92 5 607.63 	 t 1.92 2.03 t 0.86 0.03 t 0.02 
T4 / a8 16 34760 0 0 0 0 0 0.00 0.00 5 20231.10 t 0.00 0.00 at 0.00 0.00 at #DIV/01 
SURVIVAL ANALYSIS 
X-Ray Acute t  T=4 12.06.97 
Number & 
Control 
Dose 
GY 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies 
[2] 	 [3] 	 [4] [5] 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency P/o 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dee. 
T=41 	 ctl 0 500 141 156 154 185 160 159.20 16.08 5 149.60 ± 	 16.08 31.84 ± 	 7.19 1.06 ± 	 0.34 
T=4 1 	 al 2 500 134 128 129 123 134 129.60 4.62 5 149.60 ± 	 4.62 25.92 ± 	 2.06 0.87 ± 	 0.21 
T4 / a2 4 500 140 117 123 125 123 125.60 8.59 5 149.60 ± 	 8.59 25.12 ± 	 3.84 0.84 ± 	 0.23 
T=4 / 	 a3 8 500 137 132 141 141 136 137.40 3.78 5 149.60 ± 	 3.78 27.48 ± 	 1.69 0.92 ± 	 0.22 
T=4 / 	 ctl 0 125 38 37 32 39 41 37.40 3.36 5 37.40 ± 	 3.36 29.92 ± 	 1.50 1.00 ± 	 0.23 
T=4 / 	 a5 2 125 38 30 35 39 40 36.40 4.04 5 37.40 ± 	 4.04 29.12 ± 	 1.81 0.97 ± 	 0.23 
T=4 / 	 a6 4 125 29 26 31 30 25 28.20 2.59 5 37.40 ± 	 2.59 22.56 ± 	 1.16 0.75 ± 	 0.17 
T=4 / 	 a7 8 125 18 25 21 22 20 21.20 2.59 5 37.40 ± 	 2.59 16.96 ± 	 1.16 0.57 ± 	 0.13 
T=4 / 	 ctl 0 125 41 42 46 37 32 39.60 5.32 5 39.60 ± 	 5.32 31.68 ± 	 2.38 1.00 ± 	 0.24 
T=4 / 	 all) 2 125 40 38 39 32 28 35.40 5.18 5 39.60 ± 	 5.18 28.32 ± 	 2.32 0.89 ± 	 0.21 
T=4 1 all 4 125 33 37 22 25 29 29.20 6.02 5 39.60 ± 	 6.02 23.36 ± 	 2.69 0.74 ± 	 0.19 
T=4 / a12 8 125 22 33 30 18 20 24.60 6.54 5 39.60 ± 	 6.54 19.68 ± 	 2.93 0.62 ± 	 0.17 
SURVIVAL ANALYSIS 
 
12.06.97 HT X-Ray Cbronic Repeat 1 
Number & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies Scored per plate 
[2] 	 [3] 	 [4] 	 [5] 	 [6] 	 [7] 	 [8] 	 [9] 	 [10] 
Number of 
Colonies 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency t% 
(± Standard 
Error) 
Surviving 
Fraction 
Os Standard 
Error) 
Mean Std. 
Dev. 
TI 1 ct1 0 267 143 140 156 155 155 149.80 7.66 5 149.80 ± 7.66 56.10 ± 	 3.43 1.000 ± 0.0864 
T=0 / al 0.25 280 132 148 147 138 127 138.40 9.18 5 157.09 ± 9.18 49.43 ± 	 4.11 0.881 ± 0.0908 
T=3 / a2 0.5 290 113 103 135 131 110 118.40 13.89 5 162.70 ± 13.89 40.83 ± 	 6.21 0.728 ± 0.1193 
T4 / a3 0.75 300 177 153 166 180 170 169.20 10.62 5 168.31 ± 10.62 56.40 ± 	 4.75 1.005 ± 0.1045 
T=0 / a4 1 355 182 187 165 189 192 183.00 10.70 5 199.17 ± 10.70 51.55 ± 	 4.79 0.919 ± 0.1021 
T=3 / a5 2 533 209 232 219 217 214 218.20 8.58 5 299.04 ± 8.58 40.94 ± 	 3.84 0.730 ± 0.0817 
T=0 I ctl. 0 267 132 142 140 159 141 142.80 9.88 5 142.80 ± 9.88 53.48 ± 	 4.42 1.000 ± 0.1028 
TO / al 4 761 183 186 164 171 198 180.40 13.28 5 407.01 ± 13.28 23.71 ± 	 5.94 0.443 ± 0.1143 
T0 I ctl. 0 266 146 165 169 155 160 159.00 8.97 5 159.00 ± 8.97 59.77 ± 	 4.01 1.000 ± 0.0908 
T4 I a3 8 885 41 52 58 53 50 50.80 6.22 5 529.00 ± 6.22 5.74 ± 	 2.78 0.096 ± 0.0469 
SURVIVAL ANALYSIS 
 
12.06.97 HT X-Ray Chronic Repeat 2 
Number & 
Control 
Dose 
Gy 
Number 
of Cella 
Seeded 
per plate 
[1] 
Numbers of Colonies Scored per plate 
[2] 	 [3] 	 [4] 	 [5] 	 [6] 	 [7] [8] 	 [9] 	 [10] 
Number of 
Colonies 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency Rio 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dev. 
Tll 	 / ctl 0 133 57 60 52 60 93 91 102 84 74.88 19.61 
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74.88 ± 19.61 56.30 ± 	 6.93 1.000 ± 0.1742 
Tll 	 / al 0.25 133 75 83 76 83 79.25 4.35 74.88 ± 4.35 59.59 1 	 2.17 1.058 ± 0.1360 
T:1 	 / a2 0.5 133 74 81 93 75 80.75 8.73 74.88 ± 8.73 60.71 ± 	 4.37 1.078 ± 0.1538 
T;) 	 I a3 0.75 133 94 92 83 76 86.25 8.34 74.88 ± 8.34 64.85 1 	 4.17 1.152 ± 0.1601 
323 / a4 1 133 76 66 61 67.67 7.64 74.88 1 7.64 50.88 1 	 4.41 0.904 ± 0.1361 
T:1 / a5 2 177 63 69 73 69 68.50 4.12 99.65 ± 4.12 38.70 ± 	 2.06 0.687 ± 0.0923 
Tli 	 / a6 3 205 60 61 58 66 61.25 3.40 115.41 ± 3.40 29.88 ± 	 1.70 0.531 ± 0.0720 
T4 / a7 4 266 61 54 51 45 52.75 6.65 149.75 ± 6.65 19.83 ± 	 3.33 0.352 ± 0.0733 
T=0 / cd 0 133 75 80 68 60 89 107 77 109 83.13 17.53 83.13 ± 17.53 62.50 ± 	 6.20 1.000 ± 0.1581 
T=0 / a9 5 333 39 42 46 45 43.00 3.16 208.13 ± 3.16 12.91 ± 	 1.58 0.207 ± 0.0359 
T4 / al0 6 445 24 25 20 15 21.00 4.55 278.13 1 4.55 4.72 ± 	 2.27 0.076 ± 0.0375 
T=0 / all 7 666 35 40 30 37 35.50 4.20 416.25 1 4.20 5.33 1 	 2.10 0.085 ± 0.0352 
T4 / a12 8 1333 44 56 41 51 48.00 6.78 833.13 ± 6.78 3.60 ± 	 3.39 0.058 ± 0.0547 
SURVIVAL ANALYSIS 
 
12.06.97 HT X-Ray Chronic Repeat 3 
Number & 
Control 
Dose 
Gy 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies Scored per plate 
[2] 	 [3] 	 [4] 	 [5] 	 [6] 	 [7] [8] 	 [9] 	 [10] 
Number of 
Colonies 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency Ph 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dee. 
T=3 / ctl 0 200 80 78 80 91 78 58 75 68 76.00 9.67 8 76.00 ± 9.67 38.00 ± 	 3.42 1.000 ± 0.1272 
TO / al 0.25 205 122 105 148 101 119.00 21.37 4 77.90 ± 21.37 58.05 ± 	 10.68 1.528 ± 0.3129 
T=0 / a2 0.5 210 100 127 118 116 115.25 11.24 4 79.80 ± 11.24 54.88 ± 	 5.62 1.444 ± 0.1968 
T=0 I a3 0.75 216 113 128 136 113 122.50 11.45 4 82.08 ± 11.45 56.71 ± 	 5.72 1.492 ± 0.2017 
1'0 	 / a4 1 222 112 121 113 115 115.25 4.03 4 84.36 ± 4.03 51.91 ± 	 2.02 1.366 ± 0.1338 
Til 	 I a5 2 266 119 133 118 113 120.75 8.58 4 101.08 ± 8.58 45.39 ± 	 4.29 1.195 ± 0.1558 
TI I a6 3 307 174 78 155 169 144.00 44.73 4 116.66 ± 44.73 46.91 ± 	 22.36 1.234 ± 0.5989 
T4 1 st7 4 444 106 103 105 101 103.75 2.22 4 168.72 ± 2.22 23.37 ± 	 1.11 0.615 ± 0.0625 
T4 / e t i 0 200 111 116 96 108 91 103 100 122 105.88 10.38 8 105.88 ± 10.38 52.94 ± 	 3.67 1.000 ± 0.1136 
T1 / a9 5 533 74 66 65 68 68.25 4.03 4 282.16 ± 4.03 12.80 ± 	 2.02 0.242 ± 0.0439 
Ti / a10 6 640 102 95 94 102 98.25 4.35 4 338.80 ± 4.35 15.35 ± 	 2.17 0.290 ± 0.0487 
T, / all 7 800 114 103 131 132 120.00 14.02 4 423.50 ± 14.02 15.00 ± 	 7.01 0.283 ± 0.1349 
'1.3 	 I a12 8 1600 116 134 129 135 128.50 8.74 4 847.00 ± 8.74 8.03 ± 	 4.37 0.152 ± 0.0836 
SURVIVAL ANALYSIS 
 
12.06.97 HT X-Ray Chr omc Repeat 4 
Number & 
Control 
Dose 
Cy 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies Scored per plate 
[2] 	 [3] 	 [4] 	 [5] 	 [6] 	 [7] 	 [8] 	 [9] 	 [10] 
Number of 
Colonies 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Pining 
EfrIfitill7P/6 
( Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dev. 
T:1 	 / cti 0 160 86 96 94 117 98.25 1323 4 98.25 ± 13.23 61.41 at 6.61 1.000 ± 0.1523 
T-A / al 0.25 160 122 105 148 95 117.50 23.19 4 98.25 at 23.19 73.44 at 11.59 1.196 at 0.2285 
T) / a2 0.5 160 95 112 127 115 112.25 13.20 4 98.25 t 13.20 70.16 at 6.60 1.142 at 0.1634 
TO / a3 0.75 161 113 126 134 111 121.00 10.92 4 98.86 at 10.92 75.16 at 5.46 1.224 at 0.1590 
T4 / a4 1 160 108 121 112 109 112.50 5.92 4 98.25 at 5.92 70.31 at 2.96 1.145 at 0.1324 
T=3 / a5 2 228 119 114 130 110 118.25 8.66 4 140.01 at 8.66 51.86 at 4.33 0.845 at 0.1151 
T,0 / a6 3 267 170 74 169 155 142.00 45.85 4 163.95 at 45.85 53.18 at 22.92 0.866 at 0.3848 
T4 I a7 4 320 102 100 101 88 97.75 6.55 4 196.50 at 6.55 30.55 at 3.28 0.497 at 0.0756 
T) / a8 6 530 66 105 74 69 78.50 17.97 4 325.45 at 17.97 14.81 at 8.99 0.241 at 0.1486 
T:1 	 / a9 8 1600 92 80 93 80 86.25 7.23 4 982.50 at 7.23 5.39 at 3.61 0.088 at 0.0596 
SURVIVAL ANALYSIS 
 
12.06.97 X-Ray Chronic @. T=4 
Number & 
Coturol 
Delayed 
Dose (Gy) 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies 
[2] 	 [3] 	 [4] [5] 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(Jr Standard 
Deviation) 
Plating 
Efficiency P/0 
(Jr Standard 
Error) 
Surviving 
Fraction 
(Jr Standard 
Error) 
Mean Std. 
DC7. 
T=4 / ctl 0 125 50 51 54 55 56 53.20 2.59 5 53.20 Jr 2.59 42.56 Jr 1.16 1.000 Jr 0.0385 
T=4 I al 2 125 48 51 52 47 59 51.40 4.72 5 53.20 Jr 4.72 41.12 Jr 2.11 0.966 Jr 0.0561 
T=4 I a2 4 125 44 42 45 50 51 46.40 3.91 5 53.20 Jr 3.91 37.12 Jr 1.75 0.872 Jr 0.0475 
T=4 / a3 8 125 33 35 36 38 39 36.20 2.39 5 53.20 Jr 2.39 28.96 Jr 1.07 0.680 Jr  0.0312 
T=4 / ctl 0 125 55 65 58 61 52 58.20 5.07 5 58.20 Jr 5.07 46.56 Jr 2.27 1.000 Jr 0.0558 
T=4 1 a5 2 125 55 47 58 52 51 52.60 4.16 5 58.20 Jr 4.16 42.08 Jr 1.86 0.904 Jr 0.0469 
T=4 / a6 4 125 51 41 47 52 44 47.00 4.64 5 58.20 Jr 4.64 37.60 Jr 2.07 0.808 Jr 0.0497 
T=4 / a7 8 125 39 28 44 41 38 38.00 6.04 5 58.20 Jr 6.04 30.40 Jr 2.70 0.653 Jr 0.0607 
T=4 / cti 0 125 44 51 50 52 54 50,20 3.77 5 50.20 Jr 3.77 40.16 Jr 1.69 1.000 Jr  0.0500 
T=4 / al 0 2 125 51 41 52 55 46 49.00 5.52 5 50.20 Jr 5.52 39.20 t 2.47 0.976 Jr 0.0670 
T=4 / all 4 125 44 41 42 39 38 40.80 2.39 5 50.20 Jr 2.39 32.64 Jr 1.07 0.813 Jr 0.0346 
T=4 / a12 8 125 33 32 35 38 38 35.20 2.77 5 50.20 Jr 2.77 28.16 Jr 1.24 0.701 Jr 0.0363 
SURVIVAL ANALYSIS 
 
11.08.97 Iodine 131 
Control & 
Code 
Dose 
mCi 
Number 
of Cells 
Seeded 
per plate 
[1] [2] 
Numbers of Colonies t' 
[3] 	 [4] 	 [5] 
Number of 
Colonies 
No. 
of 
Plates 
Viable Fraction 
(Colonies kelt) 
(+ Standard 
Deviation) 
Plating 
Efficiency I% 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dev. 
Ti 1 1 0.000 150 47 50 43 45 54 47.80 4.32 5 47.80 ± 4.32 31.87 at 1.29 1.000 at 0.0572 
T.) 	 1 3 0.063 200 20 31 26 29 25 26.20 4.21 5 63.73 at 4,21 13.10 at 0.94 0.411 at 0.0339 
T=0 1 4 0.125 400 23 26 32 33 38 30.40 5.94 5 127.47 at 5.94 7.60 at 0.66 0.238 at 0.0230 
T:1 / 5 0.250 3340 4 4 4.00 0.00 2 1064.35 at 0.00 0.12 at 0.00 0.004 at 0.0002 
T=:1 / 5+ 0.375 1000 
T=3 / al 0.000 300 82 98 101 105 92 95.60 8.96 5 95.60 at 8.96 31.87 at 1.34 1.000 at 0.0593 
T=:l / a2 0.050 500 103 109 93 96 104 101.00 6.44 5 159.33 at 6.44 20.20 at 0.58 0.634 at 0.0321 
T.) 1 a3 0.100 500 15 18 20 16 11 16.00 3.39 5 159.33 at 3.39 3.20 at 0.30 0.100 at 0.0104 
T=0 / a4 0.200 4000 27 32 21 25 21 25.20 4.60 5 1274.67 at 4.60 0.63 at 0.05 0.020 at 0.0018 
11"
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SURVIVAL ANALYSIS 
 
11 08.97 Iodine 131 
C77-41 &. 
Code 
Dom 
inCi 
161.142r 
of Cells 
S6461. 
,-,.44 
III [2] 
Numbers of Cotoric. Scod per plate 
[3] 
	 (4] 	 (51 	 [S] 	 [7] 	 [8] 	 [D] 	 [10] 
Number of 
2517774 
172 
55 
20,35. 
Vss154 Fro:6o6 
(Colenier /cell) 
(7 932-717d 
Devia272) 
Pladrur 
EdScieney 08 
(2 916.5476 
Error) 
145.0.46 
Erection 
(7 18•Adard 
Error) M76111 016 De., 
. 
T-0 1 	 1 00000 300 143 179 161 16100 18.00 3 161.00 7 13.00 53 67 7 3.46 1.000 = 0.0913 
1170 / 	 2 0.0313 300 68 54 71 64.33 9.07 3 16100 7 9.07 21.94 = 1.75 0.400 2 0.0413 
10-0 1 	 3 0.0625 300 41 42 40 41.00 100 3 161.00 7 1.00 13.67 2 0.19 0.255 3 0.0168 
120 f 	 4 0.1250 300 3 3 3 3.00 0.00 3 161.00 2 0.00 1.00 + 0.00 0.019 2 0.0012 
1, / 5 0.2500 600 0 0 0 am aoo 3 322.00 7 0.00 0.00 7 0DIV01 0000 7 S016/01 
70 1 	 6 01000 8800 0 0 0 0.00 0.00 3 4722.67 3 0.00 000 7 SE01701 0000 2 #2511/01 
572 / 	 7 0.2000 89170 0 0 0 000 000 3 4669 00 7 000 aoo & SECV10! 0.000 7 O005/01 
750 / 	 1 0.0000 255 52 55 60 55.67 404 3 5567 2 4.04 2181 + 0.92 1000 = 0.0593 
7-01 	 3 0 0625 342 24 59 29 27.33 2.89 3 7466 2 284 7.99 7 0.49 0.366 2 0.0475 
T.0 1 3+ 0.0937 782 41 41 38 4000 173 3 17011 7 1.73 5.12 2 0.13 0.234 = 0.0423 
29.0 1 	 4 00125 593 73 60 61 64.67 7.23 3 129.45 2 7.23 10.91 2 0.70 0.5420 S 	 0.0529 
2, I 	 5 02500 6106 16 18 22 113.67 3.06 3 1332.94 2 3.06 031 2 0.03 0.014 5 0.0419 
2=0 1 5+ 0.3750 4413 1 1 1.00 0.00 2 963.36 5 0.00 0.02 7 0.00 0.001 7 0.0419 
770 I 	 7 0.0000 306 48 103 91 97.33 6 03 3 97.33 7 6.03 31 81 7 1.19 1.000 7 0 0506 
11, / 	 6 0 1250 304 BO 75 88 85 8200 572 4 96,70 7 5.72 2097 7 0.99 0.040 - 	 0.0464 
T-, f 	 5 0.2500 553 184 187 180 181 183.00 116 4 175.90 7 3.16 3109 7 029 1.040 7 0.0369 
7=0 / 	 4 0.5000 553 147 150 150 149.00 173 3 175.90 2 173 26.44 S 	 0.18 0.847 2 00362 
T. / 3 0 1000 470 75 73 76 84 77.00 .483 4 149.50 5 4.63 16 38 2 0.51 0.515 2 00392 
7-0 / 	 2 0 1500 1105 14 19 19 20 18.00 2.71 4 351.48 2 2.71 161 2 0.12 0.051 2 00360 
7-0 / 	 1 0.2000 5064 7 9 6 7.33 1.53 3 1610 77 + 153 0.14 5 0.02 0.005 2 00358 
T.) 1 	 7 00000 332 118 116 126 120.00 529 3 120.00 2 5.29 36.14 0 092 1.000 2 00360 
772 I 	 6 01250 282 112 117 108 103 110.00 594 4 101.93 2 5.94 39.01 7 1.05 1.079 0 0.0387 
7,1 1 	 5 00250 276 88 87 87.50 0.71 2 99.76 7 0.71 31.70 2 0.18 0.822 -.4.- 00259 
5,=0 f 	 4 00500 560 132 154 136 155 144.25 11.95 4 202.41 . 11.95 2576 1.07 0713 . 0.0390 
7.1 1 	 3 0.1000 576 52 60 65 54 5735 591 4 208.19 7 591 loos . 0.51 0.277 7 0.0291 
270 I 	 2 0.1500 1062 20 20 21 16 19 25 2 22 4 383.86 7 2.22 1.81 7 0.10 0.050 * o 0256 
15.0 1 	 1 0 2000 5141 10 6 13 8 0.25 2 99 4 1058 19 7 299 0.18 2 0.03 0.005 5 0.0255 
2-0 I 	 1 0.000 150 47 50 43 45 54 47.80 4 32 5 4710 5 4.32 31.87 2 1.29 1.000 2 0.0006 
1179 / 	 3 0.063 200 20 31 26 29 25 26.20 421 5 63.73 7 4.21 13.10 + 0.94 0.411 5 00005 
T20 1 4 0.125 400 23 26 32 33 38 3040 594 5 127.47 2 5.94 7.60 0 0.66 0.238 2 0.0005 
270 I 	 5 0.250 3340 4 4 4.00 0.00 2 1064.35 7 0.00 0.12 0 0.00 0.004 5 0.0004 
T. 1 .1 0000 300 82 98 101 105 72 95 60 0.96 5 95.6D 7 196 31.87 7 1.34 1.000 7 00006 
7,11 	 ga2 0.050 500 103 109 93 96 104 101 00 644 5 159.33 7 144 20.20 7 058 0.634 7 00005 
P.O4 1 	 .3 0.100 500 15 18 20 15 11 16.00 3.39 5 159.33 7 119 3.20 5 0.30 0.100 7 0.0004 
15-0 1 	 .4 0.200 4000 27 32 21 25 21 25 20 4.60 5 1274.67 7 4 60 0.63 2 005 0.020 5 0.0004 
SURVIVAL ANALYSIS 
 
28.05.97 Iodiste 131 @ T=4/8 weeks 
Number & 
Control 
Dose 
mCi 
Number 
of Cells 
Seeded 
per plate 
[1] 
Numbers of Colonies 
[2] 	 [3] 	 [4] [5] 
No. 
of 
Plates 
Viable Fraction 
(Colonies /cell) 
(± Standard 
Deviation) 
Plating 
Efficiency P/o 
(± Standard 
Error) 
Surviving 
Fraction 
(± Standard 
Error) 
Mean Std. 
Dev. 
T=4 / cti 0 125 18 11 11 14 14 13.60 2.88 5 13.60 ± 2.88 10.88 Jr 	 1.29 1.000 ± 	 0.1675 
T=4 / al 0.05 125 17 20 18 22 20 19.40 1.95 5 13.60 ± 1.95 15.52 Jr 	 0.87 1.426 Jr 	 0.1870 
T=4 1 a2 0.1 125 29 22 29 28 30 27.60 3.21 5 13.60 Jr 3.21 22.08 ± 	 1.44 2.029 Jr 	 0.2741 
T=4 / a3 0.2 125 40 28 32 31 28 31.80 4.92 5 13.60 Jr 4.92 25.44 ± 	 2.20 2.338 ± 	 0.3429 
T=4 / ctl 0 125 51 50 39 45 50 47.00 5.05 5 47.00 Jr 5.05 37.60 Jr 	 2.26 1.000 1 	 0.0849 
T=41 al 0.1 125 22 31 21 32 31 27.40 5.41 5 47.00 Jr 5.41 21.92 Jr 	 2.42 0.583 ± 	 0.0733 
T=4 1 a2 0.2 125 11 16 19 11 24 16.20 5.54 5 47.00 ± 5.54 12.96 ± 	 2.48 0.345 = 	 0.0691 
T=4 / a3 0.2* 125 36 32 30 25 42 33.00 6.40 5 47.00 Jr 6.40 26.40 ± 	 2.86 0.702 ± 	 0.0871 
/ MI 0 125 110 113 102 106 112 108.60 4.56 5 108.60 ± 	 4.56 86.88 ± 	 2.04 1.000 ± 	 0.0332 
1 al 0.05 125 84 86 96 94 90.00 5.89 4 108.60 Jr 5.89 72.00 Jr 	 2.94 0.829 ± 	 0.0391 
T4 / a2 0.1 125 71 63 65 70 67.25 3.86 4 108.60 Jr 3.86 53.80 Jr 	 1.93 0.619 Jr 	 0.0266 
T3 / a3 0.2 125 80 75 64 62 75 71.20 7.79 5 108.60 Jr 7.79 56.96 ± 	 3.48 0.656 Jr 	 0.0567 
T=8/ ctl 0 125 53 52 63 51 60 55.80 5.36 5 55.80 ± 5.36 44.64 Jr 	 2.40 1.000 ± 	 0.0759 
Ti / al 0.05 125 52 47 41 40 48 45.60 5.03 5 55.80 ± 5.03 36.48 ± 	 2.25 0.817 Jr 	 0.0668 
T=81 a2 0.1 125 28 28 40 33 32 32.20 4.92 5 55.80 Jr 4.92 25.76 Jr 	 2.20 0.577 Jr 	 0.0582 
T4 / a3 0.2 125 37 37 34 41 53 40.40 7.47 5 55.80 Jr 7.47 32.32 Jr 	 3.34 0.724 Jr 	 0.1058 
